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 Summary & Rationale 
Major depressive disorder (MDD) is a chronic, recurrent mood disorder (Kendler, 
Thornton, & Gardner, 2000; Kumar, Harmer, & Dourish, 2013) with an estimated 
lifetime prevalence of 16.2% (Kessler et al., 2003) which affects more than 350 
million people globally (WHO, 2013).  
 
MDD has a complicated and multifarious neuropathology, a result of which is 
largely ineffective and out-dated pharmacological treatments (Skolnick, 1999). 
Typical antidepressants are either serotonin re-uptake inhibitors (SRI) or tri-cyclic 
antidepressants (TCA), both of which target the monoamine system (serotonin 
and/or dopamine). However, research has suggested a myriad of distinct 
hypotheses for depression through localisation of functionally distinct 
neuroanatomical structures, identification of neurotransmitter modulation and 
receptor subunit alterations as well as genetic, environmental and behavioural 
observations that could all be targets for antidepressant therapy.  
 
Alterations of the GABAergic and glutamatergic neurotransmitter systems have 
been reported in major depressive disorder (MDD), both post-mortem in-vitro and 
ante-mortem in-vivo. Evidence from magnetic resonance spectroscopy (MRS) 
studies reported lower bulk concentrations of GABA in currently depressed 
participants as compared with healthy controls, which may reflect a neurobiological 
pathology, serve as a biomarker, and guide development of new pharmacological 
therapies.  
 
If this area of research is to see translation to a clinical setting, the roles of GABA 
(and glutamate) in depression need to be fully elucidated. Some of the questions 
that arise are: Do alterations in GABA concentration reflect state or trait markers of 
depression? Does the GABA deficit observed in depression reflect ‘ functional’ 
GABA? Does an existing pharmacological compound with antidepressant efficacy 
act on the GABA system? This thesis addresses these questions primarily utilizing 
multimodal neuroimaging techniques, along with computational neuronal modelling 
and pharmacological manipulation. 
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Chapter 1. Background & Literature 
 
1.1 Depression statistics and biomarkers 
Depression is a debilitating and recurring mood disorder, characterised by 
depressed mood, anhedonia, impaired function of everyday social, occupational 
and educational tasks, insomnia, fatigue, and a range of other symptoms. Beyond 
the diagnostic criteria, depression has been shown to be multi-causal in nature. 
Those who suffer depression are at higher risk of a range of diseases including 
cancer and diabetes, as well as brain-related conditions such as epilepsy and 
neurodegenerative disorders, which may also trigger depression. Furthermore, 
depression is assumed to have a substantial genetic component, due to the high 
probability of offspring and siblings of sufferers being diagnosed with depression 
(estimated 40-50% heritability: WHO, 2013).  
 
Producing greater abatement in health than diabetes, asthma or arthritis (Kumar et 
al., 2013), and affecting more than 350 million people worldwide, it is arguably the 
most inadequately understood widespread disorder. Current estimates of 
remission rates suggest 1/3 respond to first prescribed medication by 6 weeks, 
however the World Health Organization estimates that 1 million MDD sufferers die 
by suicide each year. 
 
Better understanding of the neurobiology of depression will be key to developing 
better treatments, however research to date has demonstrated that the underlying 
biology is complex and multifaceted.  
 
The aim of psychiatric neuroimaging, and indeed this thesis, is to utilise brain-
imaging techniques to probe the neurochemistry and physiology of disorders in 
living patients. Using these tools to ask questions about the neuroscience of 
disorders, based on theories from preclinical models and pharmacology, will allow 
development of biological markers (that is, measures which aid understanding, 
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prediction or monitoring of disease) which lead to new hypotheses about the 
aetiology of disorders (causes) and new therapeutic targets (development of new 
medications. 
1.2 Neurochemical Hypotheses of Depression 
Within the neurobiology literature there exist a myriad theories of depression and 
mood disorder neuro-aetiology. Three of the most pertinent to this thesis are the 
mutually inclusive GABAergic, glutamatergic and neurotrophic hypotheses of 
depression.  These are outlined below, while an introduction to the techniques, 
which allow testing of them, follows in the subsequent chapter. Preceding this, 
GABA and glutamate synthesis, transamination and their major receptor 
pharmacology are introduced. 
1.2.1 GABA and Glutamate Receptors 
The human cortex is broadly considered as consisting of local circuit neurons 
(including pyramidal, stellate and interneurons) and projection neurons 
(predominantly pyramidal cells). Inhibitory interneurons use the neurotransmitter 
GABA. Conversely, excitatory interneurons, stellate and pyramidal neurons are 
excitatory and use the neurotransmitter glutamate (Letinic, Zoncu, & Rakic, 2002). 
 
Across the brain, glutamate and GABA are the most abundant excitatory and 
inhibitory neurotransmitters, respectively. In specific regions they are known to 
regulate other neurotransmitters, such as the regulatory effect of GABA on 
dopamine in limbic structures. GABA is exclusively found in the nervous system 
and in concentrations 1000 times that of any monoamine transmitter (Croarkin, 
Levinson, & Daskalakis, 2011). 
 
As well as being an excitatory neurotransmitter, glutamate is also the precursor to 
GABA. Despite this, the cycles synthesizing and metabolizing GABA and 
glutamate are complex; due to neurons lacking pyruvate carboxylase, they are 
incapable of de novo synthesis (Bak, Schousboe, & Waagepetersen, 2006). 
 
  3 
Instead, GABA is formed from L-glutamate by the enzyme glutamic-acid 
decarboxylase (GAD). Once GABA is released, both GABAergic neurons and 
astrocytes clear extrasynaptic GABA via transporters. GABA is destroyed by a 
transamination reaction, which occurs endogenously by the enzyme GABA-
transaminase, which is predominantly found in astrocytes. Transamination 
produces (via tricarboxylic acid, TCA) succinic semialdehyde and then succinic 
acid as well as α-Ketoglutarate and then glutamate. Glutamate is further converted 
to glutamine via glutamine synthetase (GS). (Rang, Dale, Ritter, & Flower, 2003, 
Bak et al., 2006, reaction figure 1.1.1, cycle figure 1.1.2).  
 
Figure 1.1.1 From Erlander and Tobin (1991). Demonstrating the ‘GABA shunt’. (GAD = glutamatic 
acid decarboxylase, GABA-T = GABA transaminase, SSADH = succinic semi-aldehyde 
dehydrogenase). 
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Figure 1.1.2 from Bak (2006). Demonstrating GABA cycle (Suc = succinic acid, TCA cycle = 
tricarboxylic acid, NH4 = ammonia, α-KG = α-Ketoglutarate to glutamate to glutamine via 
GS=glutamine synthetase) 
 
Once released, neurotransmitters bind to specific receptors on the postsynaptic 
neuron. These receptors differ in numerous ways and only the main classes are 
introduced here. Almost all receptor types fall into the category of metabotropic or 
ionotropic. Metabotropic receptors are G-protein coupled receptors, which can 
trigger a range of intracellular mechanisms and are considered slow compared to 
ionotropic.  Ionotropic receptors are ligand-gated ion channels in the cell 
membrane, which allow particular ions to flow into or out of the cell in order to 
hyper- or de-polarise the cell. These receptors have fast, direct effects. Table 1 
demonstrates the GABAergic and glutamatergic receptor types. Ionotropic 
receptors comprise permutations of subunits in specific configurations.  
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Receptor Shape Common configuration Class Endogenous ligand 
GABA
A
 pentameric 1xα 2xβ 2x γ  Ion GABA 
GABA
B
 heptahelical  GPC GABA 
AMPA tetramer GluA1/Glu2 
GluA2/GluA3 
Ion Glutamate 
NMDA tetramer  Ion Glutamate 
Kainate tetramer  Ion Glutamate 
mGluR 1, 5 --  GPC Glutamate 
mGluR 2, 3 --  GPC Glutamate 
mGluR 4, 6-8 --  GPC Glutamate 
Table 1. Summary of GABAergic and Glutamatergic receptors, including ionotropic and 
metabotropic receptors. 
 
Neurochemicals can bind at a number of sites on the receptor. For example, at a 
GABAA receptor containing the most common subunit composition (1xα 2xβ 2x γ), 
GABA binds between the α and β subunits (figure 1.1.3). Other chemicals bind at 
other specific sites, which usually affect the receptor function in some way. The 
most common of these are agonists, antagonists and allosteric modulators. 
Agonists bind at the receptor and promote the action of the endogenous (or 
otherwise) ligand by increasing the permeability of the central pore. Antagonists, 
through a number of mechanisms reduce the affect of the receptor, and other 
modulators can have positive or negative functional affects on specific aspects of 
receptor function. In the context of the GABAA receptor, benzodiazepines have a 
binding site between α and γ subunits, but only bind when the subunit comprises a 
specific configuration of alpha subunits. Their effect is to potentiate the effect of 
GABA at the GABAA receptor (Nutt & Malizia, 2001). Interestingly, it is unknown 
whether the benzodiazepine site has an endogenous ligand (since benzodiazepine 
drugs do not exist organically within the brain). Some chemicals are more likely to 
bind to a certain site than others. Once bound, these then are more or less likely to 
activate the receptor. These functions properties are termed receptor affinity and 
efficacy (thus antagonists demonstrate 0% efficacy).  
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Figure 1.1.3 from Foster (2008). Depicting most common subunit composition of GABA
A
 receptors 
(1xα 2xβ 2x γ) with G (GABA) and B (Benzodiazepine) binding sites shown 
 
When binding occurs at GABAergic or glutamatergic receptors, signalling occurs. 
At inhibitory (e.g. GABAergic) synapses, receptor activation allows the cell to 
hyperpolarise by permitting chloride flow, which reduces its ability to produce 
action potentials and produces inhibitory post-synaptic currents (IPSC). 
Conversely, glutamatergic receptors, depending on subunit composition, are 
sensitive to calcium, as well as sodium and potassium (AMPA and NMDA) and are 
voltage dependent (NMDA) (Rang et al., 2003). 
 
Depending upon the brain region studied, approximately 20 – 30% (Markram et al., 
2004) of synapses use fast GABAA receptors. The balance between excitatory and 
inhibitory synapses has been shown to be delicate; accession of the GABA system 
results in amnesia and sedation, while mild debilitation of the GABA system results 
in anxiety, insomnia and excessive reactivity. This brain-wide, generalised 
behavioural consequence of altered excitatory-inhibitory balance may have been 
the starting point for the hypotheses of GABAergic dysfunction in psychiatric 
disorders such as depression.  
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Besides the common synaptic GABAA configurations, an extrasynaptic form has 
been recently described. Extrasynaptic GABAA receptors are associated with 
maintenance of tonic inhibition. Their configurations prominently feature subunits 
considered rare in synaptic GABAA receptors; namely the α4, α6 and δ subunits. 
The pharmacology of these extra-receptors is subsequently unusual in that they do 
not have a binding site for benzodiazepines (and are insensitive to 
benzodiazepines) but are sensitive to the experimental sleep drug gaboxadol 
(THIP), which is thought to bind at the alpha1-beta2 interface and function as a 
GABA agonist (Belelli et al., 2009).  
1.2.2 The GABAergic hypothesis of depression  
Evidence for a GABAergic deficit in major depression comes from numerous areas 
of neuroscientific research. Post-mortem studies have revealed that the brains of 
those who had MDD show reduced size and density of GABAergic interneurons in 
dorsolateral-prefrontal cortex, compared to those who did not have MDD 
(Rajkowska et al., 2006) and work in animal models demonstrates that chronic 
stress alters the GABAergic system (Acosta & Rubio, 1994). Neuroimaging and 
pharmacological studies, however, provide the most compelling evidence of a 
GABAergic deficit in MDD. These are reviewed extensively before introducing the 
compatible glutamatergic and neurotrophic hypotheses of depression.  
 
Kalueff and Nutt (2007) reviewed all available evidence of the effects of 
compounds targeting different aspects of the GABAergic system on depression 
and anxiety. This demonstrated that gabapentin (a GABA analogue), sodium 
valproate and vigabatrin (GABA-transaminase inhibitors), tiagabine (presynaptic 
GABA uptake inhibitor), muscimol (selective GABAA agonist) and benzodiazepines 
all reduce depressive symptoms.  These findings would suggest both that 
increasing GABAergic inhibition reduced depressive symptoms, and also that the 
GABAA receptor may specifically be involved in depression due to both muscimol 
and benzodiazepines being GABAA specific, although this does not rule out any 
role for GABAB receptors since it may be that the effect of manipulating GABAA 
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receptors upon GABA has a knock-on effect on GABAB receptors via altered 
availability, or via intracellular processes.  
 
Benzodiazepines were utilised for their antianxiety and antidepressant effects as 
far back as 1950, nearly 30 years before their binding properties (and thus 
GABAergic effect) were understood. Subsequently the benzodiazepine receptor 
complex has been studied extensively, demonstrating subtle difference is the 
effects of benzodiazepines drugs depending on the subunit composition of the 
GABAA receptor. The α1 subunit containing receptor seems to mediate sedative 
effects, but not anxiolytic. Meanwhile, α2 and α3 subunits mediate anxiolytic 
effects (Rang et al., 2003). Moreover, pharmacologically modulating the 
benzodiazepine receptor complex (BRC) directly reveals a spectrum of effects. As 
summarised in figure 1.1.4, agonizing the BRC produces anxiolytic, sedative and 
anticonvulsant effects in an efficacy-dependence manner as assumed by the effect 
of full and partial agonism. While antagonists of the BRC have little effect (because 
antagonizing the BRC simply stops it from potentiating GABA at its binding site, 
thus having zero efficacy), inverse agonists, defined by agonist-equivalent affinity 
but negative efficacy, produce anxiogenic, stimulatory and preconvulsive effects in 
a similar efficacy-dependent manner (i.e. using partial and full inverse agonists) to 
the agonist. 
 
 
Research into the functional neuroanatomy of depression has focused largely on 
brain regions associated with emotion perception and targeting brain structures 
associated with hallmark features of MDD such as anhedonia. This includes 
regions such as the dorsolateral/medial prefrontal cortices and the hippocampus 
which are thought to regulate emotion, while the amygdala, insula, thalamus, 
orbitofrontal cortex, nucleus accumbens and ventral striatum have also been 
implicated in aspects of emotion recognition, processing and regulation (Phillips, 
Drevets, Rauch, & Lane, 2003). Most of these structures are considered part of the 
limbic system or are within the mesolimbic and mesocortical pathways, which 
consist of dopamine and serotonin projections. Both serotonin and dopamine have 
  9 
previously been implicated in MDD; serotonin because of the SSRI class of 
antidepressant, and dopamine because of its role in reward seeking and hedonic 
tone, a hallmark of MDD. 
 
While the importance of serotonin and dopamine transmission in MDD is 
unequivocal, it should be noted that both pathways are interconnected with 
GABAergic and glutamatergic neurons. It has also been shown that dopamine is 
inhibited by GABAB receptors (Bowery et al., 1980) and serotonin is inhibited by 
GABAA, GABAB and glutamate (Tao & Auerbach, 2000). Figure 1.1.5 
demonstrates how dopaminergic projections from the VTA to the NAcc and frontal 
regions also feature reciprocal GABAergic connections and the VTA receives 
glutamatergic input from the frontal cortex. Additionally, the aforementioned 
amygdala, hippocampus, hypothalamus and prefrontal regions have all 
demonstrated ‘rich’ GABAergic projections (Croarkin et al., 2011). 
 
 
Figure 1.1.4 from Nutt (2001). Demonstrates the spectrum of benzodiazepine efficacy effects. 
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Figure 1.1.5. Adapted from Bailey, C, 2013. (http://www.pa2online.org). HIP, hippocampus; THAL, 
thalamus; VP, ventral pallidum; FC, frontal cortex; NAc, nucleus accumbens; VTA, ventral 
tegmental area; BLA, basolateral amygdala. 
 
Neuroimaging studies utilizing nuclear-magnetic resonance spectroscopy (NMR-
Spectroscopy or 1HMRS) have demonstrated reduced concentration of GABA in 
occipital (Sanacora et al., 1999) and prefrontal (Hasler et al., 2007) cortical 
regions. Furthermore, this GABA concentration deficit has been shown to 
normalise with successful SSRI (Sanacora, Mason, Rothman, & Krystal, 2002, 
Bhagwagar et al., 2004), CBT (Sanacora et al., 2006) and ECT treatments 
(Sanacora et al., 2003). More recently one group demonstrated that treatment 
refractory MDD (TRD) subjects demonstrated significantly lower occipital GABA 
concentration than non-treatment refractory MDD subjects, suggesting that the 
GABA concentration deficit in MDD could be severity-dependent, or perhaps serve 
as a marker of treatment resistance. Reports are conflicti ng as to whether 
remitted-MDD subjects demonstrate reduced GABA (Hasler et al., 2005, 
HIP THAL VP
FC VTA
NAc
BLA
Glutamate
GABA
Dopamine
behavioural output
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Bhagwagar et al., 2007) and therefore whether the observed concentration 
difference represents a state or trait biomarker.  
 
One study examining GABA in adolescent MDD found that, while adolescents with 
MDD did indeed show reduced anterior cingulate GABA concentration compared 
to their psychiatrically healthy counterparts; further stratification revealed that only 
anhedonic-MDD subjects drove the difference in GABA, whereas non-anhedonic 
MDD subjects did not differ from controls (Gabbay et al., 2012). Although evidence 
suggests that the GABA concentration reduction in MDD might be brain-wide, the 
local effects of this deficit will change depending on the region or structures (and 
their local computations) studied. In this case, the low GABA concentration in the 
ACC may be driving the anhedonia phenotype via the aforementioned modulatory 
effects of GABA and inhibitory-excitatory balance on dopamine transmission in 
reward processing. 
 
One limitation of GABA-MRS is that the technique is not sensitive to the condition 
of GABA (i.e. whether it is located pre or post-synaptically, in astrocytes, or is 
extracellular); it is a bulk-measure. Besides in-vivo spectroscopy, plasma-GABA 
levels have been shown to be reduced in currently depressed subjects (Petty, 
Kramer, Gullion, & Rush, 1992). This finding supports the idea that GABA is 
reduced globally in the depressed brain, however plasma concentration is a 
similarly bulk measure to MRS in that it does not provide any information on 
functional GABA. 
 
Based on the studies described above, evidence of a GABA deficit, or possible 
GABAergic dysfunction in MDD is compelling. However an important consideration 
of any GABAergic deficit in MDD should be the possible mechanisms underlying it. 
The field of neurogenetics utilises the concept of an intermediate phenotype to 
elucidate gene functions, for example the mechanism leading from a particular 
gene to an observed behaviour. It may be that the GABAergic deficit in MDD is an 
intermediate phenotype between alteration of a set of genes and the symptoms 
composing MDD.  
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Using the GABA deficit in MDD as an intermediate phenotype, Choudary et al 
(2005) investigated the molecular mechanisms that may underlie abnormal 
GABAergic function in the brains of MDD patients who died by suicide. Comparing 
brains from MDD suicide (n= 9) to non-MDD non-suicide (n= 7) using microarray 
analysis allowed identification of differentially expressed genes across the cortex. 
Results demonstrated that a number of genes falling into three distinct categories 
were dysfunctional in MDD; those which encode glutamate aspartate transporters 
(excitatory amino-acid transporters, EAATs), glutamate-ammonia ligase (glutamate 
synthetase) and subunits of ionotropic glutamate and GABAA receptors. In total 
four glutamate receptor-related genes were down regulated in anterior cingulate 
cortex in MDD while two glutamate-receptor genes were up regulated and three 
down-regulated in DLPFC in MDD. Furthermore, in DLPFC, three GABAA receptor 
encoding genes were up-regulated (specifically the GABAA β3, δ and γ2 subunits) 
(Choudary, 2005). These results provide a mechanism, which could explain, 
altered glutamatergic and GABAergic receptor function, which are likely to, in turn, 
underlie the widely reported GABA concentration deficit of MDD. The exact effect 
of up-regulating and down-regulating expression of genes encoding receptor 
subunits (proteins) is not known, beyond that it may alter the receptor function 
somehow.  
 
Depression is not the only psychiatric disorder in which altered GABAergic activity 
has been noted. A range of disorders have been reported to demonstrate 
alterations in GABA (Brambilla, Perez, Barale, Schettini, & Soares, 2003; Petty, 
1995), which has led some to propose that GABAergic compounds might be 
critical to treating a variety of CNS disorders (Whiting 2003). Notably, both anxiety 
and depression, which demonstrate many overlapping clinical features, have been 
reported to demonstrate reduced GABA levels, suggesting some neurobiological 
overlap in these disorders (Kalueff & Nutt, 2007). While this overlap may be 
important, it should not impede on-going research investigating GABA in either 
depression or anxiety – much as the clinical overlap between the disorders doesn’t 
preclude a patient from being diagnosed with one of other of the disorders. The 
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significance of the clinical and GABAergic overlap between anxiety and depression 
is largely outside the hypotheses of this thesis, however it is an on-going debate 
among researchers; a review of recent evidence can be found in Mohler (2012) . 
1.2.3 The glutamatergic hypothesis of depression  
While the evidence for a GABAergic deficit in MDD is compelling, this does not 
preclude a role for glutamate in MDD. As the brains’ major excitatory and inhibitory 
neurotransmitters, glutamate and GABA have to be, conceptually, balanced, or 
inversely correlated. In this case, alterations of GABA in MDD will either de-
correlate from glutamate or equally alter glutamate, depending upon the 
mechanism altering GABA. Glutamate is synthesised either from glucose via the 
Krebs cycle, or from glutamine (see figure 1.2). Glutamate is stored in synaptic 
vesicles by glutamate transporters and presynaptically released via calcium influx. 
Glutamate is taken up post-synaptically or cleared extracellularly by glial EAATs. 
Glutamate is also the immediate precursor to GABA synthesis. 
 
Similarly to GABA, alterations of glutamate concentration have been described in 
MDD. Increased plasma glutamate has been reported in MDD (Altamura, Maes, 
Dai, & Meltzer, 1995) and several pharmacological antidepressant therapies target 
glutamate via ionotropic receptors, notably D-cycloserine and ketamine, both 
antagonists of the NMDA receptor (the former only in high doses), and lamotrigine, 
a mood stabiliser which reduces presynaptic glutamate release (Crane, 1959, 
Zarate et al., 2006, Bhagwagar & Goodwin, 2005.  
 
To date, eleven published MR spectroscopy studies quantified glutamate (Glu) or 
the peak corresponding to glutamate + glutamine, denoted glutamix or Glx (and 
which additionally includes a small amount of GABA and macro-molecules) in 
depressed subjects. Somewhat surprisingly, 9 of these studies demonstrated 
reductions in glutamate, particularly in the ACC and VM/DLPFC (Yüksel & Öngür, 
2010) while 2 studies found no difference in glutamate in the ACC, or occipital 
cortex and one found increased glutamate in occipital cortex (Auer et al., 2000, 
Walter et al., 2009, Binesh, Kumar, Hwang, & Mintz, 2004, Sanacora et al., 2004, 
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Pfleiderer et al., 2003, Michel et al., 2003, Hasler et al., 2007, Michael et al., 2003, 
Block et al., 2009, Milne, MacQueen, Yucel, Soreni, & Hall, 2009). The voxels 
tested; along with the number of studies reporting the finding, is depicted in figure 
1.1.6. 
 
Figure 1.1.6. Summary of MR spectroscopy of glutamate, and glutamate + glutamine, in MDD. 
Arrow up signifies increased glutamate / Glx in MDD, arrow down signifies decreases and ‘X’ 
means studies reported no differences between MDD and controls. Red number illustrates the 
number of published studies reporting this finding. 
 
An interesting deviation in the trend of reduced glutamate is the reported increase 
in concentration in occipital cortex. This is the same voxel that most MRS GABA 
studies have used to demonstrate reduced GABA in MDD, usually chosen 
because of its good signal-to-noise ratio and generalisable nature (to the whole 
cortex). No study to date has demonstrated, in MDD, occipital GABA reductions 
coupled with glutamate increases, despite this being an obvious assumption based 
on the complementary roles of these neurotransmitters. This may be because, as 
suggested by the general increase in glutamate concentration in several areas of 
cortex, both GABA and glutamate are reduced in MDD. 
 
Imaging findings reporting increased glutamate concentration challenge 
assumptions made based on the actions of glutamate-acting antidepressants. The 
simplest explanation for this is that antagonism of NMDA receptors (D-cycloserine, 
ketamine) and inhibiting presynaptic glutamate release (lamotrigine) can both 
increase global glutamate by decreasing the amount metabolised extracellularly 
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and post-synaptically (because there is less available to be metabolised) while 
increasing the (intra+extracellular) concentration via ‘storage’ (in synaptic 
vesicles). However ketamine has been shown to increase presynaptic release of 
glutamate, suggesting that the mechanism is more complex, (Moghaddam, 
Adams, Verma, & Daly, 1997). This has been suggested to occur as a 
consequence of disinhibition of GABAergic inputs (Sanacora et al., 2008). 
 
The rapid and marked efficacy of ketamine as an antidepressant (Zarate et al., 
2006), yet its complicated mechanism of action, has led to several novel 
hypotheses regarding its action, and potential aetiologies of depressive symptoms.  
1.2.4 The neurotrophic hypothesis of depression (the NMDAR) 
A less comprehensively studied hypothesis, resulting from the finding of 
ketamine’s antidepressant action, is the neurotrophic-synaptogenic mechanism, 
formalised by Duman (2012) as the ‘neurotrophic hypothesis of depression’. 
 
Preclinical studies demonstrated that repeated stress tasks (e.g. forced swim) 
result in atrophy and decreased density of neurons and glia in the hippocampus 
and prefrontal cortex, (Duman & Monteggia, 2006, Duman & Li, 2012, Krishnan & 
Nestler, 2008) which led some researchers to hypothesise that depression is a 
degenerative (Lang & Borgwardt, 2013) or neurotrophic disorder (Duman & Li, 
2012). Subsequent studies revealed that stress exposure decreased levels of 
brain-derived neurotrophic factor (BDNF) (Duman & Monteggia, 2006), a growth-
factor protein found predominantly in the hippocampus and involved in 
synaptogenesis and differentiation of new neurons. Post-mortem examination of 
depressed subjects’ brains has also demonstrated reduced BDNF, while more 
recent studies have employed toxicology of blood plasma and serum to assess 
BNDF blood plasma levels in living subjects. These studies report reductions in 
serum BDNF in depressed subjects which normalises with successful (chronic) 
antidepressant therapy (Bocchio-Chiavetto et al., 2010, Sen, Duman, & Sanacora, 
2008). 
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It has been suggested that, partially through its NMDAR antagonism, ketamine 
increases synaptogenesis and neuronal spine density, off-setting the atrophy 
observed through chronic stress (and depression). This increased synaptogenesis 
could be a result of increased synaptic plasticity, a mechanism associated with 
NMDA receptors (Li et al., 2010).  Most importantly, a study by Haile et al (2014) 
has recently linked the proposed relationship between ketamine and BDNF levels 
in a randomised control trial of ketamine (with midazolam used as an active 
placebo) in individuals with treatment resistant depression (n = 22). The study 
evaluated blood plasma BDNF levels and found that ketamine-responders had 
increased BDNF plasma levels 240 minutes post infusion. Furthermore, BNDF 
levels at 240 minutes post infusion correlated negatively with Montgomery-Asberg 
Depression Rating Scale (MADRS) score. No relationship between BDNF or 
depression questionnaire score was found in the midazolam group.  
1.2.5 Proposed mechanisms of Ketamine 
The mechanism of ketamine responsible for its antidepressant action is unknown. 
It is assumed that the predominant binding affinity is for the N-methyl-D-aspartate 
(NMDA) ionotropic glutamate receptor, for which endogenous ligands include 
glutamate, NMDA, glycine and D-serine. However, ketamine is also known to 
affect the activity of BDNF, a mechanism that has recently received much 
attention. While an important consideration in the role of ketamine’s mechanism of 
action, the BDNF-related synaptogenic mechanism of ketamine is outside the remit 
of this experiment.  
 
Numerous studies have demonstrated alterations of cortical inhibition (Brambilla et 
al., 2003; Luscher et al., 2010) and excitation (Auer et al., 2000; Hasler et al., 
2007; Luykx et al., 2011; Sanacora et al., 2008) in major depression. Since cortical 
inhibition and excitation are functionally directly linked, it has been recently 
postulated that alterations in cortical excitation-inhibition balance underlie some 
aspects of the depressive syndrome (Wierońska, Pałucha-Poniewiera, Nowak, & 
Pilic, 2012).  
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Although ketamine’s primary binding affinity is for the excitatory N-methyl-D-
aspartate (NMDA) ionotropic glutamate receptors, where it elicits a direct 
antagonism, its efficacy as a dissociative anaesthetic suggests that a possible 
inhibitory GABAergic mechanism of action may additionally be involved in the 
mediation of its antidepressant effect. Indeed, ketamine has been shown to 
modulate and directly activate GABAA receptors; specifically the α6β3δ and α6β2δ 
subtypes (Hevers et al., 2008). Furthermore, early preclinical evidence in mice 
demonstrated that ketamine (0.8 mmol/kg) significantly increases whole-brain 
GABA levels via inhibited re-uptake of synaptic GABA by glia and neuronal soma 
(Wood & Hertz, 1980). Although global GABA may increase following NMDA 
receptor (NMDAR) blockade (Wood & Hertz, 1980), more recent work has shown 
that the activity of GABAergic interneurons decreases, whilst pyramidal cell firing 
increases, resulting in a net effect of excitation caused by disinhibition of pyramidal 
cells (Homayoun & Moghaddam, 2007). 
 
According to the pyramidal-interneuron gamma (PING) model, the local interaction 
of superficial pyramidal cells and inhibitory interneuron populations underlie 
oscillations in the gamma-frequency band (30+ Hz), a theory supported by 
computational, optogenetic and preclinical studies (Brunel, 2003; Sohal, 2012; 
Xing, Yeh, Burns, & Shapley, 2012), making assessment of gamma oscillations a 
useful tool for understanding alterations in cortical excitation-inhibition balance. 
More specifically, fast oscillations likely reflect reciprocal interactions of fast 
ionotropic excitatory and inhibitory receptors, such as GABAA and AMPA (see 
Buzsaki, 2012, for review). Although AMPA receptors are implicated in PING 
because of their speed, the slower NMDAR type has also been shown to play a 
role in gamma rhythm induction (Carlén et al., 2011). This may be, in part, due to 
the fact that AMPA and NMDA receptors are co-localised (Bekkers & Stevens, 
1989) and share an endogenous ligand (glutamate). Thus, modulation of the 
function of one of these receptors will have immediate effects on the function of the 
other.  
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Under the PING model, ketamine-induced pyramidal cell disinhibition (Homayoun 
& Moghaddam, 2007) would result in increased gamma amplitude via increased 
pyramidal cell excitation while concurrently decreasing peak gamma frequency via 
altered cortical excitation-inhibition balance. 
 
Consistent with model predictions, Oke and colleagues (2010) demonstrated in 
vitro that APV-induced NMDAR antagonism significantly increased low (20-45 Hz) 
and high (46-80 Hz) gamma amplitude (by 293 and 295 %, respectively) while 
significantly reducing the peak frequency of high gamma (mean reduction 13.2 Hz 
 0.6) recorded from rat dorsal neocortex. Similar findings have been reported in 
rat visual cortex in vitro, where a 10 uM dose of ketamine showed a trend towards 
increasing both layer 3 high (~54 Hz) and layer 5 low (~34 Hz) gamma power, and 
significantly decreased the frequency of layer 3 gamma (by 22 Hz (18.8 %  3.2)) 
to match that of layer 5 ‘ low’ gamma, resulting in cross -layer phase coupling 
(Anver, Ward, Magony, & Vreugdenhil, 2010). Similar effects of NMDAR hypo-
function have been reported in vivo when using APV in macaque V1 (Herrero, 
Gieselmann, Sanayei, & Thiele, 2013) and MK801 in the anterior cingulate cortex 
(ACC) but not orbital frontal cortex (OFC) of rats (Wood, Kim, & Moghaddam, 
2012).  
 
In a further study, Perrine et al (2014) utilised 11.7T MRS to assess GABA levels 
ex-vivo in CUS (chronic unpredictable stress) rats before and after ketamine 
infusion. CUS is a rodent model of depression, which utilises the forced-swim task 
at unpredictable intervals for 10 days. The day following a 40mg/kg infusion of 
ketamine, behavioural assessments were administered before euthanizing animals 
to remove brains for scanning. In keeping with human findings, ketamine 
significantly reversed stress-induced behaviours while also increasing anterior 
cingulate cortex GABA levels. Together, these results suggest that, in rodents, 
NMDA receptor blockade increases cortical excitability via disinhibition of 
pyramidal cells while also increasing global GABA concentration through inhibited 
re-uptake by both neurons and glia. 
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Recent studies investigating neurochemical effects of ketamine in humans have 
demonstrated that ketamine administration increases glutamate levels in the 
anterior cingulate cortex, but not GABA levels (administration protocol computed to 
achieve 150ng/ml-1). The study further reported a correlation between post-
ketamine ACC glutamate levels and symptom severity measured by the Positive 
and Negative Symptom Scale (PANSS). The finding of increased glutamate levels 
with no increase in GABA supports the aforementioned pyramidal-disinhibition 
hypothesis of ketamine (increased excitation = increased glutamate, inhibited 
GABAergic interneurons = no increase in GABA) (Stone et al., 2012). Another 
study, published around the same time (Taylor, Tiangga, Ni Mhuircheartaigh, & 
Cowen, 2011b), reported no increase in Glx (glutamate + glutamine) in the ACC of 
healthy subjects after an IV infusion of 0.5mg/kg. These seemingly contradictory 
results could be due to either the difference in dose administered, or the fact that 
the latter study did not separate glutamate and glutamine in the MRS spectra. In 
this case, it is possible that glutamine decreased as glutamate increased, resulting 
in Glx levels not changing (since glutamine is a precursor to glutamate).  
 
Besides the literature described above, there are several other hypotheses of 
ketamine’s action and binding properties in the brain which could explain its 
antidepressant effects (e.g. Duman & Li, 2012). Of particular relevance is 
preliminary evidence, which suggests that NMDAR hypofunction-mediated 
antidepressant effects could be D-serine related, as well as glutamatergic. 
Postsynaptic NMDA receptors require dual binding – that is, activation of NMDA 
receptors requires both glutamate and a co-agonist (Lewis, 2012). D-serine, a 
neuro- and glial-transmitter, shows high affinity for the co-agonist site of NMDARs 
(reviewed in Wolosker, 2008). Synaptic glutamate evokes D-serine release, which 
binds as a co-agonist at NMDARs (Malkesman et al., 2012). Ketamine has been 
reported to both ‘block’ NMDARs and also increase synaptic glutamate (Taylor, 
Mannie, Norbury, Near, & Cowen, 2011a), and as such the downstream effects on 
D-serine are unclear. However, in a preclinical study of D-serine as an 
antidepressant, a single, acute dose (800mg/kg rats, 300mg/kg mice, i.p.) of D-
serine significantly reversed forced-swim task induced immobility, increased sexual 
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reward-seeking (female urine sniffing test) and reversed learned-helplessness, 
suggesting a similar therapeutic profile to ketamine (Malkesman et al., 2012). In a 
similar vein, Kollmar and colleagues (2008) demonstrated in humans that one 
dose of ketamine (0.5mg/kg, i.v.) followed by daily oral administration of a different 
NMDAR antagonising drug, memantine (titrated upward form 5mg/day until 
response observed) prolonged the effects of ketamine. From a clinical perspective 
this is beneficial because memantine does not elicit the dissociative effects 
observed with ketamine. Taken together, these studies strong ly suggest that 
NMDA receptors are a key target for antidepressant treatment, and are therefore 
likely to be the primary therapeutic target of ketamine. 
 
The three neurochemical hypotheses outlined above are not disparate entities; 
since each has a wealth of research supporting it, it is likely that they are 
mechanistically linked. GABA and glutamate are linked metabolically as well as in 
their inhibitory and excitatory functions, respectively. Furthermore, the neurotrophic 
hypothesis of depression is largely a consequence of the finding that ketamine has 
antidepressant effects. NMDA receptor antagonism has direct effects on glutamate 
release and GABA levels (Perrine et al., 2014), as well as the aforementioned 
effects on growth factor proteins such as BDNF. 
 
1.3 Visually evoked fields and induced oscillations: biogenic and theoretical 
aetiology 
 
Encephalographic recordings have been used extensively in scientific and medical 
research in the quest to functionally localise experimentally induced behaviours. 
While neuroscientific literature is rich with experiments linking behaviour and 
anatomical loci, understanding of the cellular and synaptic properties giving rise to 
these phenomenon are regularly overlooked. This chapter aims to provide an 
overview of the neurobiological and physiological mechanisms giving rise to event 
related and induced cortical responses, particularly in the visual cortex. The 
imaging modalities utilised to record these measures are introduced in the 
methods chapter.  
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While the visual system might not, at first, seem the most suitable area of cortex to 
study in identifying differences in neural function between psychiatric and healthy 
groups, it is widely used for such experiments because it is generalisable in its 
neuronal architecture and function to many other areas of cortex (see canonical 
microcircuits, Douglas & Martin, 1991; Haeusler & Maass, 2007), provides greater 
signal-to-noise for most imaging techniques than most other areas of cortex and 
elicits a reliable and stable response to basic sensory stimulation (Adjamian et al., 
2004) ideal for exploring experimentally or psychiatrically induced changes without 
the confounds or processing associated with many subcortical and frontal brain 
regions. 
1.3.1 Retinogeniculostriate pathway & visual cortex anatomy 
At the posterior portion of the eye, axons of the ganglion cell layer bundle to form 
the optic nerve. The optic nerve runs to the optic chiasm, where about 60% of the 
fibres cross the chiasm and form the optic tract. This is the first point in the 
pathway that fibres from both eyes are co-localised. The majority of fibres in the 
optic tract terminate in the dorsal lateral geniculate nucleus (LGN) of the thalamus. 
From the LGN, fibres pass through the optic radiation, terminating in layer 4 (layers 
4Ca and 4Cb) of the primary visual cortex (V1, Broadmann’s 17, striate cortex). 
From V1 the visual signal is distributed to >30 visual-signal-sensitive extrastriate 
regions distributed along occipital-parietal and occipital-temporal pathways (Van 
Essen, Anderson, & Felleman, 1992).  
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Figure 1.2.1. Retinogeniculostriate pathways from (A) eyes to (B) optic nerve, (C) optic chiasm, (D) 
optic tract, (E) hypothalamus, pretectum & superior colliculus, (F) dorsal lateral geniculate nucleus, 
connected via optic radiation to (G) primary visual cortex. 
 
The LGN comprises two ventral magnocellular layers (layers 1 & 2) containing 
large neurons, and several dorsal parvocellular layers (layers 4-6), which contain 
smaller neurons. These layers are sensitive to M- and P-ganglion cells, 
respectively, which represent different aspects of optic data. M-ganglion cells (M-
cells) demonstrate sensitivity to transient visual stimuli whereas P-cells show a 
slower but sustained response. Furthermore, P-cells are sensitive to differences in 
light wavelengths and M-cells are not, suggesting that P-cells carry colour 
information. Damage to the magnocellular layers does not impair visual acuity or 
colour, but does impair the ability to perceive rapidly changing stimuli; damage to 
the parvocellular layers does impair colour vision and visual acuity but does not 
affect motion. These contrasting parvo- and magno-cellular layers follow distinct 
routes through the optic radiation and terminate in different cortical layers of V1; 
magnocellular terminating in layer 4Ca and parvocellular in layer 4Cb (Purves, 
2008). 
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The architecture of the visual cortex is predominantly the same as general 
neocortex in its columnar arrangement and laminar organisation, constituting six 
cortical layers. The concept of cortical columns stems from observations that 
specific patterns of neuronal bundling occur throughout cortical regions (e.g. a 
specific ratio between cells in vertical columns); it was this observation that led to 
the proposition of cortical microcircuits, discussed in more detail in section 1.5.  
 
A key difference between most cortical laminar and that of visual cortex is the 
division of layer 4 into 3 subtypes; A, B and C, with C further dividing into Calpha 
and Cbeta. Nevertheless, the neuronal architecture of the principal 6 laminar follows 
that of neocortex. Deep pyramidal cells with large apical dendrites occupy layers 6 
and 5 (infragranular layers), which project both across the cortical layers and also 
innervate the LGN. Layer 4 (the granular layer) constitutes spiny stellate cells and 
contains the main input layers from LGN. Layers 2 and 3 (supergranular layers) 
comprise superficial pyramidal cells, which project to extrastriate cortex (V2, V3, 
V4, MT) where feature-specific processing occurs. Layer 1 sparsely contains 
pyramidal cells and GABAergic neurons (Fitzpatrick, Lund, Schmechel, & Towles, 
1987), however the density is markedly reduced compared with other layers (figure 
1.2.2) and many consider it ‘aneuronal’ (O'Kusky & Colonnier, 1982). Finally, 
approximately 20% the cortical sheet contains inhibitory interneurons, across 
layers 2-5, which do not project outside V1. The aforementioned neurons are 
predominantly excitatory and utilise glutamate via ionotropic receptors for 
signalling with the exception of inhibitory interneurons, which utilise GABA. 
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Figure 1.2.2. Purves et al 2008. Depicting the 6 layers of visual cortex (a) histologically stained, (b) 
neuronal constitution excluding inhibitory-interneurons, (c) layers in which LGN inputs terminate, (d) 
intracortical connections between excitatory neurons, (e) laminar (output) connectivity to 
extrastriate (orange), LGN (blue) and superior colliculus (green).  
 
Eickhoff and colleagues (2007) investigated the laminar distribution and density of 
16 receptor types in V1 and extrastriate V2 and V3 in human brain using 
quantitative receptor autoradiography. Results demonstrated that, averaging 
across cortical layers, V1 contains a high density of GABAA, GABAB, 
benzodiazepine (BZ) and NMDA and to a lesser extent, AMPA receptors. 
Furthermore, they demonstrated that layer-averaged receptor density remains 
steady across V1, V2 and V3. Layer specific results in V1 demonstrated that 
significant clustering (possible co-localisation) of receptor types occurs in different 
layers. Relative to other receptor types, GABAA and BZ receptor clusters were 
more prevalent in layers 3, 4a and 4c whereas NMDA, 5 -HT2, M3 and M2 receptor 
clusters were more prevalent in layer 4b. AMPA and GABAB feature more 
prevalently in layers 2-4a and less prevalently in layers 4b/c compared with other 
receptors. 
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In V2 results demonstrated AMPA and alpha1 clusters showed bi-laminar 
distributions with the highest concentrations in layers 1, 2, 5 and 6. GABAA and BZ 
cluster in layers 3 and 4. GABAB-AMPA clusters observed in V1 are no longer 
observed and GABAB show relatively higher expression in layer 3 and lower in 
layer 5/6.  NMDA and D1 (dopamine) also cluster. In V3 GABAA/BZ show the 
same clustering profile, NMDA/D1 clusters also cluster with GABAB and show 
higher concentrations in layer 3 (Eickhoff et al., 2007). These results demonstrate 
that minor variations in receptor clustering occur between V1 and extrastriate 
regions, however mean receptor prevalences do not change. 
 
 
Figure 1.2.3. From Eickhoff et al 2007. Demonstrating concentration of receptor types across V1 -3. 
Highest concentrations are of BZ, GABA
A
, GABA
B
 and NMDA receptors. 
1.3.2 Primary visual cortex hierarchical models 
The neuronal connectivity of the visual system have been relatively well 
characterised by in-vivo rodent and mammal lesion experiments (Van Essen, 
Newsome, Maunsell, & Bixby, 1986), in-vitro human pharmacological studies 
(Eickhoff et al., 2007) and in-vivo human functional mapping (Warnking, 2002).   
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Several studies have proposed hierarchical models of V1 based on the neuronal 
architecture. Models centre on concept of feedforward, lateral and feedback 
connections (figures 1.2.2 and 1.2.5).  Feedforward connections originate in 
supragranular layers and terminate in granular layers of another area. Feedback 
connections originate in infragranular layers and terminate in supra- or infra-
granular layers of another area. Lateral connections connect to their own layer and 
can connect layers from different columns or areas.  
 
 
Figure 1.2.4. Friston 2005. Schematic of feedforward, lateral and feedback connections. 
Feedforward and feedback usually connect different areas or cortical columns. Lateral connections 
stay within layer. 
 
Coupling the concept of laminar-directional connections with the aforementioned 
neuronal architecture of the visual cortex suggests that feedforward and feedback 
connections are excitatory pyramidal neuron projections, while lateral connections 
are likely to be inhibitory interneurons, however this distinction is not clear. 
Feedforward connections are considered ‘driving’ and response eliciting, while 
feedback connections are ‘modulatory’. Furthermore, feedforward projections 
utilise the fast ionotropic AMPA and GABAA receptors while modulatory feedback 
connections utilise the slower voltage-gated NMDA receptors (Friston, 2005). 
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The primary visual cortex (V1) receives feedforward projections predominantly 
(Markov et al., 2011) from the LGN as well as, to a lesser extent, the pulvinar and 
other regions (Adams, Hof, Gattass, Webster, & Ungerleider, 2000). There also 
exist feedback connections from V1 to LGN, pulvinar and other areas, suggesting 
these areas are reciprocally connected (Graham, 1982). Moving along the visual 
pathway, V1 exhibits feedforward projections onto extrastriate areas (V2,3,4,5/MT) 
and receives direct feedback connections from these areas (Barone, Batardiere, 
Knoblauch, & Kennedy, 2000). Figures 1.2.5 ad 1.2.6 i llustrate the connections of 
the model as described by Friston (2005), with the neuronal types described by 
Purves (2008). 
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Figure 1.2.5. Illustration of extrinsic forward (arrows pointing down) and backward (arrows pointing up) interlaminar connections between LGN, V1 
and extrastriate cortical regions. Green, red and blue lines depict receptor type while line width represents the concentrati on of receptors in this 
region. This depiction does not feature intrinsic (interlayer, intracolumn) inhibitory inter neurons, which may be a more accurate location of the high 
GABAA receptor concentration, rather than on pyramidal cells. 
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Figure 1.2.6. Demonstrating both intrinsic and extrinsic connections. Amended from Bastos (2012).
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1.3.3 Neurobiological mechanisms of Event Related Potential / Field studies 
As reviewed in section 1.2, scalp recordings of event related potentials using EEG, 
or event related fields using MEG, give insight into the function of distinct brain 
regions in a temporally precise manner. These techniques can be used to test 
hypotheses about particular cognitive processes or pathologies by presenting 
specific stimuli or tasks to a subject. The signal measured contains detailed 
information about neurobiological processes.  
 
The majority of the signal detected by MEG and EEG is made up of the apical 
dendrites of pyramidal cells in layers 2/3, 5 and 6. This is because, as illustrated in 
figure 1.2.7, the multiple excitatory postsynaptic potentials sum and, from a 
distance, resemble a single dipole (Niedermeyer & da Silva, 2005). Furthermore, 
pyramidal cells parallel (but proximal) apical dendrites sum to magnify this, 
resulting in a detectable dipole, which can be detected outside the scalp. 
 
The excitatory postsynaptic currents in pyramidal cell dendrites of the primary 
visual cortex are under the influence of the neurons with which these cells 
synapse; namely feedforward and feedback projections to LGN and extrastriate 
regions. Event related scalp recordings are phase-locked to stimulus onset, which 
in primary sensory areas, such as V1, suggests input to the area. As described 
previously, this occurs via excitatory feedforward connections from the LGN, in 
turn suggesting that event related field recordings from V1 are a summation of the 
excitatory input from the LGN through pyramidal cell connections from superficial 
layers of LGN to layer 4 of V1. Furthermore, this EPSP is AMPA and GABAA 
(Friston, 2005) mediated and is more likely to be magnocellular than parvocellular 
due to the tendency for magnocellular cells to respond to transient stimuli (Purves, 
2008). This model of VEP/VEF generation is supported  by results from animal 
studies. 
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Figure 1.2.7. Laminar specific neuronal architecture. Red arrows illustrate the multiple parallel pyramidal cells apical dendrites carrying postsynaptic 
potentials, giving rise to a summed dipole detectable at the surface. 
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Lee et al (2012) demonstrated that parvalbumin-containing GABAergic 
interneurons (PV+) have a role in shaping visually evoked firing rates utilising an 
optogenetic approach. The light-activated channel rhodopsin ChR2 was expressed 
in PV+ interneurons, permitting activation of these neurons in vivo. Mice viewed a 
sinusoidal grating while PV+ interneurons were optogenetically driven. Multi -layer 
V1 spiking was recorded demonstrating that PV+ interneuron activation reduced 
visually evoked firing rate (Lee et al., 2012). While visually evoked firing rate does 
not translate to ERF per se, in the context of visually evoked firing in V1 in 
response to a grating stimulus, the ERF is likely driven by the same substrate as 
the EPSC (i.e. AMPAR mediated currents via pyramidal projections from LGN to 
V1).  
 
One study (Muhammad, 2009) explored the pattern-onset visually evoked 
response using current source density measures (current sink-peak 
measurements) across layers of visual cortex while mice viewed a visual grating 
pattern. Pattern-onset evoked three current sink-peaks; first in layer 4 at 62ms 
followed by layers 2/3 at 70ms and 5/6 at 81ms. These results likely reflect input 
from LGN to V1 and subsequent distribution across the cortical layers. Application 
of a drug combination consisting muscimol and SCH50911 (GABAA agonist and 
GABAB antagonist, respectively) eliminated the later 81ms sink-peak in layers 5/6. 
This study suggests that elevating GABAA receptor activity in V1 reduces the 
visually evoked EPSC to the point that a current sink -peak does not appear. 
Reduced EPSC in layers 5/6 would result in reduced MEG/EEG ERF amplitude 
(since EPSCs in pyramidal cells contribute largely to the MEG/EEG signal).  
 
Visually evoked cortical responses in V1 might therefore be considered as the 
summations of AMPA mediated feedforward EPSCs in layer 2/3 and 5/6 pyramidal 
cells, but which are under the inhibitory control of GABAA receptors. Alterations of 
these cortical responses under pathological (or otherwise) conditions may suggest 
alteration of one of the aspects discussed here (e.g. AMPA or GABAA receptor 
function). 
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1.3.4 Neurobiological mechanisms of Induced, High-Frequency Oscillations 
Induced responses differ from evoked responses in that they are not phase-locked 
to the stimulus. As a result of this, they often index more sustained neuronal 
activity. Time-frequency analysis of induced responses permits the signal power to 
be broken down into frequency bands. This section focuses on high frequency 
responses. 
 
High-frequency (γ-frequency band, >30Hz) induced osci llatory responses are 
elicited by a number of stimuli and behavioural tasks, which has resulted in 
numerous hypotheses regarding their nature including multisensory integration, 
facilitating working memory (Wang, 2010) and as a mechanism to attention 
selection (Lakatos, Karmos, Mehta, Ulbert, & Schroeder, 2008). Oscillations are 
assumed to reference neuronal synchronisation in local and distributed networks 
(figure 1.2.7) with γ-frequency oscillations proposed as a mechanism for 
synchronising neuronal assemblies into functional circuits for local computations 
(Singer, 1999, Spencer, 2009).  
 
Despite the dispute around their function, γ-frequency oscillations (γ-oscillations) 
have been relatively extensively studied by comparison to ERPs in terms of their 
biological conception (Mazaheri & Van Diepen, 2014; Whittington, Traub, Kopell, 
Ermentrout, & Buhl, 2000). γ-oscillations appear throughout the cortex, thus the 
striate cortical laminar architecture described previously (assumed to be cortex-
general) must contain a mechanism for generating high frequency oscillations. 
 
γ-oscillations are thought to arise from an interaction of pyramidal cells and fast-
spiking PV+ inhibitory interneurons (Traub et al., 1998; Whittington et al., 2000; 
Whittington, Traub, & Jefferys, 1995). In the cortex these neuronal types are 
reciprocally connected and utilise AMPA and GABAA receptors because these 
ionotropic receptors feature time constants fast enough to permit a fast-oscillation.  
 
Modelling studies of reciprocally connected pyramidal neurons have demonstrated 
that, when adding an external high-frequency excitatory drive to their simulated 
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network, a sustained oscillation could not establish and firing remained aberrant. 
However, adding inhibitory interneurons, so that pyramidal neurons and 
interneurons synapse in an all-to-all fashion (ratio of 4 pyramidal neurons to 1 PV+ 
interneuron), a sustained oscillation emerges at γ-frequency (Brunel, 2003). Within 
the physiology nomenclature this network is designated PING (pyramidal-
interneuron network gamma). The network parameters constitute 20% connection 
probability and modelled time constants (latency, rise time and decay time).  
 
The frequency of the PING model is dependent on the ratio of the timescales of 
the excitatory postsynaptic potentials to inhibitory postsynaptic potentials. In 
addition, Brunel and Wang’s model demonstrates that oscillation frequency 
reduces with the recurrent excitatory: inhibitory (AMPA: GABA) balance when this 
is manipulated via pyramidal cells. This decrease is unaffected by the frequency of 
the external excitatory drive (Brunel, 2003).  
 
A modelling study of PING generators by Wang et al revealed that pyramidal cell 
postsynaptic potentials (PSPs) are phase-locked to the local field gamma rhythm. 
These phase-locked PSPs reverse polarity close to the equilibrium potential of Cl-, 
suggestive of a role for GABAA receptor mediated inhibition in γ-frequency 
oscillations (Wang & Buzsáki, 1996). 
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Figure 1.3.1. PING network demonstrating interconnected pyramidal cells and PV+ interneurons, a minimum framework capable of sustained 
oscillatory activity. Arrows demonstrate sparse, seemingly aberrant firing of each neuronal population separately,  but coherent γ-frequency rhythm 
when measuring total population (LFP) (Brunel, 2003). 
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The aforementioned computational modelling experiments convincingly implicate 
GABAergic inhibition in the generation of γ-oscillations. To summarise, Wang et al 
demonstrated that GABAA mediated GABAergic inhibition (by interneurons) 
shapes the activity of the EPSP in pyramidal cells (a correlate of local field gamma 
and the main generator of scalp recorded signals). Furthermore, the recurrent 
excitatory to inhibitory balance predicts γ-frequency and increasing the ratio of 
AMPA:GABA activity reduces frequency.  
 
Several studies have suggested that a particular type of fast-spiking inhibitory 
neuron is required for oscillation maintenance (Bartos, Vida, & Jonas, 2007; Cardin 
et al., 2009). Interneurons expressing the calcium-binding protein parvalbumin, (so 
called PV+ interneurons) can fire at >200 Hz with little spike-frequency adaptation, 
meaning they are well suited for a fast-oscillation network. A further link between 
PV+ interneurons and γ-oscillations comes from the fact that schizophrenic 
patients present markedly altered γ-oscillations (Spencer et al., 2003) and also 
unusually low levels of GAD67 in their PV+ interneurons (Akbarian & Huang, 
2006). A series of optogenetic studies demonstrated that interneurons expressing 
PV+ coupled with pyramidal neurons can maintain γ -oscillations (Sohal, 2012). 
Furthermore, rhythmic activation of PV+ interneurons increases local field power in 
the gamma range, and this entrains firing of pyramidal neurons (summarised in 
figure 1.3.2) (Carlén et al., 2011, Sohal, 2012).  
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Figure 1.3.2. From Sohal 2012. Oscillation conclusions from optogenetic studies. PV = parvalbumin 
FSI, PY = pyramidal neurons. (1) PV play a role in generating oscillation, (2) this rhythm entr ains 
pyramidal neurons, (3) interaction between the neuronal populations produces oscillations, (4) 
Gamma modulated firing in PY enhance flow of information to postsynaptic targets.  
 
Gamma oscillations have been recorded in visual cortex in response to visual 
stimuli. In the context of visually induced γ-oscillations, V1 contains the PING 
oscillatory model architecture as previous described (including the external drive in 
the form of projections from LGN). Theoretically, γ-oscillation frequency in this 
region, as well as across the cortex, should provide a marker of GABAergic 
function. In concordance with this, Muthukumaraswamy et al (2009) demonstrated 
that peak γ-oscillation frequency obtained using MEG  (while participants viewed a 
grating stimulus) is positively correlated with the concentration of GABA in the 
same region in the same participants, as obtained with magnetic resonance 
spectroscopy. A recent study, however, failed to replicate this finding in a larger 
sample size (Cousijn et al., 2014).  
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Time-frequency analysis of γ-oscillatory data provides measures of frequency and 
amplitude. While γ-oscillatory frequency is understood as a marker of GABAergic 
function and is a highly repeatable measure within individuals 
(Muthukumaraswamy et al., 2010), γ-osci llation amplitude (γ-amplitude) is less well 
understood and could be less stable within subjects. Despite this, deficits in γ -
amplitude have been demonstrated in schizophrenic subjects, and amplitude has 
been shown to correlate with a number of associated symptoms and behaviours 
(Uhlhaas, 2013; Uhlhaas & Singer, 2010). 
 
Previous studies have demonstrated that oscillation amplitude reflects 
synchronisation of spiking in cortical microcircuits (Pfurtscheller & Lopes da Silva, 
1999). Spencer (2009) investigated γ-amplitude reductions in schizophrenia in a 
PING model, based on that of the previously described Brunel & Wang model 
(2003). This demonstrated that reducing fast-spiking interneuron (FSI; 
predominantly PV+ interneurons) NMDA input to the 2-population network 
increased network excitability and increased γ-amplitude (power). The authors 
suggested that this increase in amplitude occurs as a result of inhibited FSIs 
disinhibiting excitatory pyramidal neurons, permitting greater network excitability 
(Spencer, 2009). This study demonstrates both that NMDA receptors may be 
important in γ-oscillation amplitude, and that network excitability (or increased 
EPSC) is a correlate of increased amplitude. If amplitude reflects synchronisation 
of spiking, it may be that increased network excitabili ty results in increased 
amplitude purely by permitting entrainment of more neurons. 
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1.4 Event-related potentials, neurophysiology and functional imaging studies 
in psychiatric disorders. 
This section aims to introduce neuroimaging and neurophysiology as tools in 
investigating psychiatric disorders, with a focus upon biomarkers, major depressive 
disorder, event-related potential studies and neuroimaging. Neurophysiology and 
functional neuroimaging findings are reviewed.  
1.4.1 Imaging Biomarkers 
Biological markers of disease (biomarkers) are needed in psychiatry, and non-
invasive brain measurements represent a potential mechanism for discovering and 
measuring these. Biomarkers are described as either state or trait and include both 
structural and functional measures. State markers are present while the disease is 
‘active’ and therefore considered to represent only temporary changes, while trait 
markers present outside of the disease (i.e. at prodromal phase, before onset, in 
remittance or in genetically at-risk subjects). Imaging biomarkers typically fall into 
one of three categories: disease characterisation (e.g. for diagnostic utility or 
exploring pathology), therapeutic characterisation (i.e. drug discovery) or disease 
progression monitoring (measuring treatment response or stratified medicine) 
(Kumar et al., 2013).  
1.4.2 Introduction to Event related Potentials 
One of the earliest fields of biomarker research in human psychiatric subjects was 
electroencephalographic (EEG) studies of event related potentials (Luck, 2005). 
Event related potentials (ERPs) refer to electrical (or magnetic in 
magnetoencephalography where referred to as event related fields, ERF) currents 
recorded from the scalp, which are believed to represent a summation of neuronal 
postsynaptic potentials in response to a stimulus or task. In vivo techniques such 
as EEG and MEG record a comparable signal to preclinical local field potentials, 
that is, postsynaptic potentials and currents recorded from populations of neurons, 
as opposed to multi-unit recordings of single neuron action potentials (more 
specific biological underpinnings are detailed in 1.4). 
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Neurophysiological studies may be stimulus driven or record ‘resting’ function. 
Resting recordings can be used to compare differences in intrinsic activity between 
groups, for example between patient and healthy groups. However, this approach 
does not reveal differences in specific aspects of information processing. Stimulus-
driven studies, however, seek to find correlates of a specific aspect of processing 
or cognition (Haenschel & Linden, 2011). In this context, a stimulus or task is 
repeated typically fifty or more times during recording and the trials averaged to 
reveal task-related ERPs. 
 
ERPs are characterised and identified by their latency and amplitude as well as 
scalp topography. ERPs are denoted by a letter representing their polarity 
(Positive, P; negative, N; or variable, C), and their average latency in milliseconds 
(e.g. P300). The meaning of a given ERP depends largely on the stimulus that 
evokes it, and the sensory and/or cognitive process associated with the stimulus or 
task. Within the neurophysiology literature, a generally accepted threshold of 
100ms differentiates early (<100ms) and later (~>300ms) ERPs, which are 
considered to reflect predominantly sensory and cognitive processes, respectively. 
Thus, particular stimuli will produce stronger effects on the components and 
location of ERPs across time. For example, a passive task involving a visual 
checkerboard stimulus is likely to elicit an early (<100ms, sensory) ERP in a brain 
region associated with vision (a visual evoked potential, VEP). Table 1 
demonstrates the most commonly reported ERPs, their latencies, and how these 
have previously been interpreted. This section will briefly review event -related 
findings across psychiatric disorders, with a focus on depression and early 
components (Luck, 2005).  
1.4.3 Early auditory and visual evoked responses in psychiatric disorders: 
<100ms 
Early ERPs are considered a reflection of predominantly sensory processes in 
response to stimuli. Visually evoked waves are a type of early ERP, referred to as 
visual evoked potentials (VEPs) or visual evoked fields (VEFs). The early 
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responses P50, N1 and the P100 (P1) have been explored in psychiatric disorders 
and are briefly reviewed in this section.  
 
The P50 response is considered an index of sensory gating, a gating mechanism 
thought to prevent sensory overload. A typical sensory gating paradigm involves 
pairs of auditory clicks, often over a white noise background. The paired clicks 
appear approximately 500ms apart, eliciting a two-component P50, termed S1 and 
S2 (a peak for each click). In healthy individuals, the second component, S2, is 
significantly supressed compared to S1. Sensory suppression is measured as the 
amplitude of S2/S1, where lower values represent an increase in sensory gating 
(Cabranes et al., 2012). 
 
 A meta-analysis of 17 P50-gating studies in schizophrenia (Bramon, Rabe-
Hesketh, Sham, Murray, & Frangou, 2004; Cabranes et al., 2012; Horner, Ries, 
Krapcho, & Neyman, 2009; Kessler et al., 2003) demonstrated, in a sample of 359 
schizophrenics and 340 controls, that the P50 ratio in schizophrenia was 
significantly higher than in controls, with a pooled standard effect size (Cohen’s d) 
of -1.56 (p=<0.001), indicating less suppression (or sensory gating) in 
schizophrenia. They found no difference in latency and patients were taking 
antipsychotics. Furthermore, amplitude was not found to correlate with severity or 
duration of illness. For this reason, the authors conclude that the P50 gating deficit 
is a stable trait marker of schizophrenia.  
 
Cabranes et al (2012) recently demonstrated that the P50 gating deficit is also 
apparent in bipolar depressive disorders and exhibits different characteristics 
across bipolar types 1 and 2 (BP1, BP2). In their sample of 95 healthy controls, 
100 euthymic (i.e. medicated but stable) BP1 and 26 BP2, after controlling for 
confounding variables, BP1 showed a larger deficit in P50 gating compared to 
controls for S2/S1 (p<=0.001) than BP2 to controls (p=0.031). Furthermore, 
individuals with a history of psychosis demonstrated poorer sensory gating 
compared to controls than those without a history of psychosis (however with 
psychosis vs. without was not reported) and, within the BP2 group, number of 
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episodes of mania/ hypomania and depression were inversely correlated with 
S2/S1 ratio (p=<0.01 and 0.05 respectively) suggesting that P50 suppression is 
worse with an increasing number of episodes. 
 
The common finding of reduced P50 gating across schizophrenia, BP1 and BP2 
may indicate a common neurobiological deficit in the disorders. However, as noted 
by Cabranes et al (2012), the amplitude of the S1 response will also alter the 
S2/S1 ratio and this should be accounted for. In their study, BP2 had marginally 
higher S1 amplitude, which could account for the difference in S2/S1 ratio 
compared to BP1. However, besides it’s potential use as an endophenotype, an 
interesting question arises from these reports. Given suggestions from genetic 
literature that bipolar disorders 1 and 2, and schizophrenia may be seen as a 
continuum rather than distinct pathological entities (Craddock, O'Donovan, & 
Owen, 2006; Moller, 2003), a ‘disease-dependent’ increase in S2/S1 ratio across 
these disorders may add further support for a common pathophysiology. 
 
The P100 is elicited by any visual stimulus, irrespective of task. Furthermore, the 
magnitude of the response is dependent on specific properties of the stimulus, 
including luminance and contrast (Luck, 2005). The P1 VEP has been localised to 
extrastriate visual cortex (Di Russo, 2002) and middle occipital gyrus (Hall et al., 
2005) and is sensitive to visual stimuli. It has been associated with spatial attention 
and filtering of irrelevant stimuli.  
  
A reduction of P1 amplitude in schizophrenia and at-risk of schizophrenia 
individuals has been reported (Haenschel 2007) and this has been associated with 
working memory performance. Furthermore, the reduction in P1 amplitude in 
schizophrenia has been shown to persist regardless of medication, age, illness 
duration or severity and is not correlated with a specific clinical phenotype.  
 
A reduced P1 VEP amplitude has been demonstrated in euthymic bipolar disorder 
patients and participants with schizotypy (Yeap, Kelly, Reilly, Thakore, & Foxe, 
2009)  (Koychev, El-Deredy, Mukherjee, Haenschel, & Deakin, 2012). Further 
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investigation of the P1 amplitude in psychiatric disorder is warranted, particularly 
since some have suggested that the common P1 reduction across schizophrenia 
and bipolar disorder represents a common genetic liability (Yeap et al., 2009).  
1.4.4 Late Event related potentials in psychiatric disorders: the P300 
One of the most commonly used stimuli in evoking the P300 is an auditory or 
visual oddball paradigm. First reported by Squires, Squires and Hillyard (1975), 
employing a similar design to Sutton et al (1965), the odd-ball task involves 
interrupting strings of identical or matching (congruent) stimuli  with unpredictable, 
or incongruent stimuli. They found that unexpected changes in both lo udness and 
frequency of a string of sounds altered the magnitude of the P300 response. They 
further identified that instructing participants to either actively listen to the sounds, 
or ignore them, altered the waveform whereby ignored stimuli had a latency of 
220-280ms (referred to as P3a), whereas actively engaged stimuli evoked a larger -
magnitude wave with a 310-380ms latency (P3b). The authors suggest that the 
P3a is probability dependent but independent of task, while the P3b is both 
probability and task dependent.  
 
Subsequently, alterations of the amplitude, latency and topography of the P300 
have been demonstrated in schizophrenia (Morstyn et al., 1983), bipolar disorder 
(Souza et al., 1995), major depressive disorder (Diner, Holcomb, & Dykman, 
1985), generalised anxiety disorders (Boudarene, 1997), obsessive-compulsive 
and psychoses (Salisbury & Shenton, 1999), alcohol-related disorders (Cohen et al 
2006) and at-risk of psychosis and family-history groups (Fromman et al 2008). 
Authors have argued that the lack of specificity of the P300 response suggests that 
it may have little use in understanding particular psychiatric disorders, and may 
lack clinical utility as an aid to diagnosis or in monitoring treatment response 
(Singh, 2000). 
1.4.5 Common ERPs in depression 
In depression research, the P300 response is most regularly identified as having a 
reduced amplitude and longer latency than healthy controls, seemingly irrespective 
of the paradigm utilised (R Singh, 2000). Table 6, taken from Bruder et al (2009), 
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demonstrates P300 auditory odd-ball findings in depression with a clear trend 
toward depressed participants having lower P300 amplitudes. 
 
Singh et al (2000) demonstrated that the auditory odd-ball evoked P300 has a 
longer latency and lower amplitude in depression compared to non-depressed 
participants. They further demonstrated that this was absent in medicated 
depressives, that those >40 years old or with severe depression had significantly 
greater latency than those <40 years old or without severe depression, and that 
latency correlated with age and HRSD score while amplitude correlated negatively 
with age. However, the authors suggest that these findings are unlikely to serve as 
biological markers due to their lack of specificity and sensitivity to changes in 
disease state. 
 
Isintas et al (2012) attempted to elucidate the sensitivity of the P300 to treatment 
response in depression. Recording the P300 before and after 12 weeks of 50-
200mg sertraline (SSRI) in participants with and without depression, they found no 
difference in amplitude between responders, non-responders and controls before 
or after treatment. They did report significantly longer latencies in non-responders 
compared with responders and controls after treatment, suggesting that P300 
latency may be sensitive to antidepressant treatment, however this finding has not 
seen clinical use. Whether the P300 latency predicts response to other 
antidepressant treatments, and whether it is sensitive to treatment response in 
other disorders would help determine its efficacy as a biomarker.  
 
The above literature suggests that, while some ERPs are robustly elicited by 
specific stimuli, their utility in studying depression is somewhat equivocal. This is 
partially due to an imbalance in the scientific literature; the number of studies 
reporting alteration of ERPs in unipolar depression is far less than the number 
focussing on ERPs in bipolar disorder or schizophrenia. 
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1.4.6 Neuroimaging (MRI) & neurochemical imaging (PET, MRS) studies of 
depression 
Besides encephalographic studies of the depressed brain, magnetic resonance 
imaging (MRI) techniques have also been applied to study changes in the brain 
during depression.  
 
Early MRI studies of psychiatric disorder focussed on comparing structural 
measures. Since the invention of voxel based morphometry (Ashburner & Friston, 
2000), and Freesurfer mesh approaches (Fischl, Sereno, Tootell, & Dale, 1999), 
permitting easy segmentation of grey matter, this field has seen rapid growth. 
Numerous studies have reported altered structural findings in depression. 
Vythilingam (2004) and others reported equivocal results regarding hippocampal 
volume in depression despite depressed subjects exhibiting reduced performance 
during working memory paradigms. However, a more recent meta-analysis by 
Lorenzetti et al (2009) suggested robust volumetric reductions of the hippocampus, 
basal ganglia, orbital frontal cortex and subgenual prefrontal cortex. This study 
also demonstrated that gender, medication and severity and duration of illness 
affect volumetric measures, which may explain the discrepancy with some studies.  
 
The Lorenzetti study also highlights the amount of variability in grey matter 
measures, which could explain why structural measures are not regularly used as 
biomarkers in psychiatric disease. Some concordance in findings was reported in a 
series of studies which demonstrated increased amygdala volume in the early 
stages of depression (Lange & Irle, 2004, Frodl et al., 2002) but reductions in 
volume in later stages (multiple episodes) (Bremner et al., 2000, Caetano et al., 
2004, Hastings, Parsey, Oquendo, Arango, & Mann, 2004, Monkul et al., 2007). 
 
The negative-emotion bias observed in depressed subjects has been probed 
extensively using facial-expression recognition paradigms. These paradigms have 
been utilised in functional MRI (fMRI) studies with the objective of identifying 
localised changes in brain activity that occur during facial expression recognition in 
depressed subjects. Studies of face processing in depression have typically 
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reported alterations of amygdala, insula and ventral striatum activation (Kumar et 
al., 2013).  
 
In a study Fu and colleagues (2004), subjects with unipolar depression (and 
matched controls) were recruited to undergo a series of fMRI scans where they 
completed an affect recognition task discriminating between different intensities of 
sadness. The scans were completed at baseline and after 2 and 8 weeks into 
fluoxetine (fluoxetine hydrochloride, 20mg/day) treatment. This enabled both the 
identification of altered activation patterns in depressed subjects compared with 
healthy controls (correlates of the negative bias during the face task) and also 
measurement of any changes in this activation pattern induced by antidepressant 
treatment. The study demonstrated that, at baseline, patients demonstrated 
increased amplitude of the BOLD response to sad faces compared with healthy 
controls. Antidepressant treatment was associated with reduced limbic and 
subcortical capacity for activations in depressed subjects. Symptomatic 
improvement correlated with increased anterior cingulate activation, suggesting 
that the fMRI signal may be sensitive enough to serve as a marker of treatment 
response. Studies by Sheline et al (2001) and Keedwell et al (2009) have 
employed similar methodologies (fMRI, emotional face discrimination, 
antidepressant treatment). Sheline et al (2001) reported increased amygdala 
activation particularly to fearful faces in patients compared with healthy controls, 
which was decreased with antidepressant treatment. Keedwell et al (2009) 
reported that depression severity correlated with temporal changes in BOLD signal 
to sad stimuli in right visual cortex as well as subgenual cingulate and 
hippocampus. Decreases in symptom scores correlated with decreases in effec t 
size of response in right visual cortex and subgenual cingulate to sad faces. Taken 
together, these studies demonstrate that the BOLD response is altered in 
depression specifically to negative stimuli (sad or fearful faces) in both visual 
cortices and emotional regulation and discrimination associated areas in the limbic 
system (amygdala, hippocampus) and subgenual / anterior cingulate. These areas 
also change activation pattern with antidepressant treatment, suggesting fMRI is a 
powerful tool for monitoring treatment response. 
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Most studies have used event related experimental design in order to locate 
activations in a specific region in response to a task. However, recent studies have 
begun to explore functional connectivity using fMRI. These studies look at 
temporal correlation in the fluctuations of the BOLD signal in disparate regions of 
the brain. Using this approach, Anand et al (2005) demonstrated differences in 
cortico-limbic ‘activity’ and ‘connectivity’ between depressed patients and healthy 
controls. During a paradigm that involved viewing negative and neutral valence 
images, depressed subjects exhibited increased activation of cortical and limbic 
structures but decreased connectivity was observed between rostral-ACC and 
amygdala, rACC and dorsomedial thalamus and precuneus and caudate. Thus the 
patterns of activation typically described in fMRI experiments of depressed 
subjects are localised effects, with the BOLD signal exhibiting the opposite effect in 
the connections between regions regularly implicated in altered neural functioning 
in depressed subjects. 
1.4.7 Neurochemical imaging and toxicology (PET, MRS, blood plasma) 
While structural and functional MRI studies have demonstrated uti lity in localizing 
brain regions involved in specific tasks, and have evidenced sensitivity to drug 
manipulation suitable for response monitoring, the fMRI BOLD signal does not 
contain information regarding neurochemistry, and only contains indirect 
information on the neurophysiology underlying both the signal itself, and task 
induced alterations (inferred by other measures such as grey matter). To this end, 
positron emission tomography (PET) and magnetic resonance spectroscopy 
(MRS) have been employed to measure functional changes and bulk levels of 
specific chemicals in the brain, respectively. Since the efficacy of pharmacological 
therapy in mood disorders strongly suggests that neurochemistry is altered in 
psychiatric disorders, these approaches may be more suitable for probing the 
neurobiology of depression. 
 
The serotonin system is implicated in the pathophysiology of depression partially 
because pro-serotonin drugs (e.g. SSRI) alleviate depressive symptoms. In 
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particular the serotonin 1A receptor, 5HT-1A, is implicated in depression because 
depressed subjects display blunted responses to 5HT-1A agonists and because 
post-mortem studies have demonstrated reduced binding at the 5HT-1A receptor 
in the brains of those who died by suicide as compared with non-suicide. Drevets 
and colleagues (1999) used PET using the 5HT-1A radioligand [11C]WAY-100635 
to identify, spatially, where binding is altered in depressed subjects. Binding 
potentials were significantly reduced in depressed subjects in the raphe, 
hippocampus and amygdala, occipital cortex and post-central gyrus. This study 
confirmed that 5HT-1A receptor binding is altered in depressed subjects compared 
to controls in a range of brain regions including the amygdala and hippocampus, 
regions which have been repeated reported to show altered BOLD signal in 
depressed subjects. Unfortunately the sample consisted of both bipolar and 
unipolar (MDD) depressed subjects, and as such did not demonstrate reduced 
binding in an isolated MDD sample. A follow-up study by Sargent et al (2000) also 
demonstrated brain regions where 5HT-1A binding was reduced, and 
demonstrated that the medication status of the subjects does not affect binding 
potential, neither does SSRI usage. 
 
PET is a useful tool in probing neurobiological questions about depression, 
however it is limited by the availability of radioligands, which need to be specifically 
prepared and designed for experiments, are radioactive and have a very short 
decay time. Furthermore, PET is both expensive and invasive, making it unsuitable 
for many studies and as a biomarker. MRS however can be performed without the 
need for a tracer or radioligand (using 1H) and as such is less invasive and has no 
time limit. 
 
1H-MRS has been used to investigate the concentration of neurotransmitters in the 
brain. Because the technique relies on separate chemicals by their resonant 
frequency, the number of compounds that can be measured is directly proportional 
to the strength of the MRI magnet, however most scanners are capable of 
measuring several chemicals of interest to psychiatric research. Notably: choline, 
creatine, inositol, glucose, N-acetylaspartic acid (NAA) and alanine. Furthermore, 
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using difference-editing methods (see chapter 2) to suppress the resonances of 
specific chemicals permits measurement of neurotransmitters such as gamma-
aminobutyric acid (GABA) and glutamate and glutamine.  
 
An early study employing this technique demonstrated that choline (referenced to 
creatine) was elevated compared with matched controls (Binesh et al., 2004). 
Furthermore, NAA/Choline levels increased with successful pharmacotherapy, 
while choline/creatine levels decreased. Subsequent studies have investigated 
other compounds in similar experimental designs. A meta-analysis of MRS studies 
in MDD (Yildiz-Yesiloglu & Ankerst, 2006) demonstrated that, in adult MDD, 
patients typically exhibit higher levels of choline/creatine in the basal ganglia and 
reduced Glx (composite glutamate, glutamine and GABA) in frontal regions. This is 
in contrast with findings in bipolar disorder where Glx is increased (Yi ldiz-Yesiloglu 
& Ankerst, 2006). While MRS provides bulk measures, it can be used to 
investigate hypotheses about specific neurochemical differences or changes in the 
depressed brain. 
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Table 1. Summary of ERP findings in common psychiatric disease.
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Table 2: Taken from Bruder et al 2009. P300 findings in depression 
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1.5 Predictive coding and neuronal modelling 
 
Predictive coding describes the brain as a system, whose aim is minimise free 
energy. According to Friston and colleagues (2009a), minimising free energy is a 
requirement of all biological agents in order to survive (Friston, Thornton, & Clark, 
2012) and provides an account for perception and action. Minimising free energy 
equates to minimising surprise (entropy). Minimising surprise is achieved through 
changing perceptions, via sensations (the senses), which in turn, entails action 
(e.g. movement, saccades). This free energy principal of the brain is a formal 
assumption of predictive coding. 
 
A key challenge for the brain is to infer the causes of its sensations, an issue first 
formalised by Helmholtz (1909). How the brain does this is somewhat equivocal, 
however a key hypothesis is that the brain performs analysis by synthesis; that is, 
it constructs a generative, dynamic model (an internal model) of causes (the world) 
using a form of Bayesian inference, termed inverse-inference (Yuille & Kersten, 
2006). This generative model can be considered a hidden Markov model in that it 
aims to estimate hidden states, or causes, using a Bayesian approach. The 
Bayesian brain hypothesis is an example of perception as hypothesis testing 
(Gregory, 1980) whereby the internal model both predicts and explains sensations. 
This internal model constitutes priors, or hypotheses, about the incoming 
sensations, while incoming sensations constitute new data. The brain utilises these 
to perform a Bayesian inference (figures 1.5.1, 1.5.2) technique summarised 
graphically in figure 6.2. The aim, for the brain, is to calculate the most accurate 
posterior density, 𝑝(ℎ|𝑑), given a likelihood and prior; 
 
𝑃(ℎ|𝑑) ∝ 𝑝(𝑑 |ℎ) 𝑝(ℎ) 
(1) 
where ℎ  = the internal model hypothesis and 𝑑  = actual sensory data. In a 
Bayesian interpretation, the probability of the data given the hypothesis, 𝑝(𝑑|ℎ), 
forms the likelihood and the probability of the hypothesis, 𝑝(ℎ), forms the prior. The 
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posterior density updates the internal model (subsequent priors) thus suppressing 
prediction error. This is the basis of predictive coding schemes (Rao & Ballard, 
1999). Prediction error can be expressed numerically either as the difference 
between input signal and hypothesis signal, or as the distance between the 
posterior density and prior distributions, i llustrated in figure 1.5.2. Predictive coding 
is a consequence, rather than cause, of surprise minimisation. Free energy is a 
bound on surprise, where prediction error is a neurobiologically computed measure 
of free energy. Free energy is, formally, expected energy minus the entropy of 
predictions (Friston & Stephan, 2007; Friston, Kilner, & Harrison, 2006). 
 
𝐹𝑚𝑎𝑥 = 𝑙𝑛 (𝑝(𝑑|ℎ) −  𝐷(𝑞(𝜃)||𝑝(𝜃|𝑑, ℎ)) 
𝐹𝑚𝑎𝑥 = log 𝑚𝑜𝑑𝑒𝑙 𝑒𝑣𝑖𝑑𝑒𝑐𝑒 − 𝑑𝑖𝑣𝑒𝑟𝑔𝑒𝑛𝑐𝑒 
(2) 
where Fmax is maximal free energy, d = data, h = model (or hypothesis), D = 
Kullback–Leibler divergence between true and approximate posterior, and q(θ) is 
the conditional density.  
 
In a recent discussion article, some authors have questioned the assumptions of 
predictive coding under the free energy principal; see ‘the dark room problem’, 
Friston et al (2012), suggesting that, if the objective were to minimise free energy 
by minimising surprise, agents would simply find a secure, highly predictable 
location and stay there indefinitely. Contradictory to this, animals tend to explore, 
seeking new sensations (Fiorillo, 2010). This issue has subsequently been 
formalised and labelled the dark-room problem (Friston et al., 2012). The answer 
to this issue is somewhat multifarious. Firstly, entropy (average surprise) is a 
function of both sensations and the internal model, 𝐻(𝑠|𝑚), whereas the entropy 
minimised by the dark-room is a function only of sensations  𝐻(𝑠) (Friston et al., 
2012). Second, it is suggested that prior beliefs make dark rooms surprising; 
agents whose model does not consist of priors that make dark rooms surprising 
stay there indefinitely unti l death; thus natural selection dictates this will not 
happen. 
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Figure 1.5.2. Bayesian inference method utilised by the brain to evaluate and update predictions. h 
= hypothesis about the input / the internal model prediction. d = data / sensation input. The 
posterior density updates the internal model (prior) thereby minimising subsequent prediction error.  
 
1.5.1. Biological evidence and plausibility of predictive coding under the free 
energy principal: canonical microcircuits. 
Predictive coding under the free energy principal requires message passing 
throughout the brain. This section will focus on how the hierarchical nature of 
cortical architecture and neurobiology supports predictive coding. While the aim of 
this section is not to fully reiterate the review in section 1.3, some elements are 
reframed. 
 
As described in section 1.3, the neuronal populations and their laminar distribution 
and connectivity in the visual cortex are well documented. Furthermore, this 
microcircuit architecture is predominantly the same across the cortical sheet, with 
only subtle differences, which are presumably required specifically for local 
computation specialities (e.g. the primary visual cortex may have slightly different 
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local computational needs to the primary motor cortex). Despite this, the concept 
of a canonical (general) microcircuit has garnered support. Douglas & Martin’s 
work on the cat visual system first documented the concept of a distinct 
microcircuit. Their model entailed 3 neuronal populations; superficial and deep 
pyramidal cells and inhibitory interneurons. They proposed all assemblies were 
fully interconnected and functioned to amplify thalamic inputs to (in this case) V1 
(Douglas & Martin, 1991). While the architectural and functional anatomy of the 
cortical sheet is now understood to be slightly more complex than initially 
suggested, the concept of a relatively generic cortical microcircuit is sti ll accepted. 
Figure 1.5.3 i llustrates both the Douglas & Martin, and the more recently described 
Bastos microcircuits (Bastos et al., 2012; Douglas & Martin, 1991). 
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Figure 1.5.3. Left: Douglas & Martin microcircuit of V1 in the cat. Three neuronal populations: superficial and deep pyramidal cells and bipolar 
inhibitory interneurons. Red connections are inhibitory and black excitatory. Right: Human canonical microcircuit arising from Bastos literature review, 
features additional layer 4 ‘granular’ layer of spiny stellates and interneurons coupled to principal neurons in each layer (based on the density of 
pyramidal cells to inhibitory interneurons, it is more likely that the inhibitory cells are not coupled to principals, but rather fewer are better connected 
across the layers). 
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Feedforward, feedback and lateral connections, which predominantly originate and 
terminate in supragranular to granular, infragranular to supra- or infra-granular, 
and any-layer to the-same-layer, respectively (Purves, 2008), has been interpreted 
in terms of a predictive coding infrastructure (Friston, 2005). Feedforward and 
feedback connections are typically excitatory pyramidal projections, which use 
glutamate and GABA to signal via ionotropic AMPA and GABAA receptors. Lateral 
connections are modulatory and slower, hence utilising glutamate via voltage-
gated NMDA and metabotropic receptors (Friston, 2005).  
 
Within the functional architecture a distinction is made between intrinsic and 
extrinsic connectivity. Intrinsic connectivity refers to within the microcircuit, 
whereas extrinsic refers to between-microcircuit connectivity. The Bastos 
microcircuit is re-illustrated with these connections labelled in figure 1.5.4 where 
forward connections enter the microcircuit at layer 4, are excitatory projections and 
contain sensory data or convey prediction error. For example, in V1, the forward 
connection might be the LGN afferent to layer 4 of V1. Within the microcircuit, 
(intrinsic) feedforward connections are unequi vocally excitatory and convey 
prediction errors (figure 6.5). Feedback connections convey predictions (based on 
priors) and are less well understood since evidence suggests that these feature 
both excitatory and inhibitory connectivity, with an overall effect of being inhibitory 
(Bastos et al., 2012).  Backward connections carry priors (predictions) from other 
circuits, which enter via both superficial and deep layers and can therefore 
modulate both predictions and prediction errors (figures 1.5.5, 1.5.6)
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Figure 1.5.4. Bastos’ microcircuit with labelled connectivity. Adapted from (Bastos et al., 2012)
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Figure 1.5.5. Illustrating the direction of predictions and prediction error across the cortical microcircuit. Hypotheses (predictions based on priors) are 
conveyed by the black arrows (feedback connections), illustrating a supra -granular origin while prediction errors  (red) are passed by feedforward 
connections. 
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Figure 1.5.6. Illustrating extrinsic, between-circuit message passing. Amended from (Friston & Kiebel, 2009b) 
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While predictive coding remains a largely theoretical entity due to the difficultly in 
empirically investigating the underlying neuronal mechanisms hosting such as 
phenomenon, some authors have suggested that predictive coding explains (or is 
implemented via) measurable cortical dynamics. 
 
Since the crux of predictive coding is that top-down predictions are compared with 
bottom-up signals, which result in a prediction error signal, message passing may 
utilise different frequencies (Arnal & Giraud, 2012). Recent work has provided 
support for microcircuits as a means of local computation, by demonstrating that 
superficial layers of visual cortex oscillate at higher (γ, >30Hz) frequencies than 
deep layers, which oscillate at predominantly β frequencies (figure 1.5.7) (Xing et 
al., 2012). Pinotsis et al suggest that this indicates forward connections use γ -
frequencies whereas backward connections use β-frequencies (Bosman et al., 
2012), which results in a ‘spectral asymmetry’. Given the common afferent, this 
‘synthesis and segregation’ of forward and backward connections is best explained 
by local, non-linear neuronal computations (canonical microcircuits). Furthermore, 
it suggests that γ-frequency oscillations are a marker of superficial pyramidal cell 
(population) encoded prediction error, whereas β-oscillations reference deep 
pyramidal cell encoded predictions (priors). 
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Figure 1.5.7. Spectral asymmetry of pyramidal cells within the same cortical column but in superficial vs. deep layers. Left image depict s laminar 
distribution of gamma-frequency band power obtained via LFP recording in V1 of Macaque viewing a grating pattern; adapted from Xing (2012).   
Right image illustrates main laminar architectural contribution to scalp recorded LFP. 
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1.5.2. Dynamic Causal Modelling.   
The previous section provided an overview of how connectivity between neuronal 
populations, arranged into microcircuits, could host a phenomenon such as 
predictive coding. Dynamic causal modelling is a framework, which utilises these 
concepts to enable a computational estimation of population connectivity 
parameters (cf. effective connectivity, reviewed in Friston, 2011) in said 
microcircuits based on MEG spectra. 
 
Dynamic causal modelling (DCM) permits in-vivo assays of microcircuitry by 
harnessing the concept of the brain as a generative, Bayes-optimal Helmholtz 
machine. Computational techniques such as neural mass modelling and mean 
field models allow synthesis and measurement of the dynamics of large neuronal 
populations. DCM utilises this computational approach as a surrogate generative 
model. If the neuronal population dynamics of the DCM generative model match 
those of the brain, the resulting spectra from the two should match (empirical 
spectra obtained from the brain using a neurophysiological technique such as 
MEG). This procedure is depicted in figure 1.5.8. 
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Figure 1.5.8 Model overview. The MEG power spectrum is compared to the model (NMM) using a Bayesian inversion methodology, which updates 
the (generative) model parameters. 
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The populations modelled feature between-population, intrinsic microcircuit 
connections based on known anatomy, the strengths of which are estimated by the 
modelling procedure (inversion). The populations are modelled using sets of first -
order differential equations. DCM implements a variational Bayesian scheme 
(variational Laplace) to approximate the posterior density (see figures 1.5.2, 1.5.8) 
of the model parameters by maximising the negative free energy (Friston & 
Stephan, 2007). Further model specifics and modelling methodologies are 
provided in chapter 6. 
 
1.6 Aims & Hypotheses 
This thesis aims to explore the neurochemical hypotheses of depression presented 
in section 1.3, using multimodal neuroimaging, including the theories described in 
section 1.4.  
 
Alterations of the GABAergic and glutamatergic neurotransmitter systems have 
been reported in major depressive disorder (MDD), both post-mortem in-vitro and 
ante-mortem in-vivo. Evidence from magnetic resonance spectroscopy (MRS) 
studies reported lower bulk concentrations of GABA in currently depressed 
participants as compared with healthy controls, which may reflect a neurobiological 
pathology, serve as a biomarker, and guide development of new pharmacological 
therapies.  
 
If this area of research is to see translation to a clinical setting, the roles of GABA 
(and glutamate) in depression need to be more fully elucidated. This thesis 
addresses the following questions: do alterations in GABA concentration reflect 
state or trait markers of depression? Does the GABA deficit observed in 
depression reflect ‘functional’ GABA? Can computational modelling of cortical 
neurobiology add disease-relevant sensitivity to primary imaging measures? Does 
an existing pharmacological compound with antidepressant efficacy act on the 
GABA system? These questions are approached using multimodal neuroimaging 
techniques, computational neuronal modelling and pharmacological manipulation. 
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Chapter 2. Methods 
 
Study of the previously described event-related responses and neurochemistry in-
vivo requires a multimodal approach utilising neuroimaging, spectroscopy and 
neurophysiological techniques. These include magnetic resonance imaging (MRI), 
magnetic resonance spectroscopy (MRS) and magnetoencephalography (MEG). 
The general approach of the experiments in this thesis, in brief, is to use MRI to 
construct a high-resolution 3D image of the brain. This allows accurate placing of 
the MRS voxel, which contains data on the chemicals present, as well as forming a 
template upon which to project the purely functional MEG data. These techniques, 
along with methodological issues pertinent to this thesis, are introduced. 
Experiment-specific methodological particulars are detailed in the corresponding 
experimental chapters. 
 
2.1 Magnetoencephalography (MEG)  
MEG records magnetic fields arising from the brain. MEG has exce llent temporal 
resolution (greater than 1 sample per millisecond) making it ideal for measuring 
brain function, while also having good spatial resolution compared with similar non-
invasive electrophysiological techniques (Hari, Hamalainen, Ilmoniemi, & 
Lounasmaa, 1991). 
2.1.1 MEG Signal & Hardware 
Neuronal function requires communication between huge numbers of neurons, 
termed neuronal populations. Both within and between population communication 
occurs via neurotransmitters, whose ultimate purpose is to depolarise (or 
repolarise) surrounding cells. A by-product of this is an electric current, which is 
either excitatory or inhibitory depending on the cells present (and synapse type 
and neurotransmitters present). These currents are referred to as either excitatory- 
or inhibitory- postsynaptic currents (EPSC, IPSC). When a number of these 
currents occur in parallel (spatially, for example within a population), a weighted 
portions’ summation can be measured by EEG electrodes outside the scalp. The 
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neurons whose summed currents are actually detected is not equal and depends 
on the size, orientation and cortical layer in which they reside, which affects the 
field shape and is termed the lead field (Cuffin & Cohen, 1979). Furthermore, 
because electrical currents exhibit a magnetic field perpendicular to the direction of 
the current, given a large enough current (or sensitive enough measure) the 
magnetic field can also be measured outside the scalp (Baillet, Mosher, & Leahy, 
2001; Hari & Salmelin, 2012; Hillebrand & Barnes, 2005; K. Singh, 2006) , 
illustrated in figure 2.1. 
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Figure 2.1. Overview of MEG signal generation. Adapted from Singh (2006) and Muthukumaraswamy (2014).
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The MEG array comprises several super-conducting quantum interference devices 
(SQUIDS). Modern MEG systems have ~200-300 SQUIDS, which are made from 
superconducting material and resemble a ring with a section missing (a junction). 
These are kept at 4.2°K by immersing the array in liquid helium (inside the plastic 
head shape, the MEG dewar). At this temperature the SQUIDS are 
superconducting and allow current to flow across the junctions – this current is 
modulated by the external magnetic field threading the loop (i.e. a portion of the 
scalp recorded magnetic field). Modern MEG systems further utilise inductive 
coupling and pickup-coils (also superconducting) to amplify and direct the 
magnetic field to the SQUIDS (Robinson & Vrba, 1999; Vrba, 2001). Gradiometers 
(oppositely wound coils) are used as pick-up coils as this makes the SQUIDS more 
sensitive to specific gradients, and can thereby ‘tune’  them more towards known 
neuronal locations (the head), thus increasing sensitivity and decreasing 
environmental noise. Housing the MEG in a magnetically shielded room provides 
further noise isolation. While a full review of MEG hardware and physics is outside 
there remit of this thesis, the reader is directed to the works of Hari and 
Hamalainen, in particular, one of the first comprehensive reviews of MEG physics 
and methodologies, see Hamalainen et al., (1993). 
2.1.2 MEG Signal Analysis 
Once data collected by the SQUID array is converted to raw digital amplitudes, a 
number of steps are taken to make the data useful. For studies which aim to 
source-localise, that is, to estimate where signals came from in 3D space rather 
than the 2D distribution of the array, the predominant issues are the forward and 
inverse problems. If the position, orientation and magnitude of a neuronal current 
‘source’ is known, then calculating what would be recorded at each SQUID site is 
possible, and referred to as the forward problem. Solving this problem requires a 
conductivity model of the head. However, source-localisation also requires ‘solving’ 
the inverse problem. The inverse problem refers to localising a current-source (in 
3D space) given an externally measured magnetic field (outside the head) without 
knowing the whereabouts of the source. As such, possible solutions (source 
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current distributions) have to be constrained based on apriori knowledge (Hari & 
Salmelin, 2012; Hillebrand & Barnes, 2005; Vrba, 2001).  
 
There are numerous approaches to solving the inverse problem, which rest on 
different assumptions about the brain sources (different apriori assumptions). 
These include dipole fitting procedures such as equivalent current dipole (ECD), 
multiple equivalent current dipole and dipolar scanning approaches. The analysis 
approach utilised throughout this thesis is that of beamforming (de Graaf, 2008; 
Vrba, 2001). Beamforming is a mathematical procedure, which, using data from 
the real sensors, allows synthetic placement of a virtual sensor over an exact 
region of interest and the production of synthetic data. The beamformer used 
throughout this thesis is the synthetic-aperture magnetometry (SAM) beamformer 
(Vrba, 2001),  which is done by weighting the contribution each physical sensor 
can make to a virtual sensor using a covariance matric of sensor covariances, 
resulting in a set of weights – this procedure is i llustrated in figure 2.3. Weights are 
calculated based on the covariance among sensors. As with all inverse problem 
solutions, beamforming makes some assumptions about the data – in the case of 
SAM, these assumptions are that the observed data are generated by discrete 
dipolar sources and that the time-series of these sources are not correlated. As 
such, beamformer analysis is not appropriate for analysis of paradigms that are 
known to evoke responses from temporally correlated discrete sources.  
 
The SAM beamforming approach is not spatially constrained further than an 
approximation to the shape and conductance of the head, which is done by co-
registering a 3D volume, obtained from a T1 anatomical MRI, to specific locations 
in the sensor array. The result of limited special constraints is the generation of 
weights for every possible set of dipoles (source) in the source-space (brain 
space) at a set resolution (in this thesis, 4mm) (Hari et al., 1991; Robinson & Vrba, 
1999; Vrba, 2001). Despite solving the forward problem for the entire brain space, 
typically only very few discrete virtual sensors are of interest in analysing the data. 
From a given virtual sensor, data is typically subjected to a spectral estimation 
such as the Fourier transform, or a parametric equivalent. An alternate method for 
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reconstructing time-frequency is to use the Hilbert transform, an amplitude 
envelope fitting procedure (figure 2.4). The resulting time – frequency – amplitude 
data can be used to test experimental hypotheses. The specific parameters used 
in time-frequency estimation and subsequent analyses differ between experiments 
and are therefore described in experimental chapters. 
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Figure 2.3. Based on that in Baillet et al (2001; 2012). Possible sensor contributions to the virtual electrode are weighted to optimise spatial 
sensitivity.
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Another important consideration of MEG data analysis is whether the experimental 
paradigm produces evoked or induced responses. Both experimental designs tend 
to be trials based, that is, they involve repeating the same stimulus or task 
numerous times and averaging the signal over all the trials. Evoked responses are 
phase-locked to the stimulus onset. When all the trials (waves) are analysed, the 
peaks and troughs line up during averaging (figure 2.2). This type of evoked 
analysis is referred to as event-related field (ERF) analysis (or event-related 
potentials, ERP, in the case of EEG). Alternatively, some responses are not 
phase-locked and therefore simply averaging the ‘waves’ can f latten out the peaks 
and troughs (figure 2.2). These responses are, however, time-locked to the 
stimulus. For these responses, frequency or time-frequency estimation is required, 
permitting analysis of the amount of power within a certain bandwidth prior to 
averaging. These responses are referred to as induced with increases in power 
termed event-related synchronisation (ERS) and decreased power termed event-
related desynchronisation (ERD) (Baillet et al., 2001; Pfurtscheller et al., 1999; 
Singh, 2006).  
 
 
Figure 2.2. Evoked vs. induced responses. Simple t rial averaging of induced responses can ‘flatten’ 
any stimulus-evoked response. 
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Figure 2.4. Demonstrating the Hilbert transform ‘envelope’ as the procedure of fitting a line across 
the positive amplitude peaks. 
2.2 Magnetic-resonance Imaging and Spectroscopy  
2.2.1 MRI Signal & Hardware 
The core principal of Magnetic Resonance Imaging (MRI) is that it utilises a strong, 
uniform magnetic field along with radio-frequency pulses to manipulate the 
alignment and spin of hydrogen atoms. As such, the hardware comprising an MRI 
scanner includes a large magnet (static magnetic field, B0), gradient coils for 
producing gradients in field B0, and radio-frequency transmit- and receive-coils 
(field B1) for rotating the magnetisation. The MRI scanner used throughout the 
experiments in this thesis is a 3 Tesla, GE Signa HDx, located at Cardiff University 
Brain Research Imaging Centre. While a brief introduction is provided, a full review 
of MRI physics is outside the scope of this thesis. 
 
Both MRI and magnetic resonance spectroscopy (MRS) are nuclear magnetic 
resonance (NMR) techniques, relying on the concepts of magnetic resonance and 
chemical shift. Protons possess a positive charge and spin on an axis, producing a 
small electrical current and accompanying magnetic field. While the spin 
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orientations of protons are somewhat arbitrary, when placed in an external 
magnetic field, many of these spins are aligned in direction (or 180° from) of the 
applied magnetic field (magnetic moment). Application of a radio-frequency (RF) 
pulse disrupts this moment, changing the orientation of protons. Post RF pulse, 
protons re-align to the direction of the external field, emitting energy as they do. 
The strength of this signal is dependent on the number of nuclei affected by the 
process.  
 
The most common implementation of MRS is 1H-MRS (proton or hydrogen MRS). 
MRS utilises the same notion of proton resonance as MRI, but to obtain data on 
the neurochemicals instead of structure. Hydrogen nuclear spins resonate at 
different frequencies depending on chemical environment. Since a chemical’s 
resonant frequency (chemical shift) is static, MRS protocols can be developed to 
target parts of the spectrum that these chemicals occupy (de Graaf, 2008; 
Mescher, Merkle, Kirsch, Garwood, & Gruetter, 1998). An example MRS spectrum 
is displayed in figure 2.5a. MRS spectra display the chemical resonance spectrum 
(x axis) in parts-per-million of the proton frequency (ppm) against chemical shift, so 
that resonances are stable across field strengths. The y-axis as signal intensity 
(corresponding to proportional metabolite concentration) (Puts & Edden, 2012). 
Due to individual differences, MRS neurochemical data are usually reported with 
reference to a reference chemical; most often water or creatine, since these are 
stable over time and easy to distinguish in the spectrum.  
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Figure 2.5. (a) a representative MRS spectrum. (b) Illustrat ion of the problem of separation of 
chemicals, which have overlapping resonance at normal scanner magnet strengths. Taken from 
Puts (Edden, Puts, Harris, Barker, & Evans, 2013; N. Puts & Edden, 2012). 
2.2.2 MRS Signal & Analysis 
One of the main issues with MRS for neuroscience is that of multiplets. Multiplets 
occur because the neurochemicals of interest (e.g. GABA, glutamate, glutamine) 
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have overlapping spectra because of their similar structure. Furthermore, each 
chemical may contribute to multiple peaks. For example, GABA contains three 
methylene groups (figure 2.6), which correspond to three peaks in the MRS 
spectra (figure 2.5a/b). These peaks also happen to be overlapped by different, 
more abundant molecules (Cr at 3ppm, glutamine and glutamate at 2.3ppm and N- 
acetyl aspartate at 1.9/2ppm).  
 
To overcome this overlap in the resonant frequencies, a spectral editing technique 
referred to as ‘difference editing’ is employed. The most widely used method, and 
that used in the experiments of this thesis, is a J-difference sequence, MEGA-
PRESS (Fava & Team, 2006; Mescher et al., 1998). 
 
Figure 2.6. Illustrating the chemical similarities of GABA and glutamate, which are both structurally 
and metabolically, linked. 
 
The GABA peak observed at 3ppm is coupled to that at 1.9ppm. The chemicals 
that overlap the 3ppm GABA signal, however, are not coupled to the 1.9ppm peak. 
Thus, a frequency-selective pulse targeting 1.9ppm will also affect the (GABA) 
coupled 3ppm signal. Difference editing involves obtaining spectra both with and 
without this frequency selective pulse. Subtracting one from the other results in 
difference-spectra, which contains only signals at 1.9ppm and signals that appear 
due to coupling (N. Puts & Edden, 2012). The resulting 3ppm GABA peak is still 
contaminated by homocarnisine and macro-molecular content, and as such is 
referred to as ‘GABA+’ (Edden et al., 2013), but is the closest to GABA currently 
possible.  
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Chapter 3. Visually evoked and induced oscillatory dynamics and 
neurochemistry in Remitted Depression 
 
3.1. Abstract 
Magnetic resonance spectroscopy studies have consistently demonstrated 
reduced cortical γ-aminobutyric acid (GABA) concentrations in individuals with 
major depression. However, evidence for a persistent deficit during remission, 
which would suggest that GABA dysfunction is a possible trait marker of 
depression, is equivocal. Although MRS measures total concentration of GABA, 
magnetoencephalography provides direct measures of neural activity, with cortical 
γ oscillations shaped by the activity of GABAergic inhibitory interneurons. In this 
study we investigated whether γ oscillations and GABA concentrations would differ 
in individuals with remitted depression (RD) compared with never depressed 
control subjects (ND) 
Thirty-seven healthy, unmedicated female volunteers (n = 19 RD, and n = 18 ND) 
were recruited. The γ oscillation frequencies and amplitudes in the visual cortex, 
induced by simple grating stimuli, were quantified with time-frequency analyses. 
Distinct GABA/glutamate + glutamine MRS peaks were resolved from MEGA-
PRESS difference spectra in prefrontal, occipital, and subcortical volumes. The RD 
and ND individuals did not differ in the frequency of subclinical depressive 
symptoms. The ND were slightly older (mean 23 years vs. 21 years), but age did 
not correlate with dependent measures.  
 
There were no group differences in GABA levels or induced cortical γ measures. 
RD individuals had markedly reduced M80 (C1) components of the pattern-onset 
evoked response (46% reduction, Cohen’s d = 1.01, p = .006). Furthermore, limbic 
GABA concentrations correlate negatively with hedonic tone in RD but not HC. 
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3.2 Background 
Major depressive disorder is a chronic, relapsing condition with a kindling of 
depression vulnerability and severity over time. Antidepressant treatments acting 
primarily on the monoamine systems are not universally effective: and incomplete 
recovery increases the likelihood of recurrence. Our understanding of the 
neurochemical basis of MDD is still limited (Fava & Team, 2006; Hasler et al., 
2007). Recent work reinforces the need for alternative or adjunctive 
pharmacological intervention that targets other neurochemical pathways.  
 
In particular, gamma-amino-butyric acid (GABA), an inhibitory neurotransmitter, is 
increasingly implicated in the pathophysiology of major depressive disorder (MDD) 
(Alcaro, Panksepp, Witczak, Hayes, & Northoff, 2010; Kalueff & Nutt, 2007; 
Krishnan & Nestler, 2008; Luscher et al., 2010; Sanacora et al., 2003) . Several 
magnetic resonance spectroscopy (MRS) studies have measured cortical GABA 
levels during acute depressive illness:  decreases of up to 40% have been 
reported in the occipital cortex (Croarkin et al., 2011; Hasler & Northoff, 2011; 
Sanacora et al., 1999), with greater reductions in more melancholic forms 
(Bhagwagar et al., 2007; Hasler et al., 2007). Antidepressant treatments, including 
selective serotonin re-uptake inhibitors (Bhagwagar et al., 2008; Sanacora et al., 
2003) and electroconvulsive therapy (Hasler et al., 2005; 2011), but not cognitive 
behavioural therapy (Bhagwagar et al., 2007), have been shown to increase 
cortical GABA levels in depressed subjects. 
 
While there is some support for altered GABA function in acute MDD, the issue of 
whether reduced cortical or subcortical GABA levels represent state or trait 
markers of MDD remains unresolved. MRS evidence is limited and conflicting on 
the presence of GABA dysfunction in remitted MDD. While Bhagwagar et al (2008) 
found that GABA levels in occipital cortex were approximately 10% lower than in 
healthy controls, Hasler et al (2005) found normal GABA levels in the prefrontal 
cortex compared to never-depressed individuals.  
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Neither study estimated GABA concentration in subcortical regions.  This is in spite 
of a wealth of evidence demonstrating abnormal subcortical GABA function in 
animal models of depression (Kalueff & Nutt, 2007), the functional imaging 
literature in MDD (Drevets, 2003; Phillips et al., 2003) and a small study of 
[(11)C]flumazenil binding in MDD (Klumpers et al., 2009). Investigations of GABA 
levels in the subcortical regions of MDD individuals and their relatives are therefore 
warranted.  
 
While MRS-GABA concentration is presumed to have an impact on brain function 
it does not distinguish between physiologically active and inactive GABA 
compartments. Furthermore, GABA function could be disturbed at the postsynaptic 
level in the absence of presynaptic changes in production or release. Additionally, 
MRS GABA is a combination of GABA and macromolecules. As such MRS GABA 
should be designated ‘GABA+’ (N. Puts & Edden, 2012). 
 
As described in section 1.4, cortical gamma oscillations, as measured by EEG or 
MEG, are thought to reflect patterns of change in the local field potential arising 
from an interaction of fast-spiking GABA-mediated interneurons with pyramidal 
neurons (Brunel, 2003; Spencer, 2009). These rapid oscillations increase during 
the efficient performance of a task. This reflects the role of the interneurons in 
coordinating the firing of relevant pyramidal cells in task-specific cortical regions, 
through the inhibition of non-task-related local activity and inhibition of inputs from 
extraneous networks. Their putative involvement in high-order cognitive function 
and perception (Adjamian et al., 2004; L. M. Ward, 2003) has led to a keen interest 
in their role in psychiatric disorders, where such functions are impaired. Using EEG 
and MEG, previous studies have identified abnormal in gamma band responses in 
the visual and auditory system of both schizophrenia and bipolar patients (Ethridge 
et al., 2012; Özerdem, Güntekin, Saatçi, Tunca, & Başar, 2010; Spencer, 2011) , 
and abnormal gamma power in response to emotional stimuli in bipolar and 
unipolar disorders (Liu et al., 2012).  
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Previous work has demonstrated that gamma oscillations are reliably induced in 
the primary visual cortex by repeated to exposure to a simple visual grating image 
(Muthukumaraswamy et al., 2009). The frequency of these oscillations (the 
induced gamma frequency, IGF) is highly stable within individuals 
(Muthukumaraswamy et al., 2010), tends to correlate negatively with age across 
individuals, and demonstrates high heritability in twins (van Pelt et al., 2012). 
Furthermore, correlations have been demonstrated between IGF, occipital MRS 
GABA+ measures and BOLD responses to the same visual stimulus in healthy 
volunteers (Muthukumaraswamy et al., 2009).  Hence, in healthy volunteers, MRS 
measures of GABA+ concentration translate to functional changes in the post -
synaptic actions of interneurons in the cortex. The same might not be true of 
individuals predisposed to depression if independent pathologies exist at the 
synapse level, as opposed to synthesis level, of GABA function.  
3.3 Experiment: Peak γ-frequency and GABA measures in remitted 
depressed subjects compared with healthy controls 
3.3.1 Rationale 
The aim of this study was to test the hypothesis that individuals with remitted 
depression (RD) differ from never depressed controls (ND) in IGF in the occipital 
cortex, and in MRS-GABA+ in cortical (occipital and prefrontal) and subcortical 
regions.  
3.3.2 Methods 
Recruitment and sample 
Thirty seven healthy female volunteers were recruited through the Cardiff 
University School of Psychology Experiment Management System, a web-based 
recruitment facility accessed by undergraduates and staff of Cardiff University, an 
approved advert in the local Press and an through the University’s electronic 
noticeboard. The School of Psychology ethics committee, at Cardiff University, 
approved the study. All individuals gave their informed consent to participate. 
Inclusion criteria included female gender, age 18-35, normal or corrected-to-
normal vision and current good health. For the RD cohort (n=19) a previous history 
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of depression was determined using an adapted version of the MINI structured 
interview (Sheehan et al., 1998; Watson et al., 1995). 
 
Exclusion criteria for all participants included current or previous psychiatric 
disorder, determined using the MINI, (depression excepted in the RD group), 
current use of psychotropic medication, dyslexia, contra-indications to MRI, 
organic brain disease and drug or alcohol dependence (determined by the MINI). 
For RD individuals additional information about number of previous episodes, 
treatments, admissions, symptom severity and self-harm was recorded in order to 
determine a lifetime severity score based on the Bipolar Affective Disorder 
Dimensional Scale, version 3.0 (BADDS 3.0; Buckby, Yung, Cosgrave, & 
Killackey, 2007; Craddock, Jones, Kirov, & Jones, 2004). Those individuals 
reporting a history of depression secondary to some other axis 1 disorder 
(anorexia, psychosis, bipolar, drug or alcohol misuse), organic condition or 
medication were identified by systematic interview and excluded. 
 
Healthy controls were excluded if they had a first degree family history of MDD of 
bipolar depression, as determined using the Research Diagnostic Criteria, Family 
History Method (Andreasen, Endicott, Spitzer, & Winokur, 1977; Bredemeier et al., 
2010). Using the RDC Method the first degree relatives must have experienced, in 
addition to at least 2 weeks of core depression symptoms, (a) suicidal behaviour, 
(b) gross impairment of work, housework, school attainment or social withdrawal, 
(c) ECT (electro-convulsive therapy) or antidepressant medication, or (d) 
admission to a psychiatric ward. All participants completed a measure of 
subclinical depressive symptoms in the form of the Mood and Anxiety Symptoms 
Questionnaire (MASQ) (Watson et al., 1995), which has clinical uti lity in young 
help-seekers (Buckby et al., 2007) and has been employed to screen for 
depressive disorders. 
 
MEG recording and analysis 
During the MEG sessions participants completed a slightly modified version of an 
established paradigm (Muthukumaraswamy et al., 2009), lasting approximately 8 
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minutes. One hundred and fifty identical visual stimuli were presented on a on a 
Mitsubishi Diamond Pro 2070 monitor (1,024 × 768 pixels and 100Hz frame rate). 
Optimised to induce gamma responses in the right primary visual cortex, they 
consisted of circular, vertical, stationary, maximum-contrast, 3 cycles per degree 
gratings, presented in the lower left visual field on a mean luminance background, 
subtended 4° both horizontally and vertically, with the upper right corner of the 
stimulus located 0.5” horizontally and vertically from a small red fixation point 
(figure 3.1). Participants were instructed to maintain fixation for the entire 
experiment and, to maintain attention, were instructed to press a response key as 
fast as possible at the termination of each stimulation period. The duration of each 
stimulus was 0.8–2.3s (mean duration 1.55s) followed by 1.5s of the fixation point 
only.  
 
 
 
Figure 3.1. 100% contrast, 4 degrees, annular grating paradigm. Button pressed at grating offset.  
 
MEG recordings were made using a 275-channel whole head MEG system in a 
magnetically shielded room. 29 reference channels were also recorded for noise-
cancellation purposes and the primary sensors were analysed as synthetic third-
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order gradiometers (Vrba, 2001). Three of the 275 channels were turned off due to 
excessive sensor noise. Before MEG recording, participants were fitted with three 
electromagnetic head coils at the two pre-auricular points and nasion. These 
fiduciary markers were located at specific points to the participant’s anatomical 
MRI scan to enable MEG and MRI co-registration. 
 
Offline, each dataset was band-pass-filtered using a fourth-order bidirectional IIR 
Butterworth filter into the following four frequency bands: 0 to 20 Hz, 20-40Hz, 40 
to 60 Hz and 60-80Hz (Muthukumaraswamy & Singh, 2008). Beamformer analysis 
using Synthetic Aperture Magnetometry (SAM) was used to localise gamma power 
changes in the occipital cortex between baseline (-0.8 to 0s) and visual stimulation 
(0 to 0.8s) for the 4 frequency bands and a broader frequency band of 0-100Hz 
(Robinson & Vrba, 1999). 
 
Each participant had their peak activity in the primary visual cortex located and 
virtual electrodes were generated for these locations by SAM beamformer 
reconstructions obtained using covariance matrices band-pass filtered between 0 
and 100 Hz. Time-frequency analyses of these virtual electrodes were conducted 
using the Hilbert transform between 1 to 100 Hz in 0.5 Hz frequency steps and 
represented as a percentage change from the average baseline value (-0.8 to 0s) 
for each frequency band.  
 
Mean responses across all trials were then represented against time and 
frequency in three-dimensional spectrograms, with the colour of responses 
representing the power of the response in % change from baseline. A typical 
spectrogram is shown in figure 3.2. Most spectrograms revealed distinct transient 
(0 to 0.3s) and sustained (0.3 to 0.8s) gamma band responses in the primary 
visual cortex, the peak amplitude of the transient response being of higher 
frequency than the sustained response, consistent with previous work (Gaetz, 
Roberts, Singh, & Muthukumaraswamy, 2012). Spectrograms with poor signal to 
noise ratio (indistinct gamma responses in contrast to the background noise) were 
excluded from the analysis. Mean transient and sustained gamma band 
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frequencies and amplitudes were then identified for the remaining n=18 RD and 
n=15 ND individuals using time resolved power x frequency plots (mean responses 
over 0-0.3 seconds and 0.3-0.8 seconds) across the gamma spectrum (40-100 
Hz).   
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Figure 3.2. Typical MEG data from this experiment. A demonstrates virtual sensor placement (cursor point ) over best -performing V1 region (yellow). B 
shows spectrogram of virtual sensor time-frequency reconstruction where colour heat-map is a function of power (% change from the baseline).
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Magnetic resonance spectroscopy procedure 
MR spectra were acquired on a GE Signa HDx 3T MRI scanner using the body coil 
for RF transmission and an eight-channel head coil for signal reception. MEGA-
PRESS (Mescher et al., 1998) was used to acquire MR spectra in a left limbic 
volume of  3.0 x 3.5 x 3.5 cm3 and two cortical volumes, each of 3.0 x 3.0 x 3.0 
cm3, in the left inferior frontal gyrus and bilateral visual cortex, for each subject.  
The limbic voxel included the striatum, subgenual cingulate, hippocampus, 
amygdala and thalamus. 
 
These acquisition times provided the best trade off between participant comfort 
and signal-to-noise ratio, resulting in distinct GABA+ and GLX peaks of 
approximately Gaussian shape with stable baseline with TE = 68 ms, TR =1.8s, 
256 transients of 2k data points, and 16 ms editing pulses applied at 1.9 ppm (ON) 
and 7.5 ppm (OFF). Data were processed using in-house software written in 
MATLAB; 4 Hz exponential windowing was applied prior to Fourier transformation. 
A Gaussian model was used to fit the GABA and GLX peaks in the difference 
spectrum, and concentrations were quantified in institutional units  relative to the 
unsuppressed water peak from the same volume. Although the GABA+ peak is 
essentially a couplet it approximates well to a single Gaussian and alternative 
model fits (e.g. bimodal Gaussian fitting) provided no advantage over fitting to a 
single Gaussian.  
 
To correct for variable amounts of CSF within the MRS voxels across participants 
(particularly for the subcortical voxel), high resolution anatomical images were 
acquired with a T1-weighted 3D FSPGR sequence (TR/TE/TI = 7.8/3.0/450ms, flip 
angle=20° FOV = 256*192*172mm, 1mm isotropic resolution, 8min acquisition 
time) during the same session as the MRS. The images were segmented in to 
white matter, grey matter and CSF using an established segmentation method for 
MR images  (www.fmrib.ox.ac.uk/analysis/research/fast/). The reported GABA and 
GLX concentrations were scaled linearly to account for differences in CSF volume 
and variations in spectroscopy profiles for tissue and water (Geramita et al., 2011). 
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Higher-level analysis 
Student’s t test for independent samples was used to determine any differences in 
dependent measures between groups. We also examined correlations between 
IGF and occipital GABA+ measures across the whole sample. 
3.3.3 Results 
The ND individuals were slightly older than the RD individuals (23 years (SD=2.6) 
versus 21 years (SD=1.5), t(35)=2.9, p=0.006) but the small variance in age did 
not correlate with any of the dependent MEG and MRS measures. Most individuals 
in the RD group met criteria for a history of melancholic depression. Thirteen of the 
eighteen RD individuals had a BADDS score of 60 or above, indicating a history of 
at least one severe depression (defined as eight or more depressive symptoms, or 
major depression accompanied by a serious suicide attempt, ECT treatment or 
hospitalisation (Craddock et al., 2004). Despite this, groups did not differ on 
current levels of general depression symptoms or anhedonia as measured by sub 
scores of the MASQ: mean General Distress, Depression (GDD) scores = 20.4 
(RD) versus 18.5 (ND),  (t(33)=1.0 p=0.30), and mean Anhedonic Depression (AD) 
scores = 60.0 versus 57.4, (t(33)=0.9, p=0.37).  
 
Figure 3.3 Representative MRS spectra from one participant with GABA and Glx labelled. 
 
 89 
 
Representative (edited) spectra acquired from the three MRS voxels are shown in 
Figure 3.3. There were no group differences in occipital MRS-GABA+ (t(32)=0.507, 
p=0.616), IGF (transient, t(31)=0.667, p=0.509, or sustained, t(30)=0.486, 
p=0.630) or gamma power (transient, t(30)=0.183, p=0.943, or sustained, 
t(31)=0.008, p=0.994). In addition, there were no group differences in prefrontal or 
subcortical MRS-GABA+ measures (t(34)=0.288, p=0.775; t(34)=1.346, p=0.187). 
Figure 3.4 demonstrates pair-wise between-group differences in occipital GABA+ 
and IGF. 
 
 
 
Figure 3.4. Pair-wise differences between groups for occipital MRS GABA and V1 IGF.  
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Time-resolved (transient and sustained) changes in power of MEG responses 
across the entire frequency range were calculated. Observation revealed a marked 
group difference in the power of the transient responses (0-0.3s) at approximately 
10Hz, suggestive of a difference in evoked response (figure 3.5). 
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Figure 3.5. Mean power vs. frequency for each group (red, ND; blue RD). Evident difference in power between groups at ~5Hz.
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3.3.4 Discussion 
This is the first study to use IGF as a surrogate in vivo estimate of the action of 
GABAergic interneurons on cortical pyramidal cells in unmedicated RD, in 
combination with MRS measures of GABA+ concentration. It is also the first study 
to investigate GABA+ concentrations in RD in both cortical and subcortical regions. 
 
The key finding is that remitted depressed subjects have normal IGF and MRS-
GABA+ concentrations in the occipital cortex. Hence, two independent imaging 
measures support the conclusion that occipital GABA interneuron function is 
normal in young women with remitted, formerly severe MDD. Further observation 
revealed normal GABA+ levels in prefrontal and subcortical regions, suggesting 
that the lack of a GABA deficit in remitted MDD is not regionally specific. 
 
These findings contrast with those of Bhagwagar et al. (2008), who found a 
reduction in GABA levels in the occipital region in RD. This contrasting finding 
could be due to several methodological diffe rences. Firstly, this study used water 
as a concentration reference, whereas the former study used creatine. If creatine 
were affected by MDD, this could account for the discrepancy. Second, this study 
used a larger voxel size and longer acquisition, affording higher signal/noise ratio. 
Third, the former attempted to correct for the effect of macromolecules. Fourth, the 
former excluded non-recurrent depression, and participants were older. 
 
These findings are broadly consistent with those of Hasler et al. (2005), who 
demonstrated normal prefrontal GABA levels in remitted MDD. As well as 
replicating their findings for prefrontal GABA levels (albeit with a more infero-lateral 
voxel), this study provides additional evidence of normal subcortical and occipital 
GABA+ levels and normal gamma oscillations, the latter providing a 
complementary surrogate marker of inhibition- excitation balance in the cortex. The 
sample recruited by Hasler et al (2005) was similar to this study in that it included 
younger individuals with single episodes of illness. 
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It is possible that the GABA deficits previously reported in RD (Bhagwagar & 
Cowen, 2007) represent a biomarker of more recurrent illness. Although this study 
found no significant differences in GABA+ levels between individuals with single 
episode or recurrent illness, the study was not sufficiently powered to examine this 
question. Alternatively, the GABA deficits might represent markers of longer illness 
duration per se.  
 
A recent study employed MRS to measure GABA levels in the parieto-occipital 
cortex of a similarly aged cohort of never- depressed young adults with a parental 
history of MDD (Taylor et al., 2011a). Family history is the most established risk 
factor for MDD. However, no difference in GABA levels was reported between this 
group and an age-matched group without a family history of MDD. Considering 
these findings, together with those presented here, and those of Hasler et al 
(2005), it might be concluded that any GABA deficits observed in acute MDD 
reflect state as opposed to trait biomarkers of illness. 
 
3.4 Experiment: Marked reductions in early visual evoked response in 
remitted depressed subjects compared with healthy, never depressed 
controls. 
 
3.4.1 Rationale 
The previous section detailed an experiment focussing on differences in GABA 
and IGF, in remitted depression. Another common approach to analysing cortical 
responses derived from this type of visual data is that of VEP/Fs. VEFs typically 
reference early ERPs in the visual cortex and are linked with basic level stimulus 
encoding and attention. Despite this, alterations of their latency and amplitude 
have been demonstrated in current-episode major depression as well as other 
psychiatric illness. 
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3.4.2 Methods 
The sample consisted those remitted depressed subjects and never-depressed 
controls described in experiment 3.3. Virtual sensor data from the aforementioned 
visual grating paradigm were used to assess pattern-onset VEFs. Virtual sensor 
data were averaged across trials and evoked fields flipped so that the large 
~100ms response, M100, was positive going.  
3.4.3 Results 
Large group differences were evident in the time locked (evoked) responses 80 
milliseconds after the visual stimulus (the M80 or C1 response). Baseline-
corrected evoked amplitudes revealed a 46% decrease in the mean M80 visual 
evoked response in the RD group compared to the ND group (Cohen’s D = 1.01, 
t(31) = 2.92, p = 0.006; 95% confidence intervals of the difference = 14%-78%). 
Mean evoked amplitudes for both groups are shown in Figure 3.5.  The size of the 
group difference is further illustrated in figures 3.6 and 3.7, where ranked 
amplitudes for n=14 RD and n=14 ND individuals are contrasted. Samples of equal 
size were selected on the basis of age, by excluding the oldest ND individual 
(whose age, at 31 years, was more than 2 standard deviations from the mean) and 
the three youngest RD individuals (aged 19, 20 and 20 years). The resulting mean 
ages of RD and ND groups were 21 years (SD=1.6) versus 22 years (SD=1.7), 
respectively). Bootstrapping with 1000 iterations confirmed a significant group 
difference at p=0.016. M100 amplitudes were not correlated with lifetime severity 
of illness (BADDS scores) in the RD individuals (r=0.087, p=0.733). 
 95 
 
 
 
 
 
Figure 3.6. Evoked spectra for the visual evoked response. At 80ms the amplitude of RD subjects (blue) is 46% less than ND (red).
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Figure 3.7. 14 age matches RD and ND subjects’ amplitude at 80ms, obtained from the virtua l sensor over V1.
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3.4.4 Discussion 
The key finding presented here is that remitted depressed subjects demonstrated 
a 46% decrease in the C1 (M80) component of the pattern-onset visual evoked 
response, compared with the never depressed controls. This is particularly striking, 
given that subclinical depression symptom scores in the RD individuals did not 
differ from the normal, never-depressed population. 
 
The pattern-onset VEF is generated predominantly by dorsal stream projections to 
V1. In the RD individuals, M80 VEFs were not correlated with indices of illness 
recurrence or severity. This supports the proposition that early VEF suppression is 
not state-dependent and could be a trait marker of MDD. 
 
Similarly, reduced amplitudes of early (pattern-reversal) VEFs have been reported 
in acute depression, which are putatively explained in terms of reduced glutamate-
mediated plasticity (58). With the 3T MRI utilised in this study, separation of 
glutamate from similar compounds (glutamine, GABA) is not possible, however 
higher-field MR technologies enable this.  
 
It is now imperative to determine whether the early VEFs deficit observed in acute 
and remitted MDD is also present in individuals with a first-degree family history of 
depression; follow-up studies would determine its value in predicting future 
depression. 
 
3.6 General Discussion 
This study had some limitations. Personal history of depression was determined 
retrospectively and not from clinical records. However, this study utilised a valid 
structured interview to determine the diagnosis, and it was observed that the 
individuals had good recollection of their symptoms. Poor quality or incomplete 
case records are less reliable than a structured interview. It could be argued that in 
selecting unmedicated RD individuals this study was biasing the sample toward a 
 98 
 
less severely ill population. However, the great majority had experienced severe 
episodes. The main advantage of selecting unmedicated individuals is that 
confounding influences of medication on imaging and behavioural measures can 
be excluded. For example, there is preclinical evidence to suggest that 
antidepressants alter GABA function, independent of i llness (Gotlib & Hamilton, 
2008; Sands, Reisman, & Enna, 2004). Only a small number of the sample (n=6) 
presented here had experienced recurrent depression, consistent with their young 
age.  
 
There is some evidence to suggest that GABA measures are affected by the 
follicular phase of the menstrual cycle in women (Epperson et al., 2002), which 
would have added noise to the data and diminished the ability to determine group 
differences. However, GABA values did not differ between individuals taking the 
oral contraceptive pill, where the follicular phase is suppressed (n=15), and those 
not taking the pill (p<0.5), and variances were comparable. This argues against a 
significant effect of the menstrual cycle on the data. The GABA measure included 
contributions from coedited macromolecules, a limitation of MEGA-PRESS at 3T. 
Methods for correction entail a penalty in signal/noise, acquisition time, and/or 
make modelling assumptions, affecting reproducibility (O'Gorman, Edden, Michels, 
& Murdoch, 2007). However, macromolecules are unlikely to mask any e ffect of 
remitted MDD on neurotransmitters. Shimming was difficult in the subcortical 
region, reflected in higher linewidth and reduced signal/noise ratio. 
 
In summary, evidence from two independent imaging measures supports the 
conclusion that any GABA deficits observed in acute depression do not represent 
trait markers of illness. However, this study presents evidence to suggest that early 
visual evoked potentials are markedly reduced in remitted depression and might 
prove to be useful trait markers. 
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Chapter 4. Oscillatory dynamics of face processing in Remitted 
Depression 
 
4.1 Abstract 
Healthy and remitted-depressed participants performed explicit and implicit 
emotional face discrimination tasks while in a MEG scanner. ERF and induced 
gamma measures were analysed for between group differences. Whole-brain 
independent group tests on beamformer images revealed gamma frequency band 
(>30Hz) power increases in left insula in remitted depressed (RD) compared with 
never depressed (ND) subjects in response to fearful faces but not to sad, happy 
or neutral faces. Magnitude of gamma response to fearful faces in left insula 
correlated negatively with local grey matter volume in ND but not RD. Greater 
gamma oscillatory power in the left insula while explicitly discriminating fearful 
faces demonstrated in remitted depressed subjects compared to controls 
demonstrates a new role for the insula in face processing. 
 
ERF analysis demonstrated decreased M300 (P300) amplitude in right middle-
occipital gyrus during implicit emotional face tasks in RD participants compared 
with ND controls, across all face conditions (i.e. irrespective of emotion) and in two 
separate paradigm recordings. A reduction in M300 amplitude during implicit but 
not explicit emotion processing in remitted depression may reflect the negative-
emotion bias associated with depressive disorders and suggests that this may be a 
trait marker of depression. 
4.2 Background  
Functional neuroimaging studies have demonstrated that the anterior cingulate 
cortex (ACC) is associated with both processing and experience of emotion, whilst 
the dorsolateral prefrontal cortex (DLPFC) is associated with regulating emotion 
(Gotlib & Hamilton, 2008; Phillips et al., 1997). The ACC, DLPFC, orbitofrontal 
cortex (OFC), ventral medial prefrontal cortex and limbic structures (amygdala, 
insula, putamen, nucleus accumbens, parahippocampal gyrus) have been 
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repeatedly reported to demonstrate different activity in depressed participants 
compared with healthy participants across a wide range of paradigms designed to 
probe specific aspects of behaviour.  
 
Behavioural studies have demonstrated that the ‘mood congruent emotion 
processing’ commonly observed in depression is reflected by responses to 
emotional face discrimination tasks. Depressed subjects show a robust bias in 
facial emotion recognition whereby neutral expressions are interpreted as sad, and 
happy faces interpreted as neutral. (Bourke, Douglas, & Porter, 2010; Chen et al., 
2009) 
 
Face processing models, informed by behavioural and imaging data suggest a 2-
part system. The first component is primarily concerned with visual analysis of 
variable and fixed facial features and comprising the inferior occipital gyrus, 
fusiform gyri (including FFA) and superior temporal sulci. The second, higher-level 
component processes information about the face, such as emotion, and comprises 
the aforementioned emotion-related structures of the limbic system and OFC 
(Stein et al., 2007; Stuhrmann, Suslow, & Dannlowski, 2011). Abnormalities have 
been demonstrated in both parts of this processing system in depression. Current 
models suggest that emotion identification associated regions (amygdala and 
OFC) exhibit increased activity in depression while emotion regulation associated 
regions (DLPFC and ACC) exhibit decreased activity.  
 
A further structure implicated in face processing is the (bilateral) insula. Imaging 
studies have demonstrated activation of the insula to faces exhibiting disgust 
(Phillips et al., 1997; Sprengelmeyer et al., 2011), and disgust and happy 
expressions (Chen et al., 2009; Takahashi et al., 2010). However, abnormalities of 
the insula cortices during face perception have largely been reported in anxiety 
disorders rather than depression (Stein et al., 2007). While evidence of a functional 
difference in insula cortex during emotion processing in depression is lacking, 
structural abnormalities have been reported (Sprengelmeyer et al., 2011). 
Reduced grey matter volume of the insula correlated with the magnitude of 
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disgust-recognition deficit (Sprengelmeyer et al., 2011). Furthermore, volumetric 
MRI has demonstrated reduced insular cortex volume in both MDD and RD 
subjects compared with healthy, never depressed controls (Takahashi et al., 
2010). 
 
The brain regions described thus far have been implicated in depression utilising 
functional MRI, however neurophysiological measures have also contributed to the 
face processing literature. One component of the ERP, the negative-going 170ms 
response (N170) is considered face-specific and localised to the fusiform gyrus (or 
fusiform face area), occipital face area and/or middle occipital gyrus. The face-
specificity of this response suggests it represents some aspect of face processing, 
and its localisation to a predominantly visual region might suggest it reflects some 
aspect of facial feature processing (Wong, Fung, McAlonan, & Chua, 2009). 
Despite this, there is some contention over the role of the N170 as some have 
demonstrated manipulation of the response using emotional face stimuli (Monroe 
et al., 2011) and others have demonstrated manipulation by spatial attention 
(Mohamed, Neumann, & Schweinberger, 2009) while others have argued that by 
controlling for inter-stimulus perceptual variability, the N170 is actually not face 
specific (Thierry, Martin, Downing, & Pegna, 2007). 
 
Besides the N170, alterations of the P300 have also been reported in depression. 
The P300 is regularly elicited by auditory odd-ball paradigms (Squires et al., 1975), 
with alteration of this component reported in depression, anxiety (Boudarene, 
1997), schizophrenia (Morstyn et al., 1983) and other psychiatric disorders. More 
recently the P300 has been studied as a component of face processing, with 
reduced P300 amplitude reported in depression for processing of happy and 
fearful faces compared to neutral faces (Cavanagh, & Geisler, 2006). This 
suggests that the P300 component plays one of two roles: it may contribute to 
higher-order processing, rather than early-component feature encoding, and 
therefore reflect emotion processing; or, it may suggest that the processing 
dysfunction observed in depression starts early-on in the processing stream, and 
may therefore be independent of facial expression. 
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Besides stimulus-evoked activity measures (i.e. phase locked to stimulus), 
stimulus-induced measures have also been investigated in response to faces. Lee 
et al (2010) investigated differences in γ-oscillatory activity in healthy, major 
depression (MDD / unipolar) and bipolar disorder participants during an implicit 
emotional face discrimination task. The task consisted of 4 facial expressions (sad, 
angry, happy and neutral) and participants were instructed to pick the gender of 
each face. MDD participants demonstrated significantly decreased γ-oscillations in 
left parahippocampal gyrus and right middle temporal gyrus, along with an 
increase in γ-oscillations in left superior temporal gyrus, left cuneus and right 
precentral gyrus. The authors suggest this represents an over-activation of bottom-
up appraisal mechanisms, which might be associated with the generation of 
emotions in depressed subjects. However, a methodological concern of this study 
is the ability to spatially localise and discriminate between these structures of close 
proximity using MEG (as compared with fMRI) due to the inverse problem. 
 
While dysfunctions of (emotional) face-processing regions have been associated 
with subjects currently suffering a depressive episode, whether these phenomena 
occur in remittance of depressive symptoms is an important question. The 
enhanced sensitivity to negative stimuli  in depression has been suggested to 
persist in remittance in the form of enhanced sensitivity to negative feedback 
(Santesso et al., 2008). However, altered BOLD responses to emotional face tasks 
between current and remitted disease states have been demonstrated (Keedwell 
et al., 2009).  
4.3 Experiment: Explicit and implicit emotional face processing tasks. 
4.3.1 Rationale 
Based on the above literature, it was hypothesised that differences exist in the 
ERF N170, later ERF components and induced gamma, during emotional face 
tasks, in RD participants compared with ND. 
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4.3.2 Methods 
Thirty-seven healthy female volunteers were recruited from the staff and student 
body of Cardiff University. Nineteen had no history of depression while eighteen 
had suffered from depression but were currently remitted and unmedicated. All 
participants gave informed consent. Details of participants in this study have been 
reported in the previous chapter, thus a shorter description is included here. All 
individuals were aged 18-35, and had normal or normal-corrected vision. History of 
depressive symptoms and illness was determined using an adaptation of the Mini  
International Neuropsychiatric Interview (MINI) and Bipolar Affective Disorder 
Dimensional Scale (BADDS),  
 
With the exception of depression in the remitted depressed group, participants 
were excluded if they had any history of psychiatric disorder, were taking 
psychotropic medication or had contra-indications to MRI/MEG scanning. 
Participants reporting depression as a secondary to some other axis 1 disorder 
were identified via interview and excluded.  
 
MEG Paradigm, Recording and Analysis 
During MEG recordings, participants completed three emotional faces tasks. 
These consisted of an explicit emotional face discrimination task and two implicit 
emotional face tasks. The explicit task entailed pseudorandom presentation of four 
facial expressions: fear, happy, sad and neutral. The face images were from the 
Ekman faces set (Young, Perrett, Calder, & Sprengelmeyer, 2002). Participants 
were instructed to respond with the displayed expression via a four-choice button 
box (left to right: fear, sad, happy, neutral).  
 
The first implicit task entailed viewing 100%-intensity fearful, 50%-intensity fearful 
and neutral faces (as defined in the Ekman set). Participants were instructed to 
respond with the gender of the face. The second implicit task replicated the first, 
substituting the 100% and 50% fearful faces for 100% and 50% sad faces. The 
order of implicit tasks was counter-balanced. 
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Tasks ran for 150 trials where a face stimulus was displayed for 1500ms followed 
by 2500ms during which a question mark appeared on screen to prompt 
participants to respond. Participants were instructed to respond promptly and 
received an error message if no response was detected during the response time. 
Stimuli  were displayed on a Mitsubishi Diamond Pro 2070 CRT monitor (1024 x 
768 at 100Hz, physical screen size 450x300mm) at a distance of 2030mm. Faces 
were presented centrally at a visual angle of 6.556° horizontally and 7.486° 
vertically.  
 
MEG was recorded with a CTF 275-channel whole-head MEG system and sensors 
were analysed as synthetic 3rd-order gradiometers (Vrba, 2001). Three sensors 
were switched off due to excessive noise. Fiducial points were marked using 
electromagnetic head-coils attached 1cm above the nasion and anterior to each 
tragus. These were used to co-register the data to an anatomical T1-weighed MRI 
(FSPGR).  
 
In order to analyse both event-related fields (evoked) and gamma oscillations 
(induced), a broad-frequency (10-100Hz) synthetic-aperture magnetometry (SAM) 
analysis was run on a 90-300ms time window (post-stimulus onset), after bi-
directional Butterworth band-pass filtering into 20Hz windows between 0-100Hz. 
Merging all participants three dimensional functional maps into one four -
dimensional file (i.e. X x Y x Z x participant) allows searching through all 
participants datasets to find common peaks suitable for a ‘best-performing’ virtual 
sensor placement in an objective manner. In house software was used to search 
across participant files in template space and find common peaks within a specific 
trap radius. Co-ordinates were translated back to individual MRI space for virtual 
sensor placement. Applying this pipeline to the explicit task data successfully 
identified common peaks in the right middle-occipital gyrus for fear, happy and sad 
face onset and left middle-occipital gyrus for neutral.  
 
SAM analysis was run for gamma and event related analyses separately in order 
to maximise sensitivity (although used the same algorithm). SAM was on the 110-
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400ms window post-stimulus onset on data band-pass filtered to the gamma range 
(55-150 Hz) with a baseline of -290-0ms. These images depicted gamma 
responses in several areas of cortex across participants and conditions. As such, a 
group-level approach was taken to gamma analysis. Using FSL Randomise, 
(Winkler, Ridgway, Webster, Smith, & Nichols, 2014) permutation testing (unpaired 
t-tests) were performed on 15 controls vs. 11 RD individuals for each face 
condition with 5000 permutations and 5 mm variance smoothing. This resulted in t -
statistic and corrected p-value voxel maps demonstrating significant between-
group differences across the brain. 
 
For the ERF analysis, the same SAM algorithm was run on data band-pass filtered 
to low frequencies (1-30 Hz) with an active time 0-400 ms and baseline -290-0 ms. 
An averaged-statistical image revealed clear peaks in the occipital gyrus. 
Subsequent analysis found common peaks in left middle-occipital gyrus for fear, 
happy and neutral face onset, and right-middle occipital gyrus for sad face onset. 
Time frequency analysis of virtual sensors was performed and, in order to ensure 
ERF waveforms were not inverted, whole-wave flips were performed on the basis 
of the strong ~50-60ms deflection being positive. To extract peak amplitudes in a 
non-biased way, and to simultaneously correct for multiple comparisons, a 
permutation-based unpaired-t test analysis was performed in a sliding time window 
across each data point of the evoked spectra, (with 2000 permutations). This 
procedure was repeated for the implicit tasks analysis.  
 
Whole-brain gamma analysis was performed using FSL Randomise and ERF 
analysis using a virtual sensor approach. For both sad and fearful implicit tasks, 
the virtual sensors were localised over source peaks in right middle occipital gyrus.  
 
MRI Procedure 
High-resolution anatomical T1-weighted 3D MRIs were collected on each 
participant using a GE Signa HDx 3T MRI scanner for co-registration of MEG data. 
The sequence consisted of repetition time 7.8s, echo time 3s and inversion time 
450ms with a flip angle of 20° and field view 256 x 192 x 172mm, 1mm isotropic 
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resolution. Grey matter was quantified using the FAST (Zhang, Brady, & Smith, 
2001) automated pipeline built into FSL (Smith et al., 2004). 
4.3.3 Results 
Sample Characteristics and Symptoms 
Never depressed participants (ND) were slightly older than remitted depressed 
participants (RD), (ND 23, RD 20 [t(35)=2.2, p=0.032]) however age did not 
correlate with MEG measures. Further descriptive statistics in table 4.1. 
 
 RD Group ND Group t p 
Age 20 23 2.2 0.0320* 
BDI Score 5.07 3.39 -1.15 0.261 
TAI Score 14.75 12.67 -1.2 0.242 
No Episodes 2  
Melancholia 0.77 
BADDS Score 64.2 
Left Insula Y Power 1.5 0.2 5.12 0.0022* 
Left Insula Grey 
Volume 
6679 6898 1.158 0.255 
Table 4.1. *Significant at alpha = 0.05. 
 
Not all participant data was available for all tasks due to incomplete recordings, or 
the lack of a peak around which to place a sensor. Thus, for the ERF analysis, the 
explicit task sample consisted 15 ND and 11 RD. For the sad implicit task 16 ND 
and 14 RD and for the fear implicit task 15 ND and 15 RD. For the gamma 
analyses the explicit task consisted of 15 ND and 11 RD while the sad implicit 
sample consisted 17 ND and 14 RD and the fear implicit sample consisted 16 ND 
and 15 RD.  
 
Button box responses were available for the implicit tasks, during which there was 
no difference in performance between the groups for the implicit tasks. Button box 
data for the explicit task was not available due to en error in experimental design. 
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4.4 Results: Increased left insula gamma power in response to fearful faces 
in formerly depressed subjects during an explicit face-processing task  
The whole-brain group-level SAM analysis of the explicit task data revealed 
significantly increased γ- power in patients compared to controls in subcortical 
areas, with a peak in left insula cortex, in response to fearful face onset but not 
neutral, happy or sad faces (t(25)=5.12, p=0.0022, figure 4.1). 
 
Gamma power at this location correlated negatively with left insula cortex grey 
matter volume collapsed across the groups (r=-0.389, n=26, p<0.05 after 
bootstrapping) however this was stronger in controls than patients (R2=33.9% vs. 
1.1% respectively, see figure 4.2) despite a lack of difference in insula grey 
between groups.  
 
Difference (t-statistic) peaks in other regions were found for sad, happy and neutral 
face conditions, however these were not significant after correction for multiple 
comparisons. Whole-brain group-SAM for the implicit face tasks revealed 
significant clusters for each condition, however, none of these were significant 
after multiple comparison correction. 
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Figure 4.1. (a) Significant gamma power increases in left insula in patients compared to controls 
during the explicit task in response to fearful face onset (t-value cut off = 3).(b) Scatter diagram for 
never and remitted depressed groups. Pink bars represent 95% CI, grey bars demonstrate 1 
standard deviation. 
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Figure 4.2. Scatter plot demonstrating correlations between left insula grey matter volume (x axis) 
and gamma power (scaled) in the same region in response to fearful face presentation. ND = blue, 
RD = red. Significant across the sample after bootstrapping. 
 
 
Condition Co-ordinate (TC) Structure t P* 
Fear -31.1 15.1 -11 Insula 5.124981 0.0022** 
Fear 27.1 -53.2 -9 
Parahippocampal 
Gyrus 
4.987974 0.998 
Fear -43.2 -69.3 -29 
Left Fusiform 
Gyrus 
4.213851 0.995 
Happy -13.1 -21.1 -7 Midbrain 4.134197 0.0976 
Happy -19.1 -79.3 55 Parietal cortex 3.204208 0.2366 
Happy 35.1 -55.2 -15 
Right fusiform 
gyrus 
3.179447 0.1736 
Neutral 19.1 -57.2 73 
Right post-central 
gyrus 
3.773767 0.071 
Neutral -23.1 -29.1 51 
Left post-central 
gyrus 
3.735057 0.0636 
Sad -23.1 -69.3 63 
Superior parietal 
lobule 
3.345065 0.405 
Table 4.2. Explicit Task gamma frequency cluster peaks 
*Showing multiple comparison corrected p-values.  
** Significant at given p-value. 
 
4.5 Results: Reduced M300 ERF amplitude in formerly depressed subjects 
during implicit face processing as compared with healthy, never depressed 
controls 
 
One of the experimental aims was to localise the face-specific M170 response, as 
well as later components of the ERF thought to reflect higher-level (i.e. emotional 
processing) aspects of stimulus processing. Thus time points through the duration 
of the visual evoked response were statistically compared between groups where 
peaks were evident. 
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For the explicit task, the M170 was not clearly distinguished in all participants, or 
all conditions (figure 4.3) and hence was not tested statistically. The 170ms 
response emerged during the implicit face tasks (figure 4.3, lower panels). This 
was tested between groups, however, it was not statistically different in amplitude 
or latency for either implicit face task.  
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Figure 4.3. Event-related field time course around 170ms for each task. Blue = RD, green = ND. Face-specific M170 deflection evident for implicit 
tasks (sad and fear) but not explicit time course. NB. Waveforms collapsed across conditions.
 112 
 
Implicit tasks raw-spectra demonstrated a notable difference between groups for 
each condition at approximately 300ms. Subsequent analysis revealed decreased 
M300 (P300) amplitude in the RD group compared to ND in both sad and fear 
tasks. This was significant within-task when collapsed across conditions (i.e. full, 
mild and neutral intensities, figure 4.4) and also across task (i.e. concatenating 
fear and sad faces but excluding neutral, figure 4.5). 
 
 
Task Conditions Group 
M300 Amplitude 
Mean SD t p Cohen’s d 
Fear 
100% Fear 
50% Fear 
Neutral 
ND = 
RD = 
-0.1570 
-0.9369 
0.3856 
0.6818 
 
4.24 0.00005 1.4 
Sad 
100% Sad 
50% Sad 
Neutral 
ND = 
RD = 
-0.4159 
-1.1077 
0.4794 
0.7120 
-4.3231 0.000039 1.14 
Fear + 
Sad 
100% Fear 
100% Sad 
50% Fear 
50% Sad 
ND = 
RD = 
-0.1513 
-0.5452 
0.4025 
0.4232 
8.1144 0.0005 0.95 
Table 4.3. Implicit Task: M300 Amplitudes  
Implicit task M300 results per task and condition. 
 
Analyses using a two dimensional randomisation test with 2000 permutations 
revealed strong differences between the groups (fear-face task 
[t(91)=4.2358,p=0.00005], sad-face task [t(91)=-4.3231, p=0.000039], sad and fear 
excluding neutral: [t(91]=8.1144, p=0.0005], table 4.3).To determine whether the 
stronger t-statistic difference in the across-tasks comparison was due to an effect 
of emotional faces or just increased statistical power (due to increased sample 
size), an ANOVA was performed to assess whether face emotion affected M300 
amplitude (using full and mild intensities of fear and sad vs. neutral faces). This 
revealed no significant effect of emotion (p>0.05), but a significant effect of group 
(p<0.001). 
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Figure 4.4. RD (blue) had significantly reduced M300 amplitude across all faces compared with ND 
for both the fearful(a) and sad (b) implicit paradigms. [x: time (s), y: Amplitude (nAm), Pink dashed 
line represents multiple comparison corrected t-value/10].(c)Fear task per-participant M300 
amplitudes (mean of conditions full, mild and neutral). (d)Sad task per-participant M300 amplitudes 
(mean of conditions full, mild and neutral). 
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Figure 4.5. RD significantly reduced M300 in across-task analysis of emotional faces, compared with ND (excluding neutral faces). Pink dashed line 
represents t-value (-log10 for scaling).
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4.6 Discussion 
Analysis of both ERF and gamma measures revealed two main results. First, 
during the explicit emotional identification task, RD individuals demonstrate 
increased gamma power in the left insula compared to ND individuals in response 
to fearful faces, but not happy, sad or neutral faces, and this gamma-power 
correlated negatively with left-insula grey matter volume strongly in controls but not 
patients. Second, during two separate recordings of implicit emotion tasks (one 
utilising sad faces, the other fearful), RD individuals demonstrate reduced M300 
amplitude for three intensities of facial expression, including neutral, compared 
with ND individuals.  
 
Previous studies have demonstrated an important role for the insula cortex in 
processing faces expressing disgust. Studies have reported increased BOLD 
activation to faces expressing disgust (Phillips et al., 1997). This study suggests 
that the insula also responds to fearful faces, and that gamma oscillatory power in 
this structure is greater in remitted-depressed subjects than controls. Increased 
gamma oscillatory power is assumed to reflect greater population entrainment and 
synchrony, thereby assuming greater ‘activation’, a similar assumption to the 
BOLD response. This is in concordance with an fMRI study which previously 
demonstrated that the insula is involved in fear-face processing in healthy 
participants (Schienle et al., 2002) however, this is the first study to show a 
functional difference in RD.  
 
During a similar paradigm, Lange et al (2003) demonstrated a greater BOLD 
response to neutral compared to fearful faces in the insula cortex in healthy 
participants during passive viewing, gender discrimination (implicit) and explicit 
expression distinction tasks. A number of clusters were reported for both 
fear>negative and negative>fear contrasts with the insula cortex as the only 
structure significant for neutral>fear for all three conditions (passive, implicit and 
explicit). These study results are inconsistent with this finding because only fearful 
faces during the explicit task elicited a gamma peak in the left insula.  
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The difference in gamma power in remitted depressed subjects in the left insula to 
only fearful faces and during only the explicit face task suggests that this finding is 
both specific to fearful facial expressions and requires the subject to be explicitly 
attending to, and identi fying, the facial expression. Future studies should examine 
whether the left insula also exhibits increased gamma power to faces of disgust in 
RD.  
 
The finding of reduced M300 amplitude in RD individuals to differing intensities of 
both fearful and sad faces might reflect the negative stimuli bias observed in 
current depression. However, the M300 difference was also observed in the 
neutral face condition, and amplitude differences were only significant when full 
and mild intensities and neutral faces were collapsed together and compared 
between groups. Furthermore, response data (gender discrimination) indicated no 
difference in accuracy between groups. An ANOVA demonstrated no main effect 
of emotion on M300, only group. It is likely that, per-condition, the M300 amplitude 
is truly different between our groups (as evident in figure 4b/c), however due to 
lack of statistical power this is only significant when conditions are combined. 
 
A previous study reported reduced P300 amplitude in current episode depression 
in response to fearful and happy faces in a visual oddball task. Here the authors 
suggested this reflected diminished cognitive processing ability during emotional 
processing (Cavanagh et al., 2006). Although the tasks are slightly different, the 
data presented here could suggest that this reduction in cogniti ve processing 
ability during emotion processing is present in remitted depressed subjects. These 
data suggest that the P300 amplitude is modulated in remitted depression 
independent of facial expression, since neutral faces also demonstrate a difference 
between groups. A prominent different between these experiments is that 
Cavanagh (2006) selected a cluster of midline electrodes and performed a sensor 
level analysis whereas the approach in this experiment utilised beamforming 
source-localisation and a virtual occipital sensor approach with subsequent 
permutation testing.  
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Given the effect of group upon M300 amplitude during the implicit tasks, it is 
surprising that the M300 amplitude difference was not observed during the explicit 
face task. The key difference between the paradigms is that during the implicit task 
participants were instructed to identify only the gender of the faces presented, 
whereas the explicit task required identification of the emotion being expressed. 
Participants did not differ in accuracy during the implicit task however accuracy on 
the explicit task is unknown. These results suggest that some processing that 
occurs during the implicit task, but not explicit, accounts for the M300 amplitude 
difference between the groups. One explanation is that groups differed in their 
accuracy during the explicit task, and this is why the M300 difference is not present 
in the explicit task. This is unlikely due to the simplicity of the task. An alternative 
explanation is that the M300 amplitude reflects the negative-emotion-bias during 
only implicit emotion processing, and that this bias is diminished when attention is 
focussed upon explicitly identifying the facial expression.  
 
Using EEG, one group demonstrated reduced visual oddball evoked P300 
amplitude in depressed and bipolar patients compared with controls. This study 
was repeated once 18 participants reached remission (8 MDD, 10 BD) and 
demonstrated that amplitudes did not change significantly for either recovered 
bipolar disorder or major depression subjects (Bange & Bathien, 1998). A 
commonality between the paradigm in this study and that of Bange (1998), is the 
implicit discriminative nature: implicit facial expression discrimination and implicit 
visual oddball discrimination. In light of this, the result described here could 
represent a trait marker of implicit processing dysfunction (of the visual system) in 
depression. This could also account for the lack of 300ms response in our explicit 
face task data. 
 
Few studies have focussed on ERF and gamma responses during face processing 
in remitted depression. In this respect, this study is novel. Furthermore, results 
demonstrate that remitted depressed subjects exhibit higher gamma in the left 
insula to fearful faces and reduced M3 amplitude to faces, compared to controls, 
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during implicit facial emotion processing tasks. Together, these findings 
demonstrate that neuronal functioning during emotional face processing is altered 
in remitted depression compared with healthy controls. Moreover, these results 
indicate differences in both basic sensory (middle occipital / visual area) and 
higher-order (insula) regions activity in face processing in remitted depression. 
Finally, emotional face processing differences observed in remitted depression 
differ depending on task instruction (explicit vs. implicit identification). 
 
An important consideration of this work should be the molecular implications given 
the theorised biogenesis of gamma-frequency oscillations. Evidence suggests that 
gamma-frequency oscillations are generated by the interaction of inhibitory 
interneurons and excitatory pyramidal cells in the cortex. Neural network models of 
cortical microcircuits, informed by in-vitro slice work on common receptor types, 
demonstrates that the frequency of gamma oscillations is determined by the decay 
time constant of GABAA receptors on interneurons synapsing onto pyramidal 
neurons. This suggests that gamma oscillations are predominantly shaped by 
GABAergic inhibition, and specifically by the synaptic properties of GABAA 
receptors at inhibitory-excitatory synapses. However, the specific molecular 
underpinning of oscillatory power is less well elucidated. Spencer (2009) found that 
decreasing NMDA input to a pyramidal-interneuron network increased gamma 
power. A plausible explanation for this is that a consequence of reduced -NMDA 
input is mutual disinhibition, permitting increased excitation-mediated entrainment 
of pyramidal cells (Homayoun & Moghaddam, 2007), and thus RD subjects exhibit 
higher gamma power during processing of fearful faces as a function of greater 
resource load, or activation, by altered glutamatergic function. Computational 
modelling of MEG data may help to resolve exactly what increased oscillatory 
power represents, as well as further determining the roles of GABA and glutamate 
function in the pathophysiology of depression. 
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Chapter 5. Visual oscillatory dynamics and neurochemistry in 
current episode MDD and those with a family history of MDD 
 
5.1 Abstract 
Alterations of the GABAergic neurotransmitter system have been reported in 
numerous mood disorders, including current episode MDD, at both the post-
mortem in-vitro and ante-mortem in-vivo molecular level. Evidence from in-vivo 
spectroscopy studies report lower bulk concentrations of GABA in currently 
depressed participants as compared with ND controls, however this reduction in 
concentration does not appear present i n remittance. It is now important to fully 
elucidate the occurrence of GABA reductions across current episode, remittance 
and vulnerability to depression. 
 
The experiment detailed in this chapter concerns subjects with a current episode of 
depression and those with no personal history of depression, but a first-degree 
family history. These data are merged with those previously detailed, forming four 
groups: 18 never depressed (ND), and 18 never depressed but with a family 
history of depression (FH), 15 remitted-depressed (RD), and 13 currently-
depressed (CD) participants. The ND and RD groups are those data described in 
chapter 3. Resting occipital MR spectroscopy (MEGA-PRESS) were acquired, 
along with high-frequency magnetoencephalographic oscillatory data induced 
utilizing a 4° circular, vertical grating. Analysis of variance tests revealed no 
difference between GABA+ or IGF between groups.  
5.2. Background 
Section 1.3.2 reviewed the evidence for a deficit in GABAergic function in major 
depressive disorder. Subsequently, the experiment detailed in chapter 3 did not 
demonstrate a GABA+ concentration or GABAergic functional deficit in the visual 
cortex of remitted-depressed subjects using either 1HMR spectroscopy or induced 
γ-frequency oscillations as a marker of GABAergic function as compared with 
healthy, never depressed controls. The experiment did however reveal a marked 
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reduction (46%) in the amplitude of the early visually evoked C1 (M80) component 
in remitted depressed subjects. These results suggest both that the GABAergic 
deficit documented in current-episode depression is a state component or marker 
of depression and also that the reduced C1 amplitude in remitted depression could 
be a trait marker of depression. In order to evaluate these hypotheses this chapter 
describes data from two further samples: a group of currently depressed subjects 
(who meet MINI criteria for current episode MDD) and a further group with no 
personal history of depression but with a parent who suffers depression.  
 
While reports of reduced MRS GABA+ in remitted depression have, until now, 
been equivocal, multiple studies have reported reduced GABA+ in acute (current -
episode) depression in visual cortex (Sanacora et al., 1999), in adolescents with 
highly anhedonic depression in anterior cingulate cortex (Gabbay et al., 2012) and 
in treatment resistant depression in both OCC and ACC (Price et al., 2009). 
Reduced plasma GABA levels have also been reported in acutely depressed 
subjects (Petty et al., 1992), suggesting a brain-wide deficit in GABA concentration 
and/or function in depression.  
 
The biggest predictor of depression is a family history of depression (commonly a 
parent). Depression is estimated to be 40-50% heritable, although this is driven 
mainly by women, with heritability rates significantly higher in women than men 
(Bierut et al., 1999). Studying subjects with a family history of depression allows for 
identification of heritable behavioural and imaging characteristics associated with 
depression. Lisiecka and colleagues (2012) demonstrated that although healthy 
subjects with a family history of MDD did not perform differently from non-family 
history comparators during an inhibition of emotion task, they did display a 
‘negative neural drift’ in that they demonstrated increased BOLD activation during 
inhibiting of negative stimuli in the right cingulate cortex and left caudate nucleus. 
This study was the first to demonstrate that, while the negative stimuli bias 
observed in acute MDD is not observed behaviourally in family history groups, 
altered activation patterns of the cingulate cortex and caudate nucleus are 
observed when compared with non-family history control subjects. 
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The peak frequency of gamma-frequency oscillations (30+ Hz) has recently been 
estimated to be 91% heritable (van Pelt et al., 2012). Thus, altered GABAA 
receptor function may explain our hypothesised change in peak gamma-frequency. 
If observed in family history subjects as well as acutely depressed subjects, this 
would suggest that altered GABA function is a trait marker of depression.  
 
No studies to date have demonstrated altered MRS GABA+ levels in healthy 
subjects with a family history of depression, but one study has reported elevated 
glutamate (Taylor et al., 2011a). Given the coupled roles of GABA and glutamate 
in the cortex, this finding may reflect a prodromal vulnerability to altered GABA 
function.  
 
This experiment addressed the following hypotheses: in acutely depressed 
subjects, MRS GABA+ in the occipital cortex will be reduced compared with 
healthy control subjects (Sanacora et al., 1999). Furthermore, the peak frequency 
of induced gamma-frequency oscillations will be reduced, suggestive not only of a 
reduction in GABA levels, but in GABAA receptor function and altered excitatory-
inhibitory balance. Finally, the amplitude of the C1 / M80 component of the visual 
evoked field will be reduced in accordance with the finding reported in remitted 
depressed subjects in chapter 3.  
 
It is further hypothesised that healthy subjects with a family history of depression 
will demonstrate reduced MRS GABA+ and peak gamma frequency in the occipital 
cortex, demonstrating that altered GABA function is a trait marker of depression. 
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5.3 Experiment: Measures of visual cortex γ oscillations and GABA across 
current episode, remittance and a family history of major depression. 
5.3.1 Rationale 
The conclusion of the experiment detailed in chapter 3 formed two distinct 
hypotheses. Namely that the GABAergic deficit reported in the brains of subjects 
with current-episode depression is a state marker, and is thus not present in 
remittance, or vulnerability to depression. Secondly, the reduced C1 amplitude 
observed in remitted depressed subjects represents a trait marker of depression 
(or possibly of vulnerability to depression). This chapter describes two further 
samples recruited to test these hypotheses. 
5.4 Methods 
Recruitment and sample 
Thirty-one female volunteers were recruited through the Cardiff University School 
of Psychology’s online Experimental Management System and through the 
University Online Noticeboard. Besides depression or a family history of 
depression, subject inclusion criteria further included: female, aged 18-35 and 
normal or corrected-normal visual acuity. 
 
Data from the healthy subjects and remitted depressed subjects, detailed in 
chapter 3, were combined with those detailed in this chapter to form four 
comparable groups. The 31 newly recruited subjects consisted of N=18 healthy, 
never depressed subjects with a first-degree family history of depression (a 
parent). The sample further consisted of N=13 currently depressed but un-
medicated subjects who, at screening, scored >13 on the BDI and on scanning 
day met MINI criteria for a current major depressive episode. All subjects 
underwent screening using the MINI and BDI and took part in MEG and MRS 
scans. Subjects were reimbursed £15 to compensate for their time. 
 
With the exception of depression and comorbid anxiety in the depression group, 
subjects were excluded based on meeting MINI criteria for any psychiatric disorder 
(including manic or hypo-manic episode and psychotic disorders, panic disorder, 
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agoraphobia, and social phobia, OCD, PTSD, alcohol abuse or dependence, 
anorexia or bulimia nervosa). Further exclusion criteria included suitability and 
willingness to participate in MRI and MEG scans (i.e. no common contra-
indications to MRI). 
 
MEG, MRS & Paradigm 
MEG data were collected while subjects performed 2 basic visual stimulation 
tasks. The tasks were displayed on a Mitsubishi Diamond Pro 2070 monitor (1024 
× 768 pixels and 100Hz frame rate) positioned 186cm from the eye. Task 1, as 
detailed in chapter 3, consisted of a 4° static, circular grating patch with vertical, (3-
cycles-per-degree, maximum contrast) black/white square-wave blocks on a mean 
luminance background. The stimulus was displayed in the lower-left quadrant of 
the screen subtended 4° horizontally and vertically, with the upper right corner of 
the stimulus located 0.5” horizontally and vertically from a small red fixation point. 
The stimulus was on for between 0.8 and 2.3s (mean duration 1.55s) followed by 
1.5s of the fixation point only.  
 
Task two also utilised a maximum contrast, circular grating patch with square-wave 
3 c.p.d. vertical bars. This grating was larger than the first, at 8° and presented 
centrally, with the red fixation square in the centre of the annular grating. The data 
from this second paradigm are not presented here. MEG was recorded using a 
CTF MedTech 275-channel system in a magnetically shielded room. Data were 
recorded at 1200Hz and channels were analysed as synthetic third-order 
gradiometers (Vrba, 2001). 
 
MEG data were epoched into 2s trials and artefacts rejected based upon visual 
inspection of sensor-trace for every trial. Datasets were band-pass filtered using a 
Butterworth bi-directional filter in 0.5 Hz steps between 0 and 100Hz. Resulting 
data were passed through the synthetic aperture magnetometry (SAM) (Robinson 
& Vrba, 1999) beamformer, applied to estimate source-space amplitudes from 
sensor space. Subsequent source-space, spatially-filtered paired-t-statistic 
(stimulus vs. baseline) maps were used to identify peak V1 amplitudes, which 
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invariably fall around the midline of V1. A virtual sensor was created at this best-
performing site for time-frequency analysis using the Hilbert transform (with 
amplitude represented as percentage-change from baseline). Peak frequency and 
amplitude measures are extracted by averaging across a time window of interest. 
For this study, the frequency and amplitude of the non-phase locked (induced) 
gamma response were utilised (0.3 to 0.8s). This pipeline is graphically 
represented in figure 5.1. 
 
 
Figure 5.1. Graphic representation of MEG visual paradigm analysis pipeline. Best -performing 
location in t-statistic SAM image (a), is passed through Hilbert transform to estimate frequency 
contributions (b). (c) demonstrates the time-frequency-amplitude data for the virtual sensor location. 
Mean power in the sustained component of the response is plotted in (d), from which peak 
frequency and amplitude for this component are extracted. 
 
The MRI scan protocol consisted of one 10-minute F-SPGR scan and one 8 
minute MEGA-PRESS spectroscopy acquisition (Mescher et al., 1998; O'Gorman, 
Michels, Edden, Murdoch, & Martin, 2011). MR data were acquired on a GE Signa 
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HDx 3T MRI scanner using the body coil for RF transmission and an eight-channel 
head coil for signal reception. The T1-weighted scan sequence (3D structural 
FSPGR: TR= 7.8, TE= 3.0, TI= 450ms, flip angle= 20° FOV = 256*192*172mm, 
1mm isotropic resolution) was used both for MEG co-registration and for tissue-
correction of spectroscopy data.  
 
The 3 x 3 x 3cm3 MR spectroscopy voxel was placed bilaterally in visual cortex 
and aligned with the calcarine fissure (figure 5.2). The spectroscopy protocol (TE = 
68 ms, TR =1.8s, 256 transients of 2000 data points) utilised 16ms editing pulses 
applied at 1.9 ppm (ON) and 7.5 ppm (OFF) (Gannet Toolbox). Fourier transform 
revealed distinct, approximately Gaussian peaks corresponding to GABA+ and Glx 
(fig 5.2). GABA+ concentration was quantified in institutional units, referenced to 
the unsuppressed water peak. Voxel tissue composition was accounted for by 
segmenting a mask of the MRS voxel on a T1 image and approximating the 
contribution of CSF, white- and grey-matter in the voxel space. 
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Figure 5.2. Occipital voxel position (mask) overlaid on a T1 structural image. All subjects’ edited spec tra showing clear GABA and GLX peaks.
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5.5 Results 
Three subjects were excluded based on their spectroscopy data quality, with a 
quality criterion of GABA+ < 3ppm. The resulting N=12 subjects meeting criteria for 
a current major depressive episode (current depression group, ‘CD’) and N=16 
subjects with a family history of depression (‘FH’) were matched (by age as closely 
as possible) with N=12 healthy, never depressed (‘ND’) subjects and N=14 
remitted depressed (‘RD’) subjects from the experiments in chapter 3, summarised 
in table 5.1. 
 
Group Age BDI 
ND 
(N=12) 
Mean 
SD 
22.8 
3.1 
2.6 
2.6 
FH 
(N=16) 
Mean 
SD 
20 
2.1 
5.8 
5.6 
RD 
(N=14) 
Mean 
SD 
20.4 
1.3 
5 
4.4 
CD 
(N=12) 
Mean 
SD 
22.58 
3.9 
34.6 
9 
*Note: exclude GABA ppm>3 
Table 5.1. Age and BDI score for each group. ND 
 
Previous research has demonstrated that the peak frequency of induced gamma-
frequency oscillations is negatively correlated with age (Gaetz et al., 2012). This 
could be explained by a reduction in the number of parvalbumin containing 
GABAergic interneurons, which has been shown to decline with age in rats 
(Krzywkowski, De Bilbao, Senut, & Lamour, 1995). Coupling this finding with 
evidence that cortical GABA levels correlate with MRS obtained GABA strongly 
suggests that cortical GABA+ levels could also be largely influenced by age. As 
such, both dependent measures (MRS GABA+ and peak gamma frequency) were 
orthogonalised with respect to age by subtracting the regression weights from the 
original measures. Raw versus adjusted values for each measure are plotted in 
figure 5.3 showing a strong correlation (suggesting that raw values were not 
strongly under the influence of age). Group mean values both pre- and post- 
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adjusting for age are listed in table 5.2. Only age-adjusted values were used in 
statistical analyses.  
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Figure 5.3. Left: Raw peak gamma frequency (x) vs. age-adjusted peak gamma frequency (y). Right: Raw GABA+ in ppm (x) vs. age-adjusted 
GABA+ (y). 
 
Group Age ϒ Freq  
(Hz) 
ϒ Amp ϒ  Freq  
AGE 
ADJUST 
GABA+ 
(ppm<3) 
GABA+ 
AGE 
ADJUST 
ND 
(N=12) 
Mean 
SD 
22.8 
3.1 
49.83 
5.28 
25.45 
11.28 
4.34 
5.43 
1.58 
0.33 
-0.02 
0.33 
FH 
(N=16) 
Mean 
SD 
20 
2.1 
49.78 
8.45 
24.71 
14.23 
2.12 
8.31 
1.62 
0.09 
0.03 
0.09 
RD 
(N=14) 
Mean 
SD 
20.4 
1.3 
51.6 
8.91 
26.83 
15.64 
4.28 
8.72 
1.63 
0.26 
0.04 
0.26 
CD 
(N=12) 
Mean 
SD 
22.58 
3.9 
49.08 
9.42 
25.47 
14.41 
3.40 
9.56 
1.63 
0.26 
0.03 
0.25 
Table 5.2. Group means for pre- and post- adjustment of dependent measures.
-20
-10
0
10
20
30
0 20 40 60 80
-1
-0.5
0
0.5
1
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2
0 1 2 3 4
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A multivariate ANOVA was employed to address the hypotheses that GABA and 
peak gamma-frequency measures are reduced in currently depressed subjects. 
MANOVA revealed no difference between groups in age-adjusted V1 peak gamma 
frequency (F(3)=0.235, p=0.8) or occipital MRS GABA+ (F(3)=0.186, p=0.9), nor in 
the amplitude of the peak gamma frequency measures (F(3)=0.058, p=0.9). Figure 
5.4 illustrates group means with 95% confidence interval for peak-frequency and 
GABA+ measures. 
 
 
Figure 5.4. Group means for induced gamma frequency and GABA+ levels.  
 
To address the hypothesis that the amplitude of the C1 / M80 component of the 
visually evoked response will be reduced in current episode depressed subjects 
(and possibly family history subjects. In concordance with remitted subjects), 
evoked, fi ltered (0-20Hz) spectra form the time-frequency analysis were plotted for 
each subject to identify subject-specific components from the pattern-onset 
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waveform (‘W’ shape based on strong C1/M80 component). Amplitude spectra 
were polarity-flipped (multiplied by -1) for subjects exhibiting strong positive C1 
amplitude with subsequent negative deflection, as this was assumed to reflect an 
issue whereby the SAM beamformer inaccurately detects the polarity of evoked 
waveforms. Peak amplitude of the M80 was determined and entered into higher-
level statistical analysis. The spectra for each group are displayed in figure 5.5. 
MANOVA (amplitude and latency vs. group) revealed a significant effect of group 
on M80 amplitude (F(3)=6.7, p=0.001). Post-hoc Bonferroni t-tests revealed that 
CD and FH groups showed no difference to HC in M80 amplitude or latency; 
however, RD had significantly reduced M80 amplitude compared with FH and CD 
as well as the previously mentioned comparison with HC (Bonferroni corrected p-
values for RD vs. CD p=0.003 and FH p=0.001). 
 132 
 
 
 
 
 
Figure 5.5. Visually evoked spectra for each group for the first 400 ms after stimulus onset. Left: the spectra for each group. Right: Error bar diagrams 
for the latency and amplitude of the M80 component for each group.
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5.6 Discussion 
Statistical tests revealed that occipital GABA concentrations and peak-gamma 
frequency were not altered in subjects meeting criteria for a current major 
depressive episode, or in healthy subjects with a family history of depression (the 
null-hypothesis). Furthermore, the reduction in amplitude of the visual evoked 
response M80 component, observed in remitted depression, was not observed in 
currently depressed of family history groups using the same healthy, never 
depressed control group. 
 
The finding that occipital GABA+ measures are not altered in the current 
depression group is a failure to replicate previous findings which reported a 52% 
reduction in occipital GABA levels in a similarly sized (n=14) and unmedicated 
sample (Sanacora et al., 1999). A key difference between the studies, however, is 
that the patients described by Sanacora and colleagues (1999) were a mixed 
population of male and female, and were an average age of 42.9 +/ - 9.2 years, 
suggesting more variation in their ages and therefore illness-history than the 
sample recruited here (mean age 22.5). Furthermore, 12 of the 14 subjects 
reported had known comorbidities (including psychosis, OCD, alcohol abuse, 
bipolar disorder and anorexia nervosa) and 11 of the 14 were considered 
treatment-resistant. The discrepancy between study findings may be due to the 
comorbidities, since GABAergic deficits have been shown in other psychiatric 
disorders such as psychosis and bipolar disorder (Benes et al., 2007) and alcohol 
abuse (Behar et al., 1999). In this respect, the subjects described in this study 
represent a less complex pathology and are therefore better suited to answering 
the question of whether a GABA deficit exist solely in depressed subjects. 
 
Besides the differences in population characteristics, there were some 
methodological differences between this study and that reported by Sanacora et al 
(1999). While the MR spectroscopy voxel was positioned similarly (centred on the 
midline of the occipital cortex), they used a 2.1T Oxford scanner where this study 
utilised a 3T GE scanner. Additionally, while both studies employed difference-
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editing techniques, they utilised the DANTE pipeline, whereas this study used 
MEGA-PRESS, and subtle differences may exist between these acquisition 
protocols. 
 
The hypothesis that PIGF would be lower in currently depressed subjects was 
informed by literature suggesting that gamma (30+ Hz) frequency oscillations are 
driven by an interaction of cortical GABAergic interneurons acting (reciprocally) 
upon superficial layer pyramidal neurons (Sohal, 2012), a theory supported by 
modelling studies which demonstrate that peak gamma frequency is dependent on 
GABA:AMPA ratio (Brunel, 2003) and a reported correlation between peak 
induced gamma frequency and MRS GABA+ concentration in V1 
(Muthukumaraswamy et al., 2009). Together these reports suggest that PIGF 
references GABAergic function, particularly via fast GABAA receptors. Since the 
previously reported reduction in GABA+ levels in depressed subjects was 
suggested to reflect an alteration in the functional physiology of GABA in 
depression, rather than just a global volume reduction, PIGF was employed as a 
measure of GABAergic function. No difference was found in PIGF of the CD group 
compared with HC. However, since no difference was found in MRS GABA 
measures either, these null findings support one another.  
 
No difference in GABA or PIGF was found in the family history group. The 
hypothesis for GABA and PIGF in the family history group relied upon the 
assumption that both measures would be reduced in the CD group. Since PIGF is 
highly heritable, at approximately ~90%, (van Pelt et al., 2012), and so is 
depression, we hypothesised that PIGF would be reduced in the FH group. If MRS 
GABA+ was also reduced compared to the control group, this would suggest that 
the altered GABAergic function giving rise to gamma oscillations is a trait marker of 
depression and would have potential as a biological marker. Finding that neither 
measure was reduced in the FH group supports the notion that GABA and PIGF 
may not be reduced in the CD group.  
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While the GABA and PIGF results presented here do not couple with hypotheses 
from the imaging literature, this is the first study to investigate PIGF in currently 
depressed subjects as a marker of GABAergic function, and the first to combine 
this sample with samples of remitted depressed subjects and family history 
subjects in order to identify the type of biomarker any positive finding might 
represent. 
 
In contrast with the hypothesis, the visually evoked M80 component was not 
reduced in CD or FH groups. A reduction in M80 amplitude was hypothesised 
because in an earlier study (chapter 3), RD subjects exhibited a 46% reduction in 
pattern-onset M80 amplitude.  
 
Few other studies have reported changes in early VEPs in psychiatric disorders, 
and only one reported altered C1 (M80 equivalent) amplitude in major depression. 
Normann et al (2007) utilised a small (0.5°) checkerboard-reversal while recording 
EEG. Forty depressed subjects and seventy-four control subjects participated in 
the study. They demonstrated that the whole group (CD + HC) demonstrated 
markedly decreased M80 amplitude after 10 minutes of visual presentation 
compared with baseline, and increased P1 and N1 after 30 minutes of visual 
presentation. Between groups analysis of a subset of matched depressed and 
control subjects revealed that in the CD group, C1 and N1 were actually increased 
in amplitude while P1 was decreased. The authors suggest that this represents 
impaired-response plasticity in the depressed group. While this study is difficult to 
compare directly with the results described in this chapter because of differences 
in methodology, the findings of Normann et al (2007) suggest that depressed 
subjects’ visually evoked C1 (M80) amplitude is less-plastic and thereby less 
affected by visual stimulation. 
 
Finding a reduction in visually evoked M80 amplitude in remitted depressed 
subjects but not currently depressed or family history subjects rules out the M80 as 
a state- or vulnerability marker of depression. One explanation is that reduced M80 
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is a marker of recovery from depression and future studies should investigate 
whether there is a clinical-improvement-dependent decrease in M80 amplitude.  
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Chapter 6. Dynamic causal modelling of canonical micro circuitry 
under the free energy principal: predictors of imaging measures 
and inference on the depressed brain. 
 
6.1 Rationale 
Dynamic causal modelling (DCM) is a statistical inference technique for 
neuroimaging, which relies on predictive coding under the free energy principal. 
The concepts of predictive coding and free energy form a unified theory of the 
hierarchical brain, explaining how the brain is optimised in its anatomy to generate 
a model of ‘the world’ in order to explain its senses (Clark, 2012). A particular 
implementation of DCM utilises a neuronal mass model, based upon neuronal 
assemblies in a biologically plausible canonical microcircuit. Using a Bayesian 
approach to match the spectra of this generative model to MEG obtained in-vivo 
spectra permits inference about laminar specific cortical circuit connectivity from 
MEG spectra.  
 
In this experiment DCM was applied to MEG spectra obtained from the four 
cohorts described in the previous chapter. DCM may be more sensitive to 
alterations in the disease state than conventional neurophysiology or neuroimaging 
measures, which could be advantageous in studying psychiatric disorders, such as 
depression, where specific neurobiological anomalies are hypothesised. As such, 
DCM may reveal alterations of components of the GABAergic system at the 
microcircuit level, but which are not always of great enough effect size to influence 
the MRS GABA and MEG γ-oscillation measures utilised in previous chapters.  
 
Two statistical analyses were performed: first, parameters from the model were 
compared between groups. Second, the ability of the model parameters to predict 
primary imaging measures (GABA & γ -frequency / amplitude) was evaluated 
between groups using the Fisher r-to-z transform. Differences in these correlations 
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may explain why purportedly global GABAergic dysfunction in depressed subjects 
may not result in altered γ-measures. 
6.2 Background 
For an introduction to, and overview of predictive coding and dynamic causal 
modelling, the reader is directed to section 1.5 of the introductory literature.  
6.3 Methods 
6.3.1 Subject characteristics 
The data described in chapter 5 was used in this experiment. This consisted of 
four subject groups: healthy controls, healthy subjects with a family history of major 
depressive disorder, currently depressed subjects and remitted depressed 
subjects. Population size, mean age and BDI score are summarised in table 5.1. 
6.3.2 DCM & canonical microcircuit model  
A broad range of attributes including membrane potentials, conductance and time 
constants, among others, define neuronal populations. Mean field approximations 
summarise the behaviour of a neuronal population in terms of an ensemble density 
(Moran et al., 2009). Neural mass models describe the interaction of the means in 
this ensemble. 
 
Under the assumption that the data represents a stochastic, stationary process 
(i.e. the probability distribution is not affected by time), neurophysiological data can 
be summarised as a cross-spectral density matrix; 𝑔(𝑤)𝑐  at frequency w (for each 
frequency of interest). These cross-spectral densities summarise long time-series 
data compactly and additionally permit analysis of modelling using conventional 
spectral analysis. In this experiment, the power spectral density of the virtual 
sensor time series was modelled. 
 
DCM implements a neural mass model where each population within a defined 
microcircuit is modelled with pairs of first-order differential equations; 
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?̇?𝑣 = 𝑥𝑖̇  
?̇?𝑙 =̇  𝜅𝐻(𝐸(𝑥) +  𝐶(𝑢)) −  2𝜅𝑥1 − 𝜅
2𝑥𝑣 
(3) 
 
where 𝑘 = rate constant, vectors 𝑥𝑣 and 𝑥𝑖 correspond to the mean voltages and 
currents (microcircuit population output), of which each element corresponds to the 
hidden state of the population at each source. 𝐸(𝑥)  and 𝐶(𝑢)  represent 
endogenous and exogenous components respectively. These equations serve to 
convolve presynaptic inputs into postsynaptic responses. This model has been 
described and implemented previously (Moran et al., 2009, Muthukumaraswamy et 
al., 2013). The endogenous component, 𝐸(𝑥), is a mixture of the mean firing rates 
of other populations. These are a sigmoid activation function dependent on 
membrane depolarisation approximated with a linear gain function. Endogenous 
inputs can be intrinsic or extrinsic. Intrinsic connections can arise fo rm any 
population, while extrinsic connections arise only from excitatory pyramidal 
populations (i.e. projection neurons). The resulting model output is converted to 
time series data by a bilinear modelling procedure , to which the noise model 
described below is added post-hoc.  
 
Exogenous inputs, 𝐶(𝑢) =  𝐶𝑢, are scaled by the exogenous input matrix 𝐶 ∈ ℜ𝑠𝑥𝑠  
(where ℜ𝑠𝑥𝑠  is a connection matrix) so that each source-specific innovation 
𝑢(𝑡) ∈ ℜ𝑠𝑥1  excites the spiny stellate populations. The spectral density of 
exogenous input, 𝑔(𝑤)𝑤, comprises white / Gaussian (𝛼) and pink (f
--1) (𝛽) noise;  
 
𝑔𝑘(𝑤)𝑢 =  𝛼𝑢 +  𝛽𝑢/ 𝑤 
(4) 
The cortical microcircuit in figure 6.9.1 was constructed based on the description 
by Bastos et al (2012). Unlike the model described by Moran (2009), this model 
consists of four populations, superficial and deep pyramidal populations, granular -
 140 
 
layer spiny stellates and cross-laminar inhibitory interneurons. This model differs 
from that of Bastos et al (2012) in the addition of an excitatory connection between 
superficial pyramidal and deep pyramidal populations (G13+) and having removed 
an inhibitory connection between superficial pyramidal and spiny stellate 
populations (G2). The differential equations describing these populations, along 
with an overview of the signal generation, are presented in figure 6.9.2. 
 
The previously prescribed generative model is inverted to obtain the posterior 
densities of the parameters using variational Bayes, as detailed in equation (1) by 
maximising the negative free energy (equation 2) (Friston & Penny, 2011). Since 
the shape and orientation of neuronal populations, relative to the cortical surface 
are known to affect the contribution strength of each population to scalp recordings 
(see chapter 1.3), the output of each source, 𝑔(𝑥), is a weighted mixture of 𝑥𝑣 
(mean voltage) with greater weighting on superficial pyramidal populations (80%) 
than deep pyramidal or interneuron populations (20% each).  
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Figure 6.9.1. The canonical microcircuit. Each G number represents an anatomical connection 
between 2 populations. The sign (+/-) refers to excitatory or inhibitory connection. 
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6.3.3 Model Parameter Selection Procedure 
The model fitting procedure used in this experiment involved three components. 
Initially, a minimally prescribed (maximum variables) model was fit, whereby 16 
parameters are able to vary (by 1/8 around a prior). These parameters, and their 
priors, are found in table 6.2. The initial fitting of this 16 -parameter combination 
results in a ‘best estimate’ for the posterior density, but does not consider 
permutations of the parameters (i.e. including 16 parameters rather than a subset). 
As such, a post-hoc Bayesian model selection technique, described by Friston 
(2011), was employed. This technique uses the Laplace approximation (Gaussian) 
to estimate the posterior density on every possible combination of variable 
parameters without refitting the model. This method is equivalent to fitting the 
model several times over, on each iteration fixing one of the variable parameters 
then comparing the log-evidence (free energy) for each model.  
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Figure 6.9.2 Coloured boxes: Summary of state equations for the neuronal mass model describing the voltages of each population accor ding to their 
excitatory and inhibitory inputs. Population outputs are weighted (left) to produce a single model output. This is converted to a time series, Fourier 
transformed (as per empirical data) and a noise model added post-hoc so as to match brain data. 
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Parameter Description Prior π (σ) 
G1 (intrinsic) SS self-gain, inhibitory 0.0962 (1/8) 
G3 (intrinsic) II  SS, inhibitory 0.5163 (1/8) 
G4 (intrinsic) II self-gain, inhibitory 0.0405 (1/8) 
G5 (intrinsic) SS  II, excitatory 0.2708 (1/8) 
G6 (intrinsic) DP  II, excitatory 0.6978 (1/8) 
G7 (intrinsic) SP self-gain, inhibitory 0.3997 (1/8) 
G8 (intrinsic) SS  SP, excitatory 1.2351 (1/8) 
G9 (intrinsic) II  DP, inhibitory 0.4567 (1/8) 
G10 (intrinsic) DP self-gain, inhibitory 0.4379 (1/8) 
G11 (intrinsic) II  SP, inhibitory 0.5173 (1/8) 
G12 (intrinsic) SP  II, excitatory 0.3120 (1/8) 
G13 (intrinsic) SP  DP, excitatory  0.7613 (1/8) 
D ** Firing rate gain function 0.0312 (1/8) 
b1* (α)      White (Gaussian) noise  (1/8) 
b2* (β)      Pink noise (1/f) (1/8) 
L Weighting on J 1.93 (1/8) 
T1 Time constant: II 0.2460 (0) 
T2 Time constant: SP 0.3922 (0) 
T3 Time constant: SS 0.1313 (0) 
T4 Time constant: DP 0.1178 (0) 
*b1+b2 =  𝐶(𝑢) ,  
**D = 𝐸(𝑥) 
Table 6.2. Showing only parameters whose prior may vary in fitting the model.   
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6.4 Results 
The post-hoc parameter selection procedure resulted identified a best-fit model 
required 9 variable parameters, including 4 inhibitory and 1 excitatory parameter 
as well as firing rate and model noise parameters (G1, 7, 8, 9, 11; L, D and b1 & 
b2). Group averages for these parameters are depicted in figure 6.9.3. 
 
Multivariate ANOVA was used to compare means for each group (HC, RD, CD, 
FH) for each parameter with post-hoc Bonferroni tests. There was no main effect 
of group on model parameters (table 6.3.) however; custom hypothesis tests 
(simple contrasts) revealed that both CD and FH groups differed significantly from 
HC in the strength of G9 (interneuron mediated inhibition of infragranular pyramidal 
cells: CD: F=0.118, p=0.026, FH: F=0.102, p=0.038). This was not significant in 
post-hoc Bonferroni tests (p=0.157 and p=0.227 respectively).  
 
Model Parameter F p df 
G1 .375 .772 3 
G7 1.319 .277 3 
G8 1.484 .228 3 
G9 2.168 .101 3 
G11 .582 .629 3 
D 1.903 .139 3 
b1 1.588 .202 3 
b2 .937 .428 3 
L 1.024 .389 3 
Table 6.3. MANOVA interaction term for between-group effects on the model parameters. 
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Figure 6.9.3. Demonstrating the parameters needed to vary in order to fit the data. Green = healthy controls, Blue = remitted depression group, red = 
current depressive episode group, purple = family history of depression group.
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6.5 Discussion 
The results of this study demonstrated a trend towards increased interneuron-
mediated inhibition of layer 5/6 pyramidal cells in subjects meeting MINI criteria for 
a major depressive episode, as well as healthy subjects reporting a family history of 
major depression (who are therefore assumed to have a vulnerability to depression) 
compared with the healthy control group.  
 
The finding of altered interneuron-mediated inhibition (inhibitory interneuron 
function) is in support of the main hypothesis of chapter 5; that is, GABAergic 
function is altered in depressed subjects. While these differences were not 
significant after multiple comparison correction, the study does suggest that DCM 
could be a sensitive tool for studying clinical groups or differences induced by 
pharmacological manipulation, and may be more sensitive to altered 
neurophysiology than standard imaging measures (or may form a useful adjunct). A 
trend towards (but failure to reach significance in) altered G9, and therefore altered 
GABAergic inhibition, is also fitting with the MRS and peak-induced gamma 
frequency results described in chapter 5. Combined, these multimodal imaging and 
modelling results report no difference in GABAergic measures in depressed 
subjects, compared with controls. 
 
The visual stimulation (grating) paradigm utilised in this MEG experiment was 
chosen because it reliably induces a gamma-band response. As such, the intrinsic 
‘G’ parameters selected by the post-hoc Bayesian model selection procedure 
supports theoretical evidence that gamma responses are a locally generated 
phenomenon, mediated by an interplay of superficial pyramidal cells and inhibitory 
interneurons (PING) (Brunel, 2003). Parameters G1, 7, 8, and 11 act directly on 
these populations, altering the amount of excitation or inhibition within the 
populations. 
 
The inhibitory parameter G9 affects deep layer (L5/6) pyramidal cells, which 
contribute less to the gamma-band response, but are associated with beta-
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frequency responses (figure 6.7, as in Xing, 2012). As such, follow-up analyses 
should investigate whether similar paradigms induce a beta-frequency response. 
Moreover, subsequent spectral-DCM studies in healthy subjects should focus on 
the relationship between intrinsic microcircuit parameters and freque ncy-specific 
oscillatory responses. This approach could both validate the microcircuit model, and 
provide evidence from humans to support theories from computational 
neuroscience about the neuronal aetiology of frequency-specific oscillations. 
 
This experiment is the first to apply a DCM canonical microcircuit model to probe 
the neurobiology of major depressive disorder. From this perspective, this study 
suggests that the DCM approach to studying clinical neurobiology is, when paired 
with a strong hypothesis, statistically sensitive and may be particularly useful in 
studying disorders where altered spectral responses are observed, such as in 
schizophrenia and epilepsy.  
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Chapter 7. Effect of a NMDA receptor antagonist ketamine on 
oscillations in primary visual and motor cortices and dynamic 
causal modelling 
 
7.1. Abstract. 
The NMDA receptor antagonist ketamine has demonstrated remarkable and rapid 
antidepressant efficacy in treatment resistant depressed subjects. The mechanism 
of action of ketamine is complex and not fully understood, with altered glutamatergic 
function, alterations of high-frequency oscillatory power (Wood et al., 2012) and 
global effects on -amino butyric acid (GABA) levels (Wood & Hertz, 1980) all noted 
pre-clinically in animal studies. Here we used magnetoencephalography (MEG) in a 
single blind, crossover study to assess the neuronal effects of 0.5 mg/kg 
intravenous ketamine on task-related high-frequency oscillatory activity in visual 
and motor cortices. Consistent with preclinical findings, ketamine reduced peak 
gamma frequency in visual cortex and significantly increased gamma-band 
amplitudes in motor and visual cortices – an effect previously linked to cortical 
pyramidal cell disinhibition, providing directly translatable evidence of this 
hypothesis to humans. 
7.2 Background 
In the first clinical trial of ketamine as an antidepressant treatment for treatment-
refractory MDD (treatment resistant depression), Zarate and col leagues (2006) 
demonstrated that a 0.5mg/kg infusion over 40 minutes significantly reduced 
depressive symptoms within 110 minutes compared with subjects receiving 
placebo. Moreover, 71% of the n=17 subjects who received ketamine met criteria 
for ‘responding’ and 29% met criteria for remission within 24 hours. Understanding 
the mechanism of this effect, through studying its neurophysiological correlates, will 
aid in the refinement of biomarkers of anti-depressant responses, and may provide 
novel mechanistic targets for future pharmacotherapeutic development. For an 
introduction to the proposed mechanism of action of ketamine, as well as an 
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overview of the current imaging and preclinical literature on the use of ketamine, the 
reader is directed to section 1.2.5. 
 
7.3 Experiment: Effects of sub-anaesthetic, intravenous ketamine on visual 
and motor cortex responses 
7.3.1 Rationale 
The aforementioned studies support the disinhibition hypothesis of NMDAR 
antagonism because increased superficial pyramidal cell excitement permits 
increased synchrony and thereby increased gamma power. While evidence of this 
mechanism accumulates in preclinical models, translation into humans is lacking, 
despite the proposed functional link with its antidepressant effect. 
Magnetoencephalography (MEG) is a powerful tool for measuring 
pharmacologically induced changes in oscillatory dynamics in humans because of 
the increased sensitivity to altered neuronal function afforded by this approach 
compared with common imaging techniques such as functional MRI or near-infrared 
spectroscopy (reviewed in Muthukumaraswamy, 2014). Using MEG, this 
experiment aimed to determine whether ketamine-induced NMDAR antagonism 
indeed results in altered cortical excitation-inhibition balance in humans. To date, 
there has been no MEG study in humans comparing the effect of ketamine on 
gamma band oscillations in a placebo-controlled, single blind crossover design. 
7.3.2 Methods 
The study took the form of a placebo-controlled, single blind crossover design. 
Subjects made 2 or 3 visits to CUBRIC. Day 1 (optional, completed by some on day 
2) consisted of a screening questionnaire using the MINI to screen for any 
psychiatric illness and discussion about the tasks involved in the study and 
collection of informed consent signature. Days 2 and 3 were identical apart from the 
infusion (which alternated so that whichever drug was not administered on day 2 
(placebo or ketamine) was administered on day 3). Days 2 and 3 were scheduled a 
minimum of 2 weeks apart to allow for washout. Drug order was pseudo-random 
and sessions counterbalanced. 
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Experiment days consisted of a 90-minute MEG scan where a number of paradigms 
were completed, including a simple visual grating and motor abduction paradigm 
detailed below. The scan protocol is depicted in figure 7.1. On either day 2 or 3, 
subjects who had not previously had an MRI scan in CUBRIC participated in a 12-
minute structural MRI before commencement of the study day. All subjects fasted 
for 8 hours (or overnight) before taking part in each study day. 
 
After scanning, subjects were given lunch (a choice of sandwich), completed the 5-
ADSC and BDI questionnaires and remained under the supervision of an 
anaesthetist for a minimum of 1 hour (>90 minutes after infusion terminated), or 
until the clinician discharged them. 
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Figure 7.1. MEG scan and infusion timetable. S.E.M, saccadic eye movement; VISMOT, visuomotor paradigm described here; N-BACK, working 
memory task; REST, resting recording with no task.
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7.3.2.1 Sample characteristics 
Twenty healthy, male subjects between the ages of 18-45 were recruited to the 
study. None had any history of psychiatric disorder as screened by the MINI. Those 
who use recreational drugs or who smoked more than 5 cigarettes a day were 
excluded. All subjects had a BMI between 18 - 30 kg/m2. 
 
7.3.2.2 Experimental Procedure, Recordings & Analysis 
MEG & Peripheral Recordings 
The 275-channel CTF MEG suite at CUBRIC was operated in supine position to 
keep subjects confortable. A further 29 channels were recorded for noise 
cancellation. Fiducial (reference) coils were attached 1cm superior to the nasion 
and, bilaterally, 1cm anterior to the tragus for assessment of head position within 
the MEG dewar. MEG data were sampled at 1200Hz using axial gradiometers 
analysed as synthetic third-order gradiometers (Vrba, 2001). Peripheral CNS and 
physiological monitoring equipment included heart rate (HR), non-invasive blood-
pressure cuff (BP), oxygen saturation (SpO2) and expired carbon-dioxide 
concentrations (EtCO2) using a Veris MR Vital Signs monitoring system (Pulse 
Oximetry, MedRad). Further peripheral measures included bipolar electro-ocular 
(EOG) and electrocardiogram (ECG) recordings and electro-myographic (EMG) 
recordings of (facial) frontalis and temporalis musculature. Finally, pupilometry and 
corneal-reflection eye tracking was recorded (see figure 7.1 for paradigms 
recorded) using an IVIEW X MEG (‘MEG250’ by SensoMotoric Instruments) for 
monocular tracking of the right eye. 
 
Racemic ketamine hydrochloride was obtained from the Pharmacy Department, 
University Hospital of Wales. Infusions were administered a t a rate of 0.25mg/kg 
ketamine in 50mL saline, over 40 minutes (or in the case of placebo condition, 
saline only, over the same time) via intravenous cannula in the dorsum of the left 
hand. An initial bolus of 0.25mg was administered immediately prior to 
commencement of the 40-minute infusion (resulting in 0.5mg/kg total), which was 
controlled by an Asena-PK infusion pump (Alaris Medical, UK). 
 154 
 
 
Visual Grating & Motor Abduction Paradigm 
The visuomotor paradigm has been utilised and described in previous pharmaco-
MEG studies (Muthukumaraswamy et al., 2013) and is based on two separate (one 
visual, one motor) paradigms (Muthukumaraswamy et al., 2013) but which has 
been packaged into one task. Both the task(s) have been shown to elicit a strong 
response in their respective primary cortices (V1, M1), including a gamma 
frequency response widely assumed to be PING generated (see discussion).  
 
Subjects were presented with a vertical, stationary, square-wave grating patch (3 
cycles per degree) on a mean luminance background. Of a total 150 trials, 75 were 
displayed at maximum contrast, while the remaining 75 were displayed at 70%. The 
patch was subtended 8° both horizontally and vertically around the centre, with a 
continually displayed, small, central, red fixation square. The grating patch was 
displayed for between 1.5 and 2s with 3s ISI (fixation square only). Stimuli were 
displayed by a Sanyo XP41 LCD back-projection system displaying at 1024 x 768 
at 60Hz. Subjects were instructed to fixate on the red square throughout the trial 
and perform a finger abduction at grating-offset. Finger abduction was of the right 
first dorsal interosseus so that the index finger made a  short, sharp abduction in the 
direction of the thumb. This finger abduction was recorded by both a bipolar EMG 
electrode placed either end of the muscle, and by an optical displacement meter 
(Muthukumaraswamy, 2010). 
 
All subjects had a structural MRI scan (either as part of the study, or as volunteers 
in previous studies in CUBRIC). This was conducted on a GE HDx 3T MR scanner 
with 8 channel head coil. The sequence was a fast spoiled gradient echo (FSPGR) 
anatomical scan obtained with 1mm isotropic voxel resolution. Co-registration with 
MEG data was achieved by matching the fiducial coil positions recorded in MEG to 
the same location on MR images (by eye, using photographs).  
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MEG Pre-processing 
Markers were placed at the initiation of finger abduction, based on a shift in the 
amplitude of the optical displacement meter (change by 3 standard deviations 
above mean noise, as per (Cheyne et al., 2008)). Where noise masked a shift 
corresponding to a displacement, the EMG trace from the first dorsal interosseus 
was used instead. Placement of all markers was visually inspected. Data were 
epoched into 4s trials (from 2s before to 2s after the visual stimulus onset - a 
marker automatically sent to an auxiliary channel on the MEG acquisition computer 
by the stimulus host computer) to create a dataset containing only visual grating 
trials. The original dataset was further epoched into 4.5s trials consisting of 1.5 pre- 
and 3s post- finger abduction onset to create a dataset of only motor responses. 
 
Trials from both datasets were visually inspected for gross artefacts (head 
movements affecting a large number of sensors). Data were further quality 
controlled by rejecting trials based on blinks, for which a blink threshold of 70muV 
was used for the EOG trace during stimulation. Trials were further quality controlled 
using response time; either the optical displacement meter or finger EMG 
(whichever was used to epoch the dataset) was used to define a response. 
Response time was calculated as the difference between response (peak at 3 SD 
above mean noise, indicative of response) and the stimulus offset time. 
 
Motor response source localisation 
For source localisation datasets were beamformed using SAM (Vrba, 2001) (4mm 
isotropic resolution) with a set of beamformer weights calculated from a global 
covariance matrix in the gamma frequency band. The motor paradigm elicits a 
narrowband response between 60-90 Hz (Muthukumaraswamy et al., 2013). SAM 
was used to generate a virtual sensor for each beamformer voxel and statistical 
(paired t-test) images of pre-stimulus vs. post-stimulus power were generated.  
 
The virtual sensor location used for analysis was defined based on best-performing 
location (highest t-statistic). Time windows for the reconstruction were guided by 
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previous reports (Cheyne et al., 2008; Hamandi et al., 2011; Muthukumaraswamy, 
2010) where a baseline of -1.3 to  -1s was contrasted with 0-0.3s active.  
 
The motor paradigm gamma-response is termed movement-related gamma 
synchrony (MRGS). The motor paradigm also elicits a robust bilateral beta de-
synchronisation (motor related beta de-synchronisation) followed by a contralateral 
beta-rebound (post-movement beta rebound / synchronisation, PMBR). The 
beamforming and virtual sensor reconstruction procedure was repeated for each of 
these components with the beta range defined as 15 – 30 Hz. Guided by previous 
reports (Muthukumaraswamy et al., 2012), the beta desynchronisation component 
was identified between -0.3-3s while the beta-rebound component was identified 
between 1-2.5s post finger-abduction. Virtual sensors were created separately for 
each subject and each condition (pre- and post- placebo and ketamine).  
 
The time-frequency content of the virtual sensors was estimated by applying the 
Hilbert transform to estimate the amplitude content in 0.5 Hz windows between 1 – 
100 Hz. In the first instance, for both experimental paradigms, the time-frequency 
spectra were estimated on the whole trial (including baseline period), with no 
baseline correction applied, to check for drug-induced differences in the pre-
stimulus period which might confound any stimulus induced changes in frequency 
or amplitude. Those sensors that did not show a difference in baseline time-
frequency content were included in a second spectral estimation analysis using the 
same approach (Hilbert transform on 0.5 Hz windows between 1-100 Hz) with 
amplitude calculated as percentage change from baseline (baseline defined as the 
trial duration up to stimulus onset or finger abduction). Alternatively, sensors that 
did show a difference in baseline spectra in the initial analysis were re-analysed 
using a subtracted baseline approach. This approach permits analysis of stimulus-
induced changes in time-frequency content while accounting for pre-stimulus 
changes and has been used previously (Campbell, Sumner, Singh, & 
Muthukumaraswamy, 2014; Muthukumaraswamy et al., 2013). For gamma-range 
analysis, peak amplitude measures were utilised. For beta-band analysis, mean 
amplitude was used in place of peak amplitude.  
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Visual response source localisation 
Analysis of visual responses was procedurally the same as motor responses, 
however, based on previously reported optimisation, the visual paradigm gamma 
range was defined as 30-80 Hz (broad), beta as 13 – 30 Hz (Muthukumaraswamy & 
Singh, 2012) and for SAM, a -1.5s to 0s baseline was contrasted with 0-1.5s active 
period. As per the motor analysis, time frequency content was reconstructed at a 
best-performing virtual sensor location (this time in V1), this time using the Fourier 
transform, which, given that frequency is stable across time, provides better  
estimation of frequency content, but as a consequence is less sensitive to time 
resolved changes than the Hilbert transform. 
 
For statistical analyses, a 2 x 2 repeated-measures ANOVA was used, with 
condition and time as factors (condition = ketamine or placebo, time = pre- or 
post/during- infusion), with the interaction term of primary interest.    
7.3.3 Results 
Mean subject age was 25.7 (SD 6.2, range 19-39). Of the twenty recruited subjects, 
1 withdrew prior to ketamine infusion and an error was made in MEG acquisition for 
a second, so that at analysis n=18 subjects. 
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Sub No. Age Post-QC. Data Available For: 
  Visual Analysis (all) Motor Gamma Motor Beta 
1 34 Yes Yes Yes 
2 23 Recording error 
3 36 Yes Yes Yes 
4 24 Yes  Yes 
5 25 Yes    
6 -- Withdrawn 
7 28  Yes Yes 
8 29 Yes Yes Yes 
9 30 Yes Yes Yes 
10 21 Yes Yes Yes 
11 23 Yes Yes Yes 
12 21 Yes Yes Yes 
13 20 Yes Yes Yes 
14 20 Yes   
15 22 Yes   
16 19 Yes Yes Yes 
17 21 Yes Yes Yes 
18 20 Yes   
19 39    
20 35 Yes Yes Yes 
Table 7.1. List of subjects and ages. Those included in each step of analysis indicated by ‘yes’.  
 
Measures such as response time during the motor abduction, number of visibly 
noisy trials and extent of head-movement could bias any effects observed in 
dependent measures if these are significantly increased or reduced by either drug. 
As such, these were compared between conditions (see table 7.2). Response time, 
head movement and trials rejected did not change between conditions. As 
expected, EOG velocity during a saccadic eye-movement task decreased 
significantly in velocity after ketamine (drug by time interaction, F(1,16)=6.833, 
p=0.019), demonstrating significantly more sedation in the post-ketamine condition 
than other conditions.  
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Eye tracking data with corneal reflexion was available for only 2 subjects both pre- 
and post- ketamine. For these subjects, maximum eye movement (in visual 
degrees) was calculated for each trial for both vertical and horizontal movements. 
These were entered to a paired-t of post vs. pre infusion for each subject and 
condition, revealing no differences in eye movements post ketamine infusion (table 
7.3, figure 7.3). 
 
 Pre Placebo Post Placebo Pre Ketamine Post Ketamine 
Response 
Time 
(emg) 
Mean 0.31 0.26 0.33 0.35 
SD 0.07 0.11 0.10 0.08 
Response 
Time  
(LM) 
Mean 0.47 0.49 0.60 0.57 
SD 0.24 0.17 0.16 0.21 
Amp 0.23 0.11 0.26 0.29 
SD 0.51 0.36 0.62 0.75 
Head 
Movement 
Mean 0.48 0.37 0.33 0.30 
SD 0.40 0.30 0.56 0.38 
Visual 
Trials 
Rejected 
Mean 24 18 18.11 29.44 
SD 24.27 18.27 15.41 17.66 
Motor 
Trials 
Rejected 
Mean 11.16 8.91 9.66 14.16 
SD 14.34 15.58 13.65 11.73 
Table 7.2. Mean response time and head-movements by condition. No significant difference in the 
number of rejections between conditions. 
 
Subject Direction Mean SD t DF p 
1 Horizontal 0.049 0.39 0.535 17 0.6 
Vertical -0.35 1.36 -1.098 17 0.287 
2 Horizontal -0.018 0.13 -0.702 26 0.489 
Vertical -0.34 0.30 -0.589 26 0.561 
Table 7.3. Pre and Post ketamine infusion corneal reflexion eye movements compared for 2 
subjects.
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Figure 7.3. Eye tracker eye movements in visual degrees for 2 subjects showing horizontal and vertical movements, pre and post ketamine infusion.
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Visual grating stimulus 
The visual grating stimulus utilised here robustly elicits both phase-locked and 
induced gamma responses in V1. The virtual sensor reconstruction demonstrated 
no difference in pre-stimulus gamma-frequency content, so a percentage-change 
from baseline approach was uti lised for analysis. Peak analysis was conducted by 
collapsing data over time into transient (0-300ms, evoked / phase-locked) and 
sustained (300-1500ms, induced / non-phase-locked) responses and plotting the 
frequency vs. power plots so as to visually inspect peak amplitudes.  
 
Two-way, repeated measures ANOVA was uti lised to assess both frequency and 
amplitude measures. For high contrast, ANOVA interaction (drug x time) revealed 
no difference in amplitude (F(1,15)=1.361, p=0.261) but, as hypothesised, an effect 
whereby ketamine infusion reduced peak frequency (F(1,15)=4.461, p=.052). 
 
The same analyses were performed for the lower contrast grating. This revealed a 
significant elevation of induced gamma amplitude after ketamine (F(1,15)=4.79, 
p=.045) but no effect on frequency (F(1,15)=.319, p=.58). These measures are 
summarised in figure 7.4 with condition mean measures in table 7.5. 
 
For both maximum and 70% contrast visual stimuli, beta frequency (13 - 30 Hz) 
event related desynchronisation was reduced post ketamine (see figure 7.4, top). 
For both contrasts the ANOVA was highly significant (F(1,15)>120, p<10-8). 
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HIGH 
CONTRAST 
Pre Placebo Post Placebo 
Frequency Amplitude Frequency Amplitude 
Mean 50.66 184.08 51.40 184.99 
St Error 1.42 30.50 1.20 34.64 
 Pre Ketamine Post Ketamine 
Frequency Amplitude Frequency Amplitude 
Mean 51.22 170.80 49.10 205.98 
St Error 0.84 23.81 1.19 37.65 
LOW 
CONTRAST 
Pre Placebo Post Placebo 
Frequency Amplitude Frequency Amplitude 
Mean 42.96 86.47 45.40 85.48 
St Error 1.93 14.29 1.52 15.55 
 Pre Ketamine Post Ketamine 
Frequency Amplitude Frequency Amplitude 
Mean 45.35 86.57 46.58 113.82 
St Error 1.29 10.83 1.56 16.07 
Table 7.5. Average frequency, amplitude and fit error for each condition for the induced response.  
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Figure 7.4. Top: spectrogram showing time, frequency and amplitude for the high contrast grating for each condition. Bottom: induced gamma 
response in V1 for frequency (left) and amplitude (right) for high (top) and low (bottom) contrasts.  
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In addition to high frequency oscillatory activity, VEFs were also analysed. Using 
source-localised data from V1, data were band-pass fi ltered (Butterworth) 1 – 30Hz 
and baseline adjusted using a relative change method (-0.2 – 0s relative to stimulus 
onset). Since SAM data is sometimes missing the polarity data present in VEP data, 
waveforms were manually orientated (where necessary) based on a positive M1 
(P1) component. Repeated measures ANOVA was run at every sample point for 0 – 
3s and corrected using a post-hoc false-discovery rate (FDR). No significant drug, 
time or drug*time interaction was observed at any data point after FDR correction. 
Figure 7.5 shows waveforms for each condition, with both pre - and post-FDR 
correction overlaid.  
 
 166 
 
 
 
 
 
Figure 7.5. Visual evoked spectra from V1 virtual electrode. Red = placebo (saline), blue = ketamine. Light colour = pre-drug administration; dark 
colour = during drug administration. Pink dashed line = uncorrected p-value from repeated measure ANOVA interaction effect, cyan dashed line = 
FDR corrected.
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Motor paradigm 
The finger abduction task robustly elicits 4 components: a contralateral movement-
related gamma synchrony, bi lateral beta desynchrony followed by a contra-lateral 
beta-rebound (described previously, see Muthukumaraswamy (2010)). A virtual 
sensor was created corresponding to each component. Time-frequency analysis 
revealed an effect of drug on the baseline amplitude of the beta-rebound sensor 
(PMBR) (F(1,12)=4.18, p=0.0463), hence subsequent time-frequency analysis of 
this sensor utilised a subtracted-baseline approach. The MRGS and bilateral MRBD 
sensors did not differ in pre-stimulus amplitude, thus a relative change approach 
was used in subsequent time-frequency analyses (in percentage-change from 
baseline).  
 
Movement related gamma synchrony 
Repeated measures ANOVA with drug and time (pre vs. post) as factors was used.  
Gamma amplitude was significantly increased in a drug*time interaction 
(F(1,11)=8.95, p=0.014) as evident in figure 7.6. There was no effect on frequency. 
 
Movement-related beta-desynchrony & Post-movement beta synchrony 
Time-frequency analysis of the left and right movement-related beta desynchrony 
virtual sensors revealed increased power of ipsilateral (right) beta desynchrony 
(drug*time interaction, F(1,12)=7.178, p=0.02) but no effect on contralateral beta 
desynchrony (see figure 7.6) or frequency measures. There was no effect of drug or 
time on beta frequency or amplitude in the PMBS sensor. Mean measures for each 
component are listed in table 7.7. 
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Figure 7.6. Top: time-frequency reconstructions for each condition (averaged over subjects) from M1 contralateral gamma-located virtual sensor, with 
amplitude depicted by heat-map colours. Note increased colour-intensity (power) of MRGS in post-ketamine. Bottom: power-frequency for each 
condition (shading = SEM). Red = placebo, blue = ketamine. Light = pre- drug and dark colour = post / during drug. 
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Figure 7.7. Top: Left beta-desynchronisation virtual sensor, amplitude-frequency plot. Bottom: Right 
beta-desynchronisation virtual sensor. Red = placebo, blue = ketamine. Light = pre- drug and dark  
colour = post / during drug. 
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 Peak Frequency Peak Amplitude Mean Amp 
(Where used) 
MRGS Pre 
Placebo 
Mean 76.54166667 41.422475  
SD 3.414263752 29.14563436 
Post 
Placebo 
Mean 75.75 45.24466667 
SD 5.211438468 36.7904114 
Pre 
Ketamine 
Mean 78.20833333 45.577275 
SD 4.387266354 41.02053198 
Post 
Ketamine 
Mean 74.16666667 85.3874 
SD 3.277563766 66.12037713 
MRBD 
Left 
Pre 
Placebo 
Mean 21.84615385 -21.76375385 -15.31340735 
SD 3.19103311 6.588722662 6.056783654 
Post 
Placebo 
Mean 21.19230769 -20.26270769 -14.76864615 
SD 3.544587785 8.11810032 6.412487294 
Pre 
Ketamine 
Mean 19.61538462 -24.102 -17.06655101 
SD 3.001068186 8.948937082 8.116998527 
Post 
Ketamine 
Mean 23.65384615 -17.3404 -12.15338103 
SD 4.718688975 8.666206369 7.656192715 
MRBD 
Right 
Pre 
Placebo 
Mean 20.92307692 -17.68454615 -13.00123507 
SD 3.296754426 6.901485208 5.459895518 
Post 
Placebo 
Mean 20.26923077 -18.04042308 -12.4140248 
SD 3.677722261 7.814619336 6.610371443 
Pre 
Ketamine 
Mean 20.46153846 -17.54250769 -12.57946412 
SD 2.410580311 7.426666701 6.064520655 
Post 
Ketamine 
Mean 23.11538462 -13.5219 -8.656081052 
SD 3.465026732 11.13654697 7.743854137 
PMBR Pre 
Placebo 
Mean 18.92307692 0.5367846154 0.3349063845 
SD 2.243937702 0.2697239788 0.1629812574 
Post 
Placebo 
Mean 17.76923077 0.5943307692 0.3858602254 
SD 1.985524538 0.2093755413 0.1148808263 
Pre 
Ketamine 
Mean 19.15384615 0.6368 0.4263542046 
SD 1.985524538 0.2093755413 0.1148808263 
Post 
Ketamine 
Mean 21.80769231 0.5915076923 0.4140593392 
SD 1.588217837 0.2445059524 0.1617528074 
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Table 7.6. Summary table. Mean frequency and amplitude for each component of the motor 
response. 
 
7.3.2 Discussion 
This study reported findings from a combined visuomotor MEG paradigm recorded 
during a placebo-controlled, crossover, and single blind study of the effects of 
0.5mg/kg/40 minutes intravenous ketamine on cortical oscillations.  
 
In motor cortex, repeated measures ANOVA revealed significant amplitude increase 
of MRGS and right MRBD after ketamine administration. In visual cortex, induced 
gamma amplitude was significantly increased following ketamine to low-contrast 
(70%) grating patches, but not maximum contrast patches. During high contrast 
visual stimulation, peak gamma frequency was reduced. Furthermore, for both 
contrasts, alterations in gamma co-occur with a highly significant decrease in beta 
frequency event related desynchronisation (i.e. increased beta amplitude). These 
findings are in accordance with hypotheses from preclinical studies, however in 
human V1, the two hypothesised findings (increase amplitude and reduced 
frequency of gamma) occur in different tasks and appear to be contrast dependent. 
 
According to the PING model, gamma-band oscillations are generated locally by an 
interplay of superficial-layer pyramidal cell and inhibitory interneuron populations 
(Brunel, 2003; Sohal, 2012); a hypothesis supported by preclinical and primate 
studies (Bastos, Briggs, Alitto, Mangun, & Usrey, 2014; Xing et al., 2012). Both 
PING and preclinical studies, such as that described by Wood, Kim and 
Moghaddam (2012), demonstrate that NMDA receptor antagonism increases 
gamma oscillation amplitude, presumably via disinhibition (Homayoun & 
Moghaddam, 2007) of pyramidal cell populations. Our results in motor and visual 
cortex are in support of this mechanism.  
 
The lack of increased gamma amplitude to maximum contrast gratings in visual 
cortex is surprising, given that the visual stimulation paradigm used in this study has 
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been widely utilised for the primary purpose of eliciting a robust gamma response. 
This raises the possibility of a ceiling effect, whereby the visual paradigm response 
is so strong that affected receptors are at full saturation, meaning pharmacological 
up-regulation, or subtle modulations, are ineffective. Indeed, several studies have 
shown strong contrast dependence of MEG visual gamma responses (Perry, 
Brindley, Muthukumaraswamy, Singh, & Hamandi, 2014). While previous human 
pharmacological studies have shown increases in gamma oscillatory responses 
(Campbell et al., 2014; Saxena et al., 2013) here we used a different stimulus 
configuration which induces a higher amplitude response than those studies used. 
Similarly, the lack of effect in visual cortex is unlikely due to a dose-dependence 
issue, since the primary receptor target of ketamine, the NMDA receptor, has a 
similar density and laminar distribution in visual cortex as motor cortex (Zilles, 
Palomero-Gallagher, & Schleicher, 2004). 
 
It is known in both animal (Ray & Maunsell, 2010) and human (Perry et al., 2014) 
data that contrast strongly predicts frequency in V1 and the frequency and 
amplitude of LFP measures in V1 are not independent (Gieselmann & Thiele, 
2008), and our data are consistent with this showing lower peak frequencies to the 
lower contrast stimuli. The finding of reduced peak frequency to high contrast 
grating, but not the low contrast grating may reflect limitations in the estimation of 
peak frequency. It may be that high contrast stimuli, which elicit high amplitude 
responses close the amplitude ceiling, result in drug manipulation altering the 
frequency of the response. In this case high signal-to-noise levels permit excellent 
estimation of frequency.  
 
Conversely low contrast stimuli elicit lower amplitude responses (not at ceiling), and 
hence estimation of peak frequencies to low contrast stimuli is less accurate than of 
high contrast stimuli due to decreased signal-to-noise ratio. This might result in an 
amplitude shift but no reduction in frequency to the lower contrast stimulus. 
Alternatively, it may be that for the lower contrast stimuli, parameters determining 
peak frequency may be closer to floor levels making them more difficult to 
modulate. Nevertheless, when taken together, the visual data from this study can 
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be interpreted as directional modulation toward both reduced frequency (visual) and 
increased amplitude (visual and motor).  
 
This is not the first study to demonstrate localised effects of ketamine; Wood et al  
(2012) showed that NMDAR antagonism using MK801 in rats increased gamma 
amplitude in ACC but not OFC. Given that ketamine is used to model schizophrenia 
(Frohlich & Van Horn, 2014), and also shows efficacy as an antidepressant (Zarate 
et al., 2006), mapping the brain regions which show increased gamma amplitude to 
NMDAR antagonism is an important step in understanding how resulting 
behavioural effects are related to locally observed phenomena.  
 
Individuals with treatment refractory major depressive disorder and schizophrenia 
have both demonstrated altered excitability in the motor cortex in TMS studies 
(Maeda, Keenan, & Pascual-Leone, 2000; Pascual-Leone, Manoach, Birnbaum, & 
Goff, 2002), suggesting that this region may be particularly well suited to studying 
effects related to these disorders.  
 
Previous work has revealed a ro le for NMDA receptors in long term potentiation 
(Collingridge, Isaac, & Wang, 2004). LTP provides a molecular mechanism 
accounting for learning via synaptic potentiation and associativity. LTP is 
considered a driver of neuronal plasticity, which is defined as the ability to acquire 
information and make appropriate responses to subsequent stimuli. The ability to 
modulate plasticity, through pharmacological manipulation of NMDA receptors, 
could therefore be beneficial in depression, where sensory, cognitive, emotional 
and social remodelling may be therapeutic (Duman, 2002).  
 
A recent preclinical study demonstrated in vivo that NMDA receptors in the 
sensorimotor and motor cortices are critical for task-related learning. Furthermore, 
in visual cortex, the expression of NMDA receptors is experience-dependent on a 
short timescale, whereby visual experience can result in rapid insertion of NMDARs 
at the postsynaptic membrane. As such, the NMDAR antagonist induced increase 
in gamma amplitude in the visual and motor cortices presented in this paper may 
 175 
 
reference a modulation of synaptic plasticity in response to a simple visuomotor 
paradigm.  
 
To summarise, this study demonstrated that ketamine mediated NMDAR 
antagonism increases the amplitude of both beta and gamma oscillations in the 
motor and visual cortices and reduced the peak gamma frequency of visual cortex 
in response to 100% contrast visual stimulation. This supports a preclinical model of 
NMDAR antagonism increasing cortical excitability via disinhibition of pyramidal 
cells, and may be important for NMDAR mediated LTP. Given existing hypotheses 
about altered cortical excitation to inhibition balance in major depressive disorder, 
the finding presented here may reflect both the mechanism by which ketamine 
exerts its antidepressant effect, and a potential biomarker. 
7.4 Experiment: Ketamine affects microcircuit effective connectivity in V1: a 
DCM pilot study. 
7.4.1 Rationale 
Preclinical evidence suggests that the NMDA receptor antagonist ketamine 
increases the amplitude (power) of high-frequency (gamma band) oscillations via 
dis-inhibition of cortical pyramidal cells. The aforementioned study failed to find 
increased gamma-band amplitude in a maximum contrast visual stimulation task, 
but did find increased V1 gamma to 70% contrast stimulation and M1 gamma-band 
amplitude in a motor (finger-abduction) paradigm. Dynamic causal modelling of 
canonical microcircuits for spectral responses provides a novel; non-invasive, in-
vivo method for addressing the disinhibition hypothesis is humans.  
 
The neuronal mass model utilised in this experiment has been described previously 
(see chapter 6). This canonical-microcircuit, guided by the known architecture of 
human V1, contains four distinct neuronal populations: superficial pyramidal cells, 
granular layer spiny-stellate cells, infragranular (layer 5/6) pyramidal cells and 
across-layer inhibitory interneurons. Each of these populations has known 
anatomical projections (either excitatory of inhibitory) to other populations within the 
same microcircuit (intrinsic connections), thus if the mechanism of ketamine is to 
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increase gamma-power by disinhibition of pyramidal cells, particular connections 
within the model will be increased or decreased accordingly.  
 
This pilot study aimed to address 2 questions: first, does ketamine significantly alter 
the strength of any model parameters, as compared with placebo? Second, in 
addressing the aforementioned disinhibition hypothesis, after ketamine, which 
parameters predict the amplitude of gamma-band oscillations? 
7.4.2 Methods 
Data from the subjects described in section 7.3.2.1, who were included in the visual 
grating paradigm analysis, were used in this experiment. The participant sample 
consisted of 19 male subjects aged between 19-39 with a BMI between 18 - 30 
kg/m2 and no history of psychiatric disorder.  
 
The DCM canonical microcircuit described in chapter 6 was implemented. See 6.3.2 
for a full description of the model and implementation. The V1 virtual electrode time-
frequency data served as input for the model to match. Briefly, the procedure 
entailed fitting a full model, whereby the parameters in table 7.7 were able to vary 
by 0.125 around a prior value in order to fit the data. Post-hoc Bayesian model 
selection using the Laplace approximation (as described by Friston, 2011) was 
implemented to select the minimally-required selection of variable parameters (a 
subset) to fit the data and estimate their strength without having to rerun the model.  
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Parameter Description Prior π (σ) 
G1 (intrinsic) SS self-gain, inhibitory 0.0962 (1/8) 
G3 (intrinsic) II  SS, inhibitory 0.5163 (1/8) 
G4 (intrinsic) II self-gain, inhibitory 0.0405 (1/8) 
G5 (intrinsic) SS  II, excitatory 0.2708 (1/8) 
G6 (intrinsic) DP  II, excitatory 0.6978 (1/8) 
G7 (intrinsic) SP self-gain, inhibitory 0.3997 (1/8) 
G8 (intrinsic) SS  SP, excitatory 1.2351 (1/8) 
G9 (intrinsic) II  DP, inhibitory 0.4567 (1/8) 
G10 (intrinsic) DP self-gain, inhibitory 0.4379 (1/8) 
G11 (intrinsic) II  SP, inhibitory 0.5173 (1/8) 
G12 (intrinsic) SP  II, excitatory 0.3120 (1/8) 
G13 (intrinsic) SP  DP, excitatory  0.7613 (1/8) 
D  Firing rate gain /  0.0312 (1/8) 
b1 (α)      White (Gaussian) noise (1/8) 
b2 (β)      Pink noise (1/f) (1/8) 
L Weighting on J 1.93 (1/8) 
T1 Time constant: II 0.2460 (0) 
T2 Time constant: SP 0.3922 (0) 
T3 Time constant: SS 0.1313 (0) 
T4 Time constant: DP 0.1178 (0) 
Table 7.7. Parameters in the DCM CMC NMM. SS = Spiny stellate cell, II = inhibitory interneuron,  
SP = superficial pyramidal cell, DP = deep pyramidal cell.  
7.4.3 Results 
Post-hoc Bayesian model selection found that variation in 6 parameters was 
needed to fit the data (G1, 3, 5, 7, 8, & 11). These correspond to spiny-stellate 
population self-inhibition (G1-), Interneuron-mediated inhibition of spiny-stellates 
(G3-), Spiny-stellate mediated excitation of inhibitory interneurons (G5+), superficial 
pyramidal cells self-inhibition (G7-), spiny-stellate mediated excitation of superficial 
pyramidal cells (G8+) and interneuron-mediated inhibition of superficial pyramidal 
cells (G11-). These are depicted in figure 7.9. 
 
To address the question of whether ketamine significantly altered the strength of 
any of these parameters, they were entered into a repeated-measures ANOVA with 
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drug (saline vs. ketamine) and time (pre vs. post administration) as factors. 
Parameter G1 demonstrated a significant increase in a drug by time interaction, 
demonstrating that ketamine significantly increased the strength of G1 (F(1, 
15)=5.408, p=0.029), see table 7.8 for ANOVA results for the interaction term, for 
each parameter tested. 
 
Drug*Time Interaction F p df 
G1 5.805 .029 1,15 
G3 2.091 .169 1,15 
G5 0.160 .695 1,15 
G7 0.137 .717 1,15 
G8 0.13 .723 1,15 
G11 0.132 .721 1,15 
Table 7.8. Repeated measures ANOVA, drug*time interaction univariate results.  
 
To address the pyramidal cell disinhibition hypothesis of ketamine’s mechanism of 
action, a correlative analysis was performed. Note that this preliminary analysis 
aimed to demonstrate a relationship between gamma-band peak amplitude and 
model parameters in the absence of ketamine-elevated gamma amplitude (i.e. as 
per section 7.3.3, ketamine did not significantly increase gamma amplitude in the 
100% contrast visual data analysis, although a trend was evident).  
 
Correlational analyses were performed by investigating correlations between post-
ketamine infusion model parameters (6 G-parameters) and peak gamma-band 
amplitude. Where model parameters were significant, the same comparison was 
made in the pre-ketamine administration data. Analyses demonstrated that post 
ketamine infusion, G5+ (r=.572, n=16, p=.021 r2=32.7%), G7- (r=.518, n=16, p=.04 
r2=26.9%) and G8+ (r=.704, n=16, p=.002, r2=49.6%) significantly predicted peak 
gamma-band amplitude. G7- and G8+ also predicted peak gamma-band amplitude 
in the pre-infusion data (G7: r=.518, n=16, p=.04, r2=26.8% and G8: r=.688, n=16, 
p=.003, r2=47.3%), however G5+ did not (r=.-.177, n=16, p=.513). Critically, false 
discovery rate calculation (based on the number of comparisons and p-values 
obtained) revealed that only the G8 correlations (both pre and post) met FDR-
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adjusted significance thresholds (adjusted p-values (q-value) = 0.0135 and 0.0135, 
respectively). The post-infusion G5+ correlation did not reach significance after FDR 
correction (FDR-derived threshold 0.016, FDR-adjusted p=0.063) however a Fisher 
r-to-z transform demonstrated a significant difference between the pre- and post- 
infusion G5+ and peak gamma band amplitude correlation coefficients (p=0.0349 
two-way). 
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Figure 7.9. Showing the variable intrinsic ‘G’ parameters required to fit the model. Repeated-measures ANOVA revealed that ketamine significantly 
increased the strength of G1- (red box). Correlative analysis further revealed that during ketamine administration the strength of G5+ predicts 
gamma-band (30-80Hz) peak amplitude, but not pre-ketamine.
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7.4.4 Discussion 
The results of this study, illustrated in figure 7.9, demonstrate that ketamine 
significantly increased the effective strength of spiny-stellate self-inhibition (gain). 
Furthermore, correlational analysis demonstrated that model parameters G8+ and 
G7- predict peak gamma-band amplitude. However, with administration of 
ketamine, G5+ also predicts peak gamma-band amplitude (and that the relationship 
is significantly different to pre-ketamine infusion).   
 
The excitatory drive to the canonical microcircuit enters the column in layer 4, the 
spiny stellate population. Since it is the self-gain of this population (G1) which 
ketamine increased, this suggests that ketamine must act locally to increase G1 via 
a presynaptic modulation or autoregulatory mechanism whereby NMDAR 
antagonism increases self-inhibition (self-gain). Little literature has examined NMDA 
receptors located on spiny stellate cells, however (in rats) layer-4 spiny-stellate 
populations have been shown to possess co-localised AMPA and NMDA receptors 
(Feldmeyer, Egger, Lubke, & Sakmann, 1999) and (in mouse) contain functionally-
distinct subunit compositions in barrel cortex (Fleidervish, Binshtok, & Gutnick, 
1998). Thus, while spiny-stellates contribute a minimal ‘direct signal’ to non-invasive 
neurophysiology measures such as MEG, ketamine binding to spiny-stellates with 
multiple configurations of NMDAR may have a number of local microcircuit effects.  
 
Of particular interest is the effect that layer 4 stellate cells might have on the 
gamma band response, since this was also shown to be altered by ketamine in 
experiment 7.3. The predictive coding model of cortical message passing suggests 
that modulatory connections between columns (inter-microcircuit) use NMDA 
receptors, and as such an extended model of the visual cortex, which links V1 with 
up- and down-stream visual processing area microcircuits (e.g. V2 and LGN) would 
help to further explain the effects of NMDAR antagonism on local gamma. This is 
particularly relevant since the superficial ‘gamma generating’ cells are a major 
postsynaptic target for modulatory NMDAR projections between columns (Friston, 
2005). Figure 7.9.1 demonstrates how deeper layer NMDAR mediated modulatory 
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connections from V2 synapse onto the superficial pyramidal cells of V1 responsible 
for the gamma oscillation studied in experiment 7.3. This model explains how 
NMDAR antagonism could directly modulate the dynamics of gamma oscillations, 
but does not provide a mechanistic explanation for the pyramidal cell disinhibition 
noted in rodent studies (Wood et al., 2012).   
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Figure 7.9.1 Depicting extrinsic feedforward/ feedback and modulatory connections, which are thought to be mediated by AMPA /  GABAA and 
NMDARs, respectively (Friston, 2005). 
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The second finding, that spiny stellate excitation of inhibitory interneuron 
populations (G5) predicts gamma-band amplitude after ketamine but not before 
suggests that ketamine has an effect across the microcircuit, and does not just 
affect the superficial-layer ‘gamma generator’ populations. This finding, coupled 
with the finding that both G7 and G8 predict gamma-band amplitude regardless of 
ketamine administration, suggests a level of cross-layer coupling. That is, after 
ketamine administration, deeper-layer (L4, G5) interactions could also be 
contributing to oscillations in the gamma-band.  
 
A known issue with this study is that the microcircuit architecture is modelled on V1, 
however the amplitude response from V1 to 100% contrast stimuli (experiment in 
7.3) was not significantly altered by ketamine administration. While the lower, 70% 
contrast stimulus, and motor (M1) spectral response were both altered (gamma-
band amplitude increased), there is no available microcircuit based upon the known 
laminar-architecture of M1. Therefore, modelling of the lower contrast visual stimuli  
is indicated. Future work should also develop detailed microcircuits for other cortical 
areas of interest. This microcircuit models only one type of excitatory parameter, 
which is fast and therefore best reflects AMPA receptor mediated excitation. 
Ketamine, however, shows affinity for NMDA receptors, therefore a model that also 
includes a slower excitatory parameter (NMDAR) would be beneficial. Such a model 
has been described by Moran and colleagues (2011).  
 
Despite these limitations, this study demonstrates a methodological proof-of-
principal that a spectral-DCM approach to pharmacological-neurophysiology studies 
in humans can add additional insight into the underlying functional changes induced 
by a pharmacological manipulation.   
 
7.5 General Discussion 
The experiments described in this section aimed to investigate possible 
mechanisms of the NMDA receptor antagonist drug, ketamine. While preclinical 
rodent reports allowed generation of a strong directional hypothesis for the effect of 
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ketamine on high-frequency oscillatory activity, little or no previous reports have 
investigated the action of ketamine on pattern-onset, visual-evoked responses or 
using a spectral-DCM canonical microcircuit.  
 
The analysis of oscillatory activity revealed that human primary motor cortex (M1) 
displays the same gamma-band amplitude increase previously reported in 
preclinical local-field potential recordings using similar drugs (Homayoun & 
Moghaddam, 2007; Oke et al., 2010), however analysis of primary visual cortex 
(V1) activity demonstrated this only for 70% contrast stimuli, and not for 100% 
contrast grating stimuli. Failure to demonstrate a significant amplitude increase in 
visual cortex to 100% contrast gratings may be due to the small dose administered 
(0.5mg/kg) compared with preclinical studies. Alternatively, it may reflect a 
difference in the local neuronal architecture between M1 and V1 since the size and 
density of cell populations and receptor distributions change subtly across the 
cortex (for example, the motor cortex does not have a granular layer). Nevertheless, 
the finding of increased gamma-band amplitude in M1 after ketamine administration 
strongly supports the disinhibition hypothesis put forth by Homayoun and 
Moghaddam (2007).  
 
The DCM results provide proof-of-principal that spectral-DCM analysis using an 
informed and suitable cortical model will add useful information about laminar-
specific population dynamics in future MEG studies. Development of a motor-cortex 
microcircuit, which contains both AMPA and NMDA excitatory receptors, would be 
of great use in addressing the link between preclinical hypotheses (such as the 
aforementioned hypothesis of disinhibition) and human spectral responses.  
 
This experiment was motivated by the fact that ketamine has recently demonstrated 
rapid antidepressant efficacy. Evidence of altered inhibitory-excitatory balance in 
depression suggests that ketamine’s antidepressant action might be to address this 
imbalance (since it is an NMDAR antagonist). Previously described literature 
demonstrated that in computation models, excitation to inhibition ratio directly 
affected the peak frequency of gamma-band oscillations. However, the results of 
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this experiment indicate that ketamine affects the amplitude of gamma-band 
responses. Future experiments should evaluate whether ketamine-induced changes 
in gamma-band amplitude correlate with depressive symptoms or severity, as this 
would suggest a common pathway between its mechanism as an antidepressant 
and mechanism in boosting gamma-band amplitude.  
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Chapter 8. General Discussion 
 
8.1 Summary of findings 
This thesis utilised MRS GABA+ and MEG obtained visually evoked and oscillatory 
responses to investigate the GABAergic hypothesis of major depressive disorder. 
High frequency oscillatory activity is interpreted under the pyramidal-interneuron 
gamma (PING) model, whereby peak oscillation frequency reflects a local 
interaction of GABA and glutamate via pyramidal cells and inhibitory interneurons 
and is highly dependent on GABA concentration.  
 
The experiment detailed in chapter 3 found no alteration in GABA+ levels or 
gamma-frequency oscillations in V1 in remitted depressed subjects (previous 
reports were equivocal), and a subsequent experiment  (chapter 5) demonstrated 
no alteration of these measures in currently-depressed subjects or healthy subjects 
with a family history of depression compared with a never-depressed control group. 
 
Chapters 3 & 5 further demonstrated that formerly depressed subjects 
demonstrated significantly reduced (46%) amplitude of the pattern-onset visually 
evoked field M80 component. This was not evident in subsequent analysis of 
current depression of family history groups, suggesting the visually evoked M80 
may be a trait marker of recovery from depression.  
 
Chapter 2 investigated MEG responses of remitted depressed and healthy subjects 
while completing explicit and implicit emotion discrimination face tasks. Compared 
with healthy controls, the remitted depressed group exhibited increased gamma  
amplitude in the left insula during explicit processing of fearful faces, supporting 
previous functional MRI studies. During the implicit face task, the remitted group 
demonstrated significantly decreased M300 amplitude in the middle occipital gyrus 
irrespective of facial emotion.   
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Dynamic causal modelling for spectral responses was employed to investigate 
microcircuit effective connectivity between the four populations, using the MEG data 
form a visual grating stimulus paradigm. DCM has been suggested to be more 
sensitive to disease state differences that primary imaging measures such as 
oscillatory frequency. DCM did not reveal a significant difference between groups 
for model parameters after multiple comparison correction, however the depressed 
group demonstrated a trend towards increased inhibitory interneuron mediated 
inhibition of deep-layer pyramidal cells. This may support preclinical hypotheses 
implicating altered GABAergic interneuron function in psychiatric disorders.  
 
The final experiment explores the effects of ketamine, an NMDAR antagonist 
anaesthetic drug, on oscillatory MEG measures. This was motivated by the 
remarkably rapid antidepressant effect of ketamine reported by Zarate and 
colleagues (2006). In accordance with preclinical pharmaco-neurophysiology 
studies, ketamine significantly increased gamma band amplitude in primary motor 
cortex (M1) and in primary visual cortex (V1) to 70% contrast stimuli, but not 100% 
contrast stimuli. Furthermore, ketamine reduced the peak frequency of gamma 
oscillations in V1 to 100% contrast stimuli. Ketamine additionally increased the 
amplitude of beta oscillations in both M1 and V1 regardless of stimulation paradigm 
of contrast. 
 
An implementation of dynamic causal modelling of the visual MEG response to 
ketamine, utilising the aforementioned V1 canonical model, revealed preliminary 
evidence that ketamine significantly increases self-gain in layer 4 spiny stellate 
populations in V1. Furthermore, the strength of an excitatory parameter from deep-
layer pyramidal cells to inhibitory interneurons was found to predict gamma 
amplitude after ketamine.  
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8.2 Interpretation and future research 
8.2.1 No difference in V1 GABA+ or gamma band responses in remitted 
depression but markedly reduced pattern-onset M80 amplitude  
 
Addressing an apparent conflict in the GABAergic deficit hypothesis literature 
(Bhagwagar & Cowen, 2007, Hasler et al., 2005) this experiment examined GABA 
in remitted depressed subjects using both MRS GABA+ and high-frequency visual 
cortex oscillations. Neither measure differed between formerly depressed subjects 
and matched controls, suggesting that the previously reported GABAergic deficit 
present in acute MDD is not a trait marker of depression and may therefore 
normalise with remission. MRS GABA+ was also obtained for a prefrontal and a 
subcortical limbic voxel, neither of which showed differences between the groups, 
suggesting that the lack of a GABA deficit in remitted MDD is not regionally specific.  
 
These findings are broadly consistent with those of Hasler et al. (2005), who 
demonstrated normal prefrontal GABA levels in remitted MDD. As well as 
replicating their findings for prefrontal GABA levels, this study provides additional 
evidence of normal subcortical and occipital GABA+ levels and normal gamma 
oscillations. It is possible that the GABA deficits previously reported in formerly 
depressed subjects (Bhagwagar et al., 2008; Bhagwagar & Cowen, 2007) represent 
a biomarker of more recurrent illness.  
 
The experiment reported that remitted depressed subjects demonstrated a 46% 
decrease in the M80 (C1) amplitude component of the pattern-onset VEF, 
compared with never depressed controls. This is particularly striking because 
subclinical depression symptom scores in the formerly depressed individuals did not 
differ from the normal, never-depressed population. In the remitted depression 
individuals, M80 VEFs were not correlated with indices of illness recurrence or 
severity, supporting the proposition that early visually evoked response suppression 
is not state-dependent and could be a trait marker of MDD. 
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8.2.2 No difference in V1 GABA+, gamma band responses or spectral DCM 
microcircuit connectivity between currently depressed subjects, formerly 
depressed subjects, family-history positive healthy subjects and healthy 
controls 
 
A follow up to the previous experiment recruited subjects experiencing a current 
episode of depression (‘CD’: unmedicated, female, meeting MINI current major 
depressive episode criteria) and healthy subjects with a first-degree family history of 
depression (FH group) in order to explore both the lack of GABAergic deficit 
observed in the previous chapter, as well as to characterise the M80 amplitude 
reduction observed in remitted depression. 
 
The finding that occipital GABA+ measures were not altered in the current 
depression group was a failure to replicate previous findings which reported a 52% 
reduction in occipital GABA levels in a similarly sized (n=14) and also unmedicated 
sample (Sanacora et al., 1999). The experiment sample characteristics may 
account for this difference, since the subjects described by Sanacora and 
colleagues (1999) were male and female, and were an average age of 42.9 +/- 9.2 
years, suggesting more variation in their ages and illness history than the sample 
recruited in this experiment (mean age 22.5). Furthermore, 12 of the 14 subjects 
reported by Sanacora et al had diagnosed psychiatric comorbidities and 11 of the 
14 were considered treatment-refractory. Thus the discrepancy between 
experimental results may be due to the subject comorbidities (because GABAergic 
deficits have been shown in other psychiatric disorders including bipolar (Benes et 
al., 2007) and alcohol disorder (Behar et al., 1999)). In this respect, the subjects 
described in this study represent a less complex pathology and are therefore better 
suited to answering the question of whether a GABA deficit exist solely in 
depressed subjects. 
 
No difference in GABA or peak gamma frequency was found in the family history 
group. The hypothesis for GABA and peak gamma frequency in the family history 
group relied upon the assumption that both measures would be reduced in the CD 
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group. Both peak gamma frequency and depression are highly heritable (peak 
gamma: ~90%, see Van Pelt, 2012), suggesting that peak gamma frequency would 
be reduced in the FH group (since their affected family would be assumed to be 
also). If MRS GABA+ were also reduced compared to the control group, this would 
suggest that the altered GABAergic function, giving rise to gamma oscillations, is a 
trait marker of depression and would have potential as a biological marker. Finding 
that neither measure was reduced in the FH group supports the notion that both 
GABA and peak gamma frequency may not be reduced in the CD group.  
 
While the GABA and peak gamma frequency results presented here do not couple 
with hypotheses from the imaging literature, this is the first study to investigate peak 
gamma frequency in currently depressed subjects as a marker of GABAergic 
function, and the first to combine this sample with samples of remitted depressed 
subjects and family history subjects in order to identify the type of biomarker any 
positive finding might represent. 
 
In the DCM analysis, finding altered interneuron-mediated inhibition (inhibitory 
interneuron function) is actually in support of the main hypothesis of chapter 5; that 
is, GABAergic function may be altered in depressed subjects – despite a null 
findings reported in the experiment. Combined, these multimodal imaging and 
modelling results report no difference in GABAergic measures in depressed 
subjects, compared with controls. 
 
The inhibitory parameter G9 affects deep layer (L5/6) pyramidal cells, which 
contribute less to the gamma-band response, but are associated with beta-
frequency responses. As such, follow-up analyses should investigate whether 
similar paradigms induce a beta-frequency response. Moreover, subsequent 
spectral-DCM studies in healthy subjects should focus on the relationship between 
intrinsic microcircuit parameters and frequency-specific oscillatory responses in 
order to validate the microcircuit model. 
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This experiment is the first to apply a spectral-DCM of a V1 canonical microcircuit 
model to probe the neurobiology of major depressive disorder. The results suggest 
that the DCM approach to studying clinical neurobiology is, when paired with a 
strong hypothesis, statistically sensitive and may be particularly useful in studying 
disorders where altered spectral responses are observed, such as in schizophrenia 
and epilepsy.  
 
8.2.3 Increased gamma band amplitude in the left insula of formerly 
depressed subjects in response to fearful faces during an explicit  emotion 
recognition face paradigm, and reduced M300 amplitude irrespective of face 
emotion during implicit emotion recognition task 
 
During the explicit emotional identification task, RD individuals demonstrated 
increased gamma amplitude in the left insula compared to ND individuals in 
response to fearful faces. This measure of gamma-amplitude correlates negatively 
with left-insula grey matter volume in ND, but not RD. During two separate MEG 
recordings of implicit emotion processing face tasks (one uti lising sad faces, the 
other fearful), RD individuals demonstrate reduced M300 amplitude regardless of 
face expression and intensity. 
 
Previous studies have demonstrated an important role for the insula cortex in 
processing faces expressing disgust, where authors have reported increased BOLD 
activation to faces expressing disgust (Phillips et al., 1997). This experiment reports 
that the insula also responds to fearful faces, and that gamma oscillatory amplitude 
in this region is greater in remitted-depressed subjects than controls. Increased 
gamma oscillatory power is assumed to reflect greater population entrainment and 
synchrony, and thus increased neuronal resources are being used, a similar 
assumption to increased BOLD response. This is in concordance with an fMRI 
study which previously demonstrated that the insula is involved in fear -face 
processing in healthy participants (Schienle et al., 2002), however this is the first 
study to show a functional difference in remitted depression.  
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Reduced M300 amplitude in remitted depression individuals to differing intensities 
of both fearful and sad faces could reflect the negative stimuli bias observed in 
current episode depression. However, the M300 difference was also observed in 
the neutral face condition, and amplitude differences only reached statistical 
thresholds when full and mild intensities and neutral faces were collapsed together. 
Response data (cued gender discrimination) indicated no difference in accuracy 
between groups and an ANOVA demonstrated no main effect of emotion on M300, 
only group. It is likely that, per-condition, the M300 amplitude is truly different 
between groups, however due to lack of statistical power this is only significant 
when conditions are combined. 
 
It is surprising that the difference in M300 amplitude was not observed during the 
explicit face task. The key difference between the paradigms is that, during the 
implicit task, participants were instructed to identify only the gender of the faces 
presented, whereas the explicit task required identification of the emotion being 
expressed. These results suggest that an experimentally induced difference in 
neuronal function occurs between the implicit and explicit tasks, which accounts for 
the M300 amplitude difference between the groups. Thus, the M300 amplitude 
could reflect the depression-related negative-emotion-bias during only implicit 
emotion processing, with the bias being diminished when attention is focussed upon 
explicitly identifying the facial expression. 
 
This study is novel in that few studies have focussed on ERF and  gamma 
responses during face processing in remitted depression. Together, these findings 
demonstrate that neuronal function, during emotional face processing, is altered in 
remitted depression compared with healthy controls. Moreover, these results 
indicate differences in the activity of both basic sensory (middle occipital / visual 
area) and higher-order (insula) regions in face processing in remitted depression. 
Finally, emotional face processing differences observed in remitted depression 
differ depending on task instruction (explicit vs. implicit identification). 
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8.2.4 Ketamine significantly increases beta and gamma oscillation amplitudes 
in primary motor and visual cortices and reduced peak gamma frequency to 
100% contrast stimuli. 
 
Under the PING model (pyramidal – interneuron gamma) Homayoun and 
Moghaddam (2007) demonstrated that NMDA receptor antagonism resulted in 
disinhibition of pyramidal cell populations, which resulted in increased gamma 
amplitude. Results reported in chapter 7 are in accordance with the preclinical 
findings of both Homayoun and Moghaddam (2007) and Oke and colleagues 
(2010), whereby NMDAR antagonism increased gamma-band amplitude in motor 
cortex, suggesting that ketamine exerts the same mechanism in humans, and this 
may ultimately involve disinhibition of superficial pyramidal cell populations.  
 
Increased gamma-band amplitude observed after ketamine administration could be 
a ‘cortex-wide’ phenomenon (Lazarewicz et al., 2010) and the results of this study 
are in accordance with this hypothesis.  
 
This study is the first to explore changes in oscillatory dynamics in humans brought 
about by ketamine administration. It provides an important translation of a 
preclinical theory of ketamine’s effect on high-frequency oscillatory amplitude to 
humans. 
 
The pilot DCM analysis of the effect of ketamine on V1 microcircuit effective 
connectivity demonstrated that ketamine significantly increased the effective 
strength of spiny-stellate self-inhibition (gain). Excitatory drive to the canonical 
microcircuit enters the column in layer 4, the spiny stellate population. Since it is the 
self-gain of this population (G1) which ketamine increased, this suggests that 
ketamine must act locally to increase G1 via a presynaptic modulation or 
autoregulatory mechanism whereby NMDAR antagonism increases self-inhibition 
(gain). 
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Additionally, correlational analysis demonstrated that while model parameters G8+ 
and G7- (reciprocal superficial pyramidal cell and interneuron connections) predict 
peak gamma-band amplitude regardless of drug manipulation, after ketamine G5+ 
(excitatory connection from deep layer pyramidal cells to interneurons) also predicts 
peak gamma-band amplitude. This suggests that ketamine has an effect across the 
microcircuit – not just targeting the layer 4 population (as described above). 
Coupled with the finding that both G7 and G8 predict gamma-band amplitude 
regardless of ketamine administration, this suggests a level of cross-layer coupling, 
that is, ketamine administration results in deeper-layer (L4, G5) interactions also 
contributing to oscillations in the gamma-band. Such cross-layer coupling has been 
reported after NMDAR antagonism preclinically, where it resulted in frequency 
matching of layers in laminar specific recordings (Anver et al., 2010). 
 
A known issue with this study is that the microcircuit architecture is modelled on V1, 
however the spectral response from V1 (experiment in 7.3) was not altered by 
ketamine administration. While the motor (M1) spectral response was altered 
(gamma-band amplitude increased), there is no available microcircuit based upon 
the known laminar-architecture of the region. As such, future work should include 
developing detailed microcircuits for other cortical areas of interest. Additionally, this 
microcircuit models only one fast excitatory connection, reflecting AMPA receptor 
mediated excitation. As such, a model possessing an NMDAR mediated connection 
would be better model effects of an NMDAR targeting drug such as ketamine (such 
as model has been described by Moran and colleagues, 2011).  
8.3 Research impact  
 
The experiments detailed in the earlier chapters of this thesis are primarily 
concerned with investigating reports of altered GABAergic function in depressive 
disorders. The most important outcome of these experiments is the finding of 
normal MRS GABA+ levels in the visual cortex of both depressed and formerly 
depressed individuals. This disparity with the literature may be reflected by the 
differences in clinical characteristics – where the subjects described in the 
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experiments of this thesis represent a relatively simpler pathology and clinical 
history than in other reports such as in Sanacora et al (1999). This finding should be 
taken into consideration by other experimenters working on refining the GABAergic 
hypothesis of depression and mood disorder more broadly.  
 
Findings in formerly depressed individuals that the 1) M80 VER amplitude is 
reduced, and 2) that altered function during emotional face processing is observed 
in the insula cortex and middle occipital gyrus, are both suggestive that the study of 
remitted depressed subjects may provide a tool to better understand 
neurobiological mechanisms in depression. These experiment findings should 
inform follow up studies attempting to characterise responses as biological markers 
of disease.  
 
The later experiments of this thesis are concerned with neuronal modelling of 
spectral responses (DCM of MEG data) and pharmacological-MEG. The DCM 
analyses, although preliminary in nature, suggest that spectral-DCM could add an 
extra level of sensitivity to both clinical and pharmacological MEG and EEG studies. 
As such, these methodologies mean that neurophysiology studies can address 
more neurobiologically specific hypotheses about abnormal or drug-induced 
alterations of neuronal function without having to move to the preclinical domain.  
 
Finally, the pharmacological MEG experiment in chapter 7 demonstrates that the 
pharmaco-MEG approach to studying neuropharmacology is a sensitive enough 
measure to compare with preclinical invasive methodologies, and is therefore useful 
in translating preclinical research into humans. The methodology also has the 
potential to better characterise and validate hypotheses about the neuronal 
generators of the MEG signal. Combining the data-rich MEG signal with pharmaco-
therapy has great potential in the relatively novel domain of ‘personalised medicine,’  
where a scan at diagnosis may help predict which patients are most likely to 
respond to a given drug.  
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Appendix 1 
 
Spectrogram data of participants in the experiment detailed in chapter 3. 
Controls listed first (1:n) followed by patients (1:n). 
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Appendix 2. 
 
Individual level (error bars) data for the face-processing experiment in chapter 4. 
 
Explicit task event related field data: 
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Implicit task event related field data (top: fear, bottom: sad): 
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Spectrogram data for the explicit task data at group level (averaged by face type). Left: neutral, Middle: fear, Right: sad.  
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Representation of the group difference in the amplitude of gamma-frequency responses between groups.  
PH = Personal History of Depression. 
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Peak difference (t-statistic above 3) maps for the explicit face task for remitted 
depression group > than healthy control group for data in the gamma range.  
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Appendix 3. 
 
Individuals’ spectrogram data for the groups not presented in appendix 1: 
individuals with a current episode of depression (n=1:13) and those with a family 
history of depression (n=1:18). 
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